var title_f39_62_40928="Hydrocephalus due to a Chiari II malformation";
var content_f39_62_40928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydrocephalus due to a Chiari II malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1 weighted magnetic resonance imaging (MRI) showing acquired hydrocephalus due to a Chiari II malformation in a child with spina bifida. Note the shallow posterior fossa and descent of cerebellar tonsils past the foramen magnum. Other findings include large massa intermedia, low lying torcula, and partial agenesis of the corpus callosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40928=[""].join("\n");
var outline_f39_62_40928=null;
var title_f39_62_40929="Absorbable collagen (dental): Drug information";
var content_f39_62_40929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Absorbable collagen (dental): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CollaCote&reg;;",
"     </li>",
"     <li>",
"      CollaPlug&reg;;",
"     </li>",
"     <li>",
"      CollaTape&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of bleeding: Topical: A sufficiently large dressing should be selected so as to completely cover the oral wound",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Wound dressing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     &rdquo; x",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo; x 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1&rdquo; x 3&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostatic",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used on infected or contaminated wounds.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The highly porous sponge structure absorbs blood and wound exudate. The collagen component causes aggregation of platelets which bind to collagen fibrils. The aggregated platelets degranulate, releasing coagulation factors that promote the formation of fibrin.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8882 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40929=[""].join("\n");
var outline_f39_62_40929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154257\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154247\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154252\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154248\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154241\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154231\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154242\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154255\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154244\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154235\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299088\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154239\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154249\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154234\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8882|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40930="Disseminated coccidioidomycosis";
var content_f39_62_40930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of patient with disseminated coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 592px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    42 year old woman with paranoid schizophrenia who presented with weight loss, fever, and malaise. Patient had previously been evaluated at another hospital for multiple vertebral lesions and right breast mass that was eroding through right anterior chest wall.",
"    <br>",
"     (Panel A) Sagittal T2-weighted MR image of cervical spine shows large paraspinal fluid collection (arrowheads) with contiguous vertebral body involvement from C5 to T3 with relative sparing of intervertebral disks.",
"     <br>",
"      (Panel B) Sagittal T2-weighted MR image of thoracic spine shows T7-T8 discitis and osteomyelitis with anterior epidural extension (arrow) and resultant spinal cord compression and edema (arrowhead).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       From: Wilde GE, Emery C, Lally JF. Radiological reasoning: Miliary disease, vertebral osteomyelitis, and soft-tissue abscess. AJR Am J Roentgenol 2008; 190:S11-7. Reprinted with permission from the American Journal of Roentgenology.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40930=[""].join("\n");
var outline_f39_62_40930=null;
var title_f39_62_40931="Arcuate lesion";
var content_f39_62_40931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Arcuate lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5o5BxnNPHGKYvWpQOOa6CBCckY4pOgIp3FA55oAMZOaUA0oHFIBk8DHvQADJAoPb1p3QnFI1ADTxnNOJ4WgAHg07gdqAGcAg9zTmoxzk80YyOOtADeaXpnI/WlwwFBGetACYz1OaTOOP4vT2pwBHamlecmgBSCPpSc0/n8KT15xQA38M04UAUDOB6etIAPfHembTnJ6VJ2znIpuc0AH0ox60uMUHk/SgBDmgZ7U4+tHegCMAjPvS/nTyM00rQA3n6UU7HFGKAG4pVzS7TS49KBoTBpPrTwDSFMjnpQMZg5pRTjnt2oweKAGYIJpT2A7U/FIRzigBvNGcdacB3/CgAen0oAbn8KTBzT8H1/SkwcmgBF60EEHnpTvwxRjmgBAOpowfXFOxxRj8aTATjHvSYNPxx0pMUuYBuDRs4xTsUvI5wTRcBpyaTBBp+OfqaeiF3CruJ9hScgsRgEDpTgpPY1qWui3UyB/L2Qk4yTz+Vb2n6DDH8zq0jdscis5VYo2hRlI5az0+4unHlRkqT1PSt6x0URMC6faJQecnCr/jXSJZBVw4EUf8AdUdau20KYAjRUTp1G41zTrNnVDDxjuUIbLEOCMkfeZQAB7VJLDGOI4wznsTgD6itBod6nau1h1Z6fBbBMAru9wKycrm6XYow2oy0kvzEDAGcY+lWoLZkRQ6jGeAP61pRRbhyuFBzzViOFF5VOo4Yip5h2KkVsxb7uARyOvFXYbZVycAZ4yoqeGHdjcdoHYCrEcIYgAfQf1PoKVykiqIC+VXlRzx/U0VqJAWwBgj6cLRRYLHzIM7qk7UIAB7GnFe4r2TwxMD8aORjgfhSgc0pFAByPSjj3pSORS9OtIBBznnFIQPrSgA0u3jigBO9GKAM04UANNIenHWnEZoxQA05yKMdOad3xSnkdKAEzSZ5pcDvRgDpQAn1o+lLij6c0AN78dKXFKAAe9OoBIYBgEe9J36U/wDlSYoBoTtSZ+YDHXvTiPegDjGKAQnY/Wgj0NLgDtmgZ28gZ9qB2G/5zSinY4oIwtAWE6UmMd807GaQrxQFhKXtTgM0mOMUrgJRS5yKSQEBdoz60XGIeORyfT1o5zz1P6UvNGKLgIvfOPalx6c0oznkCl/Ci4DcYH1oAp2OfTNLtpNgMI5owad0OKXGOf0pXYDMUEc05V5pTjdRdjGhcijGAM0/bzzU8drNMMpE5x/smk5W3BK+xWxRjHatq30C6YbpsRjsMZNa9n4YU4LAn1yeT+FZyqxRrGjJnIJGXICg5PpV620i6n52bB/tGu2h0lY8CKEHseMH8607fTREFLbMnsDnFYvE9jeOF/mZx9p4eQFTO7Of7o4Fb1rosUEav5K88jiuhhs1UA8hce2amVEBVQCO2etYSrSZ0RpRjsZKWrZJkUKTxgDjmrAgIUAISexJ/pWqlsrnAwD0z1P51MtkqjcAWbsTWd2WomStnkjdtUjqdvNWEtFYkqDnvu61oR2jEEtnb61IIF4CBnwaXMyuVFBbYYO1d3qamFt0+8a1o4NoV9uc9QeKUQlsnaQemfShBYzxFyI0wWHU9atRW653MeexIwB7VZ8kJxgZA/Op4YWYjjao7UyuUrxxM55GFH5A/wBatpa54IyDznoKmWAg4J/rVqODPQFv7oPerSEQiIbAAOB+GaKu+UAuc/NjGBRV2QHyMg7HpT6RBxTq9M8NoTp1oOfypRzS4oEJjODSgA8Gl6dBmlIAHuaAG4wtJ+NPHHJ6U3HNACAYpwopRjHIoATFIeKdjPSgD1oATbnnBoxTsGkwaAYmBSEU6koGkJQRmnDHegD0oCwmKSnnoMCkwaBiYpKcQCPTFHGOOtADfenYx+PQ0oIxSEUAIKU89KOO4owaQCY6896KcaQ9qXMAnelxmlI4oXpRzAN5Bop9JtpANApQSKXHv+FLigLDAPWjA9aeRkY70uMcGkFhmM9OlG01JgjtTo4zIWA6gZP0oGRY/Olwat29jNMQFjbB9eK17XwzPKhaRgg9hnFQ5xXU0jSlLZHPbfmp6xs33VLH0AJrtLfw1bIBu8yVj/s5Fben6PbxDCIFPbPGKyliYrY3jhZP4jzy10m8uMbYiB6mtm08JXDEGQ4P6GvQItPWJVDpuXPHQGrCRHBESbXzjg4rCWIk9jaOGgtzlLDwvHAcyQqx9W5rah0obAwT5scKTityK0k+UmTDdwPmNTLbn5S25sdm4z+NZOpJ7m8YJaIwxpKgAuUZjz8oPy/U1P8AZtoA2lnPfFbAiDuR5ZQe+KnECgZA+Y8EhqlXZfKjLisnA3FVKjsoNTCyYsAqAZ6/LzmtRU2rkgADqeuTU6Qhl2nG487h1NFrByozf7PZgQihAe/rUpsNoAYgNWhHCFYoELEdycCphERgyFOOgAxTsOxnpaqR6r6gY5pwtypxtyT225rTityzAMWYdR6CpfJBJDMijpjHNOwWMkW7Ox3Kc+hqZbViBlTx2PT8q1PKC4DAke5wPyqXyXfkDauD2xT5STJFrtwQMnnpjpTktC/3uB2xzWkkSgZB3Z9B1p2wZG3149qpR0AoR2MYY/xN2BHSrMdp5eBwc9wOKuxxDcTgE5/OnlAOWAP0q1EZXSHaOQT9Kk8luOBk9B6CpgveQ7R6U5gcbiM59DimkJkIyATt57n1oqRyMYHX68UU9BHxxH0NPxSRCpMdxXoHijcdj1owRRg5xS7fegBAMilA5x2pQOKKAEx3zRjilwT0pccc0AIBikIzS96XFACLxQeaXFGKAEpacBTcUAIPakIOadiloAZjjrR0HFKwyD60uOKAAc0YpaKm7AQj3pAKdSYpXYBijFOA460hHNF2AmKMU7GaMe9FwGijjPNLil6UgG+1CDinUAHjjj1oGJjJoxU0UZYnnoMkirVvps9wHKLjaMjdxu9hSuluNRb2M8Dmlxk+g9a6Cy8MzzJ5ksqRp1561q2nh2GPOd8gJ796zlWijaOHnI46KAy5KjJHYdTWnbaRLKqgxujE8sx/pXdW2hxxtvWFSe6gdq1YNOixklI0PUMuDmsJYnsjeOES3OItPCqs43uxDdASK6Cy0GCJFjeE4z0wOK6RLUSN+6zsAxknrUsemSsBg7Ubo2eaxlVm+pvGjGOyMZLCKPIX5AOgVBk1ZSyZ1C+WQvUnPNbMWmbGDfaBlfTFSrpjKN+92B7YHSs9WapGbFZBeADz3J4qdLcbv7zdCVGcfTNaUdmrD95v2+7f4VZjsI8DYi8fXNFirIzY7VCuCfmznJGc08WyBiQij021sJaKvABDf3QxJqzHAIyN7KpPQYp8twsY8ELYbO0g/wAIOKljtctn5T+BJFbDIGBCgE56kUeSTgswGOoHGadgM7yiowc7ewGeamMTclkGfbmrhVR0cJnoWNIQpzzLISfvfw5oasMrgJtAbaO5FN8sORhQkefvDjNWgCDhUAJ/iIz+lEzMeFUljxn/AOtQBXiQouCUG3oAeKsQCQKQuPcnAzSR2pGMkknqKtKYkAUL/jTQDBAzHPmE59egpTGsfDOPmPO0VMCS33QM9s9KeWVFBYrnt71aQituQcRozE/xYx+eaeRsTlwxP3QDQzgnBUlm6ZOBQU34GACOhFAWBTgAqck9WxxT43Rl42le5NOaNQuAOOpqJIxuJ2kg847UwsTFhgCPAz1xT48pliRnOKru+zJHU9qh3sMAgMRzyaLisW2lR+GYkjknpTmIbbwCx688VWXA+Y43egPammXJJJYDHAHequFi28nAwAAM4yKKqKCVAyT7nmii47HyLGOakFNQYOafiu+J4QUhHcdaXFGKLgIBxS4pRRg0XARelBpduBxRRcBB70v0p3tSVQCUUtAoASilI70YpNgJRxS0YqAExS4oHtSDJB7Y70AFGB3paOByaADFJinYJ6UoUnpTAZiipNvOBT4beSZiqKT9BSbtuUk2Q444pMVr2+iXbgF1WP03nn8q2LHwrLJnzpHUY6BetRKpFdTSNGb6HJbPmxk5+lWILOaUDYm4fXmvQLTwpAm0LbsWxklhn/8AVWrDpkSgKAuVGMKAKxeJS+FG0cK+rPPbPw7d3TcKqY5OeTitCLw5GNquZZTnOwDiu+jsmXs/sAMYFTx20aD5QwbqS/T8qxliJPU3jh4o5Oz0G2jwfJ2t2G3P51ox6dC+S7KirxtTrW8LaSTGFeTb1/u1PHak8OqKPoBWLqNm8aaWxipYxg7lhkKN/FIKv29pGfmVHc+oOBW5BZwgrkS7T78VKLOHO0kq3bknFG5SiZMdqojUtHId3UdgPerkVnFIduecZwwArQi01hzbzbs9u361PLAyBfNY8jIPl5I9uKLA1Ypi0iOcx7Ao78596lS3jZfkXBPRsfyFWUs5zHgspQ8gquOKne1AI8x1hHGA55/OnYdyqlmf+fche7E4yf8AGpY7YgEl4sZx8681aS0+Vdshkwcrk5x9KsJAQTtXqMHcc1SQyqtr0y6n2HGKkaKEYyQT6Ek1YlGzgzb3PRIxUY4ydu5uwBFOwhoiCgsqvs643AD86aHjIxtAB/E/hUhgk4aWMY6gbgRUip5g5A9setHqMhRYwMjBI7s9SqYzk/ugvqadhUICqABxnAx+VNecjIHJPoKBCPgqOpz/AB4wBTFiZ1O5txHfcADSuk2NxKc9dxJpFQYO3ax75GAKTVxod+7G2MbdxHYE0rDbwoCY6sxpQ3IVSfqOBTeNxIAcDv2pWATgnA5B5yBT1iyc7QpHQCkaVFUElmHdVHFJ5m3Cs3lsedq8mmmBIeFyW5Hb1qF5IwQTl26AdhSFSSSQI0J/E1IpCruxkjgE8UwHIpYAyqVB9O9T7lC8bcVEDwGZSx9B0phcEZcjg52imS2SOw2ktnHTgUwnHLZVT0QHk00y7ju5OODjgZqPeWwBgk9/SgpEc0nPK5Y/wr0H40x5DtyWw3TGKbI2wBckvnHTtUYk4O7bg988VLY0h/mHO7jjHBHSnF9w2scAgc9KptKOQpzkctUDT85yWX+dLmCxpJKVY4ORRWasxxliFHUZNFPmCx80gAEgnnNLj0r0+88E6fKcpG0bdco2P0rIu/AjoSba4bB/vLmu5Vo9Tx3Qn0OHox0966C68J6lDuZAkgHp8ufzqjJpF/EhJtJSO5AzVKpF7MzdOa3RmgUuDVg2d0hO63l477DUckUkRxIjKSAQCPWquuhNmtyPFJinEgcEigdO3FADcGlwadSg4zkjFXcCOnAUvHTv6UYJ4HJ9KAG96dTljcnAUk+mKsJZXLH/AI9pce4xUcy6hysq0mMjpWhHpF6xz5DAHpkgVZh8P3knQqMjOCc4qfaQXUtUpvoYoIB9KeOcDgCulXwpOxBlYR55AUcVfh8MW6Srld5x93Pf1qHXgjWOHm+hxjQsuMkYPOQc0qwNJwEcnHy4Feh2+gW6SKvkID7HrWjHokSPuVFLZ+6VyKzliV0RrHCPqzz600G7uF3FFjUnHzHBP4VqWHhVjlrhn6AfL/nmu8j0pw6hLcoD0bO4CpLbTlPEjEjpyOp9qyeIkzSOFijlrXw9ZQoR5YeQdQ4yRWpaacfl8mAEKM4OAK6KHTo4mEbA5zxnoPyrROnRtGFIJwOjCsnOTN1SS6HOw2Jj2s8DDPJKjJ+lWrcRbisKYf0YVsR2KiX7pPHKg4/GpzYwHBY4J4BVcGosy1Gxjrpr/MW3c8kh8CrEelgKpDJGD/COg+p61rrYzxbhG8bjGCccio/s8o2vMQE/2hkA/SgdkQR2axxs0bbjn5j1xUTRbnIihLkdWc4B/CtEwIxDNIqydTtUY+lW4YWZCBK44yNpHNOwGdb2dxj5kRojgkKKlNnswAgIP8IWtODcpxK5ZR024BH+NSEpKWaOQtIOMsMYqlEOplRQMgIVWljPdeMGtBIdiDCnPqfmpWEhbMQJC8sM8fjSOZlAZAwAHIXkU9hjUQj5ozFG46DkE1PHJOpy0ILHgEvVdBLLgkuA3TAyBU+ZouXj3qBnO3BFNO4FhPOIYn5B3xSJHs+8N57Fjk0xLpywLBkXt3zUm9yNwMWCcEMcGmTYVUzIcELxnA4z9aYZEXciNlu4J/rTWdY2IB2+5XIp7FpU2goATkHFLcCNHHCxxB89cDAH496lBmJ/dsiL0IJz/KnmNNq+ZICo7DmgFQo8uIfip596dh3EWIlgehPHXGaCCjEMUT0HJoleQJwhBz6g1AS5X5AM9SW/+vSskCJHCdyzE84C7RSorhfkYLjoF7fWodsgOfMDsPUfypwV35JbYOoA25oGSblwRuD4HJxj9aYMuAGHyE8ANx+JpzquPmAyD2GRQImbggAdRkg/yoAasQB6Koz0zkU5mAAACZz94imsxGQpQMOlKoCn75LdeQCTQA0x5y+5t3rjp9KVVK5WPAX9aXemSWwfqeRQzKPvk47Ad6EAZiQAs27Hc9KRm3uWfCgDge3rTVRnKhlQY6DsPf60kir/AAHp1PrSbAVySnUhT0JPJFNO2OPaqbT1yaYznBzhVx171E7gHIGfXNSVYcJSWwpxgYyaSa4jQ4j+Y44HamAEcgnPU46VC5wTjnHcDg072CwjyMQBgtn8hULFfuPj6dqcz7QwU9Tkk1G86gKoGR1yRUDEc7QRggenQVBI45CgEDnApZyXGcn8RVKY4ByOnvjNIB7yncd3T6ZxRWdPNtXJYrnoPSigOZEoJAGOQalC5xkYrQW2wNwAwenFTC2XHIFbWZg4pGPcReYFjYYDc571D/Z+/IZQPT/69bzW6jadoOPWkaMKo2jj+VFmCRzsuhxSL+9BB/ug4FRHw3BKCGVAR0CjpXURRs7Fv4R0z3FTSRI3JUK45pK4OKODu/C1ujDeIyp4+4Mg1Rm8N2/IeC2YdNwQgmvQvISUASLtZud5P6UNZsGIJjaPI57impSWzJ5I9jzoeF7RFzJEiqehxuxU6eFI3A228ZA7+X2rvTpI81jKN3svTFTJYJEAVJA9BwafNN9Q9nHsecy+FUjVjHBHKhOcbMEVNDoFn5YHkkH+9jp7V6K9vEFOzcrD/ZqjLbq2WMcg9TjH40nKS3Y1BdjkIdKiCAKGbBwDsHH1qw2lLICxQDHBU9vp7V0nkRuAFBxj7y8En1qTyZk5ADn/AGyFIFRdlciOcj00xL8gWSM8DA6VYjtf4SkYYdD0raQeXIN6Dk/KVxgVOEhY8hDngDGMUmmx8pjRwwOMNt3gdCpNQzW3RgFIAzjp+FbctjFN8pAJBzgkrimpYxxEHyWG04LlzxRYpJIx4LV5CR5OAR3FX4bGSPO4lfryK0I7dY8bHUnr97IP41pw7JAMRsOOckZFNRBmI8BTcSFQjHIJqU20oG6NBhuhPI/CtaezVywQbtvLbf04psUSKeJHWM9ATwD/ADFPlAylgaM4aNjnrj5TmrMazAjBmZAMFcYKj+taMdtKCPLKlexPOanEYL7ZoghPQk8H6GnygZ6QnG1fKz23E7sVNHAyoC8hYjv6fWrCW0iSmInLL0JGcg1IYWVFCLGU9QMc01ETIfI6NFhvdfvD69jSeTITm4jBT1xnP1Hapo5wsoSaPy+2Mc09WeNyEEwQd8hgR7UWQGf5cUUo+dEBOcdCKtHc8mwwqQR8shwtWJLa3ucRuigA8+aCpz6inmwSFSpaTb/DKG4HsaaiwuU7ZGdeWU4P1xU8cJL72iU453AHn2NNNm88h+fOThXXr+GKd5MttEpFw4IyCSMqfb607Ax5t42kySqv/sk4+hqNofLJCyIMHIAOQPxP8qkCSSKpZmUseSWA59qnXCqVnUuAPvbNw/SiyFcpCLcvytHtPLFRyfwpYnU/IXAX+9nGauM8TAMqE+pC4poidm3BmYAY28YxRawXRGFZwAJQQD3GacsY3HlSO+VFTpGnO/apyOMGnRhGB24kPr2ppA2V92R8zquPTp+lRbkbJGx8djyKuMifZ2DxiRiflONoqFCN2EA2+uN2KTQtxq4CKSctngKMAU15Y43HCtIe+ScirIkAUqFAUd8VFCwaR8YXvzg0MpIqPIXmywKjPGwcip1jDYZNx56H+tWJEITliwP9081WLMkoVTwevT9aVh77DnKM4ADM3cAcVE2QGCqQBwVH+NTM7PkdgOdo603YCPunb70MSItqAjG5m7jrSsN2PlwR61NkKo2kgD+HNQyDzCGKnP8AtUm7AtRjE7ikmDxnanH50wKDjChfb+tP284Lrx1waSRlUBhtHoTSuUkIrKhJYliPQYpgdmO9m2jsOlRvKHPygs3p0oRiT823A55HFRcGrE4YnI+6g6k96Y5ABJYBRyAo61E8nB5JWmMWOOg9B1oGhJXLPhsA9TTQUGSxYimTSbEJXhv1+lVZZspu2kDjgnBpNjJzLuP7w/J2HpUErbvukgHk1EXCxlpWAUelZVzqkUbEKkjD1BFFwuaspHUvUDzqnXceOKxpdWxwAkfu2DVO41MjaWLMG4yDjFCTZLmjamulXJzjI71j6hqgyUiUkno3YVj3V2HdipLYOAuSc1DvmDfKBtAwCg/SmokOVyaW6cuQ5Mh9jwKKRIWMSuUKqTgE9/air5ULmPTo0bBBI4NS4BHQFqmZF3EHihUj2dSTWtiyPyhtG/jPWoGUKrAHPpVsL8uFH196R4y2FBH09KTQtSlFtVsZAx1JNPcljlQcepp7W+yVWPIzyferB5HSpsN+RUC/utrqePXoRSMwRSwGI+4z1+lWwm+TJBOO3alIDHAOCf4SOnvSsyblWKSNm3Ln1zng/Wre8FhuYKvXIYY/Oqr28AYlWVST3FMSKMt80RO3neD/ACFNXHYtCZTkJJhfTG40fIH+d257YzTkUumw/KOxHBP19KkjtvLOIhtP949MUxbEACKwKxKBnBL8H8qekSkOdoCk9UbIpZg6EgSR7SOcEHFVx55Jwqseo25P54pXGhrwQkgrHll6nGKnhSModvltyMjGKbHJO3ySKAMHtgVciKhfLIQZ/iXBWktRshfYjHerqE7OM/jT/MTYxeNnyMBtud3tU8luEyYmIwPmJHUVFFDkhGjGwjgEkZ+nvT1EiuphlxiAquO4xj6ilaOBQPM2lem8dVqz5EeMLIwZTnay81agA25mSHDcbmGM00rjbKgi2hTEjlgMgkcEfWkIfeVYKyNxjGOfetqCNFjzFuX/AGQdy1DJHFuGUwW6gHg+4p8hMWzPSBo5lG1UBHXGR9KvBBIuwRluOdh5B9cUoEqMCsodVOQWGOavQmMqRKgjkbnIyBmmohK6MtLaWSQ+VLudRx2I9s1JbkncksRDnI4UDI9x6/Sr9zAQ4ZVyOxzhqgZ96DPEijGSP1FNKwr3K9xaSqqPDt3qcqWHDexNR7o7tGVrXyZCMNg/dIqdy5ZTGBvXO4Zxzjv9fWljIlRjsy6fLuPXp3oArR2L7QTJNg8qd24GmxyFSVdP3inBX7rD3x0NXLe7K2+3cpRTtwy9D9e1VbqdhKknyo68KcZx7H296HZLQqMGyaOWOQ7EYbz82PumrMMzSMwA4PDKRVYtHNESQdw5BTtSqQ2FnRRIBwehI7UkxNWCWzjRXKADP3cHkGoyrKAA5Ze0iPtI+oqVPlOHMi45QqCQfqKI5irHIjbPGQMbqQiGMNGo8xwADw46fjVglg+0sCSMr1xn60DYRhflY/dBHGKbJGUXgdT7/KaLDIGNw5yr4YcZJyPpUqszBAVAYjkDufwoSRWf5wQ+evQA96ChDnBAUH6UIB8oYKPlUeoHB/WqDypG4UmRAexGQT9RWk42jgsPlx6isyaQpKAxQqPzpS02NKaHKpYhsR89eCDmopBkqQoDDr8taQfK4DqFPTHaqN3gMdys3+0On4ilJFQd3ZoGDypnym57g4qSCIp8zouegGOlQ2oUxkhGPPUGphuJXBXr65P60EyfQm35JJBPtxTZM4CkbCTxmo8uvB3D3AGaYzbcHCr/ALTnk0iB+3nko3vjNRNu3ZOwjp06Uya7WMdT6dOlVzf8lcnBGQdtS2WoNlmRgDtDHnsoqvMAGGd2R0zzn8KiS5LnHOPyBpDdW0KHfKi9RndmpB6bj3mC9Bz3HpUMjFsZPA9eB+ArPn1yyhU/PuHTIXrWddeIYFJKn5uys2T+lAnJG+z8HLkkD+L5R+VMMpYHbj3Ydq5G41+eQ8IEbPO3nNUpb+9lD7mcKRjOeaQnNHXXF9DACJJFz3yeaw9Q8RxxjEMfX+JqwPLmkBzJknjDZJ/Onw2e084yeMGj1Ic7jp9RvJ+rAey8DFRQw3chLKAoPBBJ5q4kaqDvUBunByakUR9CzAnucmi4rlRNObOZG/I1YFlFhCeBnndyKtq0Ij6c9MqODT+AAQjBT2zimmFkV1trcHgEL6qKk8hCDsbjOeoHP0qdApAKx4PqD/SnOoI+dUb0zwaNwsUzaoDwFDN196KslicK0W33zxRQFjt2jZTluvemDLt9057Ve4wRzhsnNChSgAI3DvXa4l3IRC4AKjI6cVM5Xb2BH86tLgEKDj1xQYgQScY9cVDixcxmgO2QOM0kaMQQqk45zWgIgATtAb0ppiBHzcDjgHiocWFzPkA55Klup9KrwzorsrNkcAYHFaM1urOWAHpn2qOGEDlRljwvOKmwyMsNhZlUIPUEn8adDHliY/k9eMfzpsw8lsu53DphulXITLJh1QMPR+MfjQhtWVxq2p6ebJt6kAjmg2wIHmzNg87Cf6VOpkVgw2KMfdXr+dSAORiNYyD3Y8/nVqNyNSCO0hGfOjUAj2IFMnshGoMalk9EOD+BHWrUkEO4GSIZPcHP6U0Wse5mjI46lc4P4dqLIaZVEUYUNFJvP92Tr9DUscA3OY4wkuMHaf6dKcUDlSbfZzg4bOakeJQoKHMg6EHH4GklcZCXMQDSrINpwzEEg1YW5icEb2YY6DP+FJnk7yyOwwGJyD7VHDLIH5ByD065HsaaWoWGyH58mOV0AxvxyB6cVfRI0wuRz3cZ/Sn7mlzs2FQOqdffIoFyq7VmJVTwCAMD/wCtVpJEtsrTzPEjLGLfB6Kcqfz6UyG/LgwPAyyddw5A+h71avIgYicLJC393tVIu8aBHVHQfcZRx/8AWNRdp6GkbNWZbnJkVWTduByy56n6VPE5kHythweQ1VIirqolIHYZ4OPY0rDykCF8jnaWPIPpVXuNpNWRYmlaBJH8sjHXHP4j0pHKXEQbBVl6Ed6bFJvjYHcT0I9arsDby7gpEZODuHH59qnm1MrW0Jp3ZHXf80bHBbHr60KC2XVi00YIYD+Ie/8ASkuJN9vuKsVU529SKeZhtjmUFgB95RyB70XHuY9/kzq6NsZ+w6H2PvVyJEnhIk+9jDY6j3qtqigkXMJymdzbeCPU0RzvKVVQWuBwQeNw9cVF7Nm+rjoJG8kU4RXyy4A/2h6Gr4BcZIIKtj5gSF/+tVbZ5r/vR8yngqeVqYuSm9WDMoxg9RTWhnJ3sScrnYf/AB4kfn6U1sdlUMD0pglUgGIKWBwynvmq5nxM+GQDhWSTjH40EFwFo4tyEBR1STnB9jUiXKOhQggsAcZyPqDVXzUUZ2srgYJHP5io45Qd6bckcgqeR+FF7DSuW5PmcBgWOeO2RQEOd33lHU9x7VDLeR+SD5iLjj5jgg/Sq0mrW8RD/aYV4+Yh/wCtFxNF44EYG5gp5DK3UelUp2TIYDI6H5elZtz4l0uMkrdJkj5lIwDWPP4zt1bbaxMwzyMZB9xUtopSsdI1wYjt5K56gdPrTirTE8BVPcnrXGXHiq+kJEUO3vkjGKoT6jqVyAS+0cnBOam4/adj0bzrW2UBpolPThhmqNzrNnDJh2yR/FkYrz945piPMnc/Q4H6U0WB/hDP7nnFLntsZ6tndT+JNNRGKzZfpgc/yrMuPFVsCfJQk8/w7q56GyjZQpyPUYwRUyWAToiuB0OcGlzXK1JJ/EMszA7ZAp9emagbWb0jDECPH3QTUw0/O0hMk8/SpVtdgUhBgHkAdKm425PqZf2i5kGcv7YWonilyfv8nnII5+lbrQO/3VVvY8EU028zdBg9skYouQ79zBFnmP8AeHae2ST+lMSHqFKEjnGOa6FYnDjci8dDgGnm3Vxt2Kc9wKOYVjCWFOMBCe/UH86UqzH5cDH+zmtn7HGz4MZGP4cc042YVT97kZGM5ouFjHCZA2sw9sU8R8+gxyS2K0/sgYndEdo4wMA5o+xl2CCFiT07mlcLGUSgzjb6YU5pdu7BLBT6Fe1aK2y84C/Q9RTkh35wCvb/ACaC+RmUofAP3fUU9Q+Tk7s+tbK2auwKBfl+9gA1IluuOUG7sCKaYuUw/nABVGG09jTliuZTtUMxY8Lg5/8Ar11Gm6cLy6ighfEjtjlMAe9adppsI1Qot1tAOIpthHz9s+nPerSE9Dh1iuRw2Qw7MMfhRXXXliVnkExPnhzuJ6k55opFWNLcQoGeBxTlA38knIzg9qr+Y2RgAt2z2qRS27K8E9z611XJJ0mIAznOMc9alErhhnJHpUKLksWPPtTkJ2kg8joKTbAsM+PmyTjtVeZ978Ek+maOSAOretMMTljnilzMaEMjAqjnvnP9KedxZcoFUfqTR5YBByGU05GRcsZfz7UiiuYB5mCxBJ/i5FacNuVAO5QfWqcrqxym0kD7x/w7003NzgELwB948fpQrJlSfMjSKiI8Im5uTgYzUa3AAO22YjPLt0/KqMdw5O5TDv8Ac8VK825TzGrD+INiquRyFwvHn92VLeoYD9Kd5o2EyIR23A4/WsCeRZgymMbv+egOcUxJJolPnIrY6EEk/wCFLnsUoGw7xRbt8skeeh4YGoJJmLlz5YGcB0YgVRj1FAhjdHVzwG4C0iXChnzJtXqMLxScioxszWjnZnYSIpUHBDHhvfNRzh0CtFCSPTPPH/1qr6ZdZb5imDnqNp/Oi7uRDJ5chXy/vhgeaVyWveLUVz52WSTec4KYCsDVpHzGTv3Efwk8/T3rFMMUjK+0HdyGB2n86ljlaGbEvlKAfvMpyPxFNS7g4robEZzGxRiiHrtGOfcdqikUJl4dm0H58ehqpJcRGMSoG3Dq8TZ//XUD6m5jAWMFumWwuRQ5IUYN6lu5ukMWPNQnvGRnP09DVVZi0YCyqU7Bh09ifWqxlWUKWBBz1UdKe8kUZKlNpboVOc/Wpvc1cVFF6CffOyOqjHK5OM1YW4HlsGDuq/eVuwrCeWJHjZd+xjjb6GpvtjLKf3pwABkrj8DS5jOSRrEhWYxKHUjDJnGR2xVeObYp3yFPVsfzHaqst5lCoyuOVwaptqTB9xdZAPlLhfvfhQ2iTVllCcMV2MM5B6is8PKZ4/KBk2Dg52sP8+lULjWraOIpKy4wePQj69KzW8ShVXykBz0br+lS2Up8p1clyH2yElcD+H1pPt6xxgyhTkcOpFcNNrF08jssbA9M7sfyqp594+4xvgE5O0Z/U9aOYjmR3Eup25XEhYBuemMH61nya9a+Zu3Fx0LM3UVywtp7gjz5Zj6dRipo9LRRlzyexB4qeYLs17nxR5OPJbzQBjpn9apXHie/dvkXbgYHHOfbFNjskAHBGP8AZ4/WrDWag7QuVP8AfyB+lJyDmZkteahOxLSFSeThP5ZqFraWYsZfPk9Q54FdKdOcgMGUMOgzT0t3XBAAJ65PSk2w1Zz0NmGYBUVmHAB//VUsdmxJGxVPpmt0qijl03g7gD/MGpEAbJEbH6dRSuwsZMNh8ikbj2IA5qZdOUtuUZHoRg/nWssJeNm5Cjg7uDTXgIC/c2nsx+Y0ajsZ8FoqNn5Megp5tEL8yMM8jaOKvxR5DDKcds85pxQIATtTvkHNFmUih9jjVt2ct+Z/WhYGGCoV/wDZHB/KtFYMEHzmAbngZqZYwcgyAtjuME0JDZQihJPK7MeoFTGFPmYMM9gAeaupasBuZVYA+xNOEfy/ufmUckdMfhVWJMownccKQfU55o8lgoyCF9OlaCK+SdrKD2xj9akjidlVWRSfQHBxS5QM5bUlmAOAeuec0G2BchQrDua1Eto9wDYX15zini34YpksOmxeDT5RmOYWCYG5SOmOQfzpRCTtADCTr2IArVa1lYZKylT68ChbDCneMDttHSlyhoZX2bLsqrvY/wARxkULaopIVWL++Sa24IlBCKvvlTxQ1ohBZZNr55BPWqsIw5LXcpTygqYz8wxUUMRQgEFgTjGBiumaMBBld4xjHUj/ABrPlijiOSQFz061Movc1g76EUVoA7EfKe6gVNFb9WCoW6YGadF+8fDKF44Yjr+FWWVQFKO7E+nc1aVyWmS6fF5E0U1uD5ytwuM5NbQsWEvnRaTIJwdwDS/KD9KzNLKrqUD7gAhBJboPxq6LdWlO2/t2AY9yCR71oloYz3Mq5hl892nV/MZjvbg896KuusQldAD5mSOvX3FFLlHcxhHgEHmp449qjPGOlSmEBvenbNo+9znpWohFTpzg/SmFeTk/j61IGzjvmgqV3E9qGBFkpkgcd+KbPNIiZAy2OFUVKdzJweeoqu0jI4OxdxXgnpUMqxCRJKGMjK3YKTgH8acVh+6AFx17/lTsSAHMcciYyOeV9qh228pQuJFGeFB4+tT0GPNz5WdrOw/2UwaSS4ZskpJ6jLZP5GombySfKdMnorc1HJczMu0uufbgUAPkvCqbYokcepNNAkYfviDnk4bP6VGj4TKuu7qPlxmm+dHGCzkFz1JBGKLlXLQmSFSCRgdyBkVC15FJINgUD/a71ReWE5dYGJ7uW6+1QStC/wDrI4yOoI5x+NJyYI0CACQUPrsPIP09KryNdWsiqEOwk/d7CqKFo0ABRoh3Dcj60TyMiALJK0fcbs4/EVLkO5prcjOI5iO2x0yac9wjghuGwDnBWsR77DAeYrgfxEHd9KlfUkMRJlkLHggihMTaNqC5AXLEr656U9blXkG7ay9QuTg1y9zqRLKzmOPORx/FUP8AaTGPaJcDGAFycGi7JTR1wfa26EKrkdDwDUcjvJCS+1cfeAOeK5P+0HRdzK5BPIBH6Ui3F8zKYI9gODhsnPPem3cfOlsdOrldzeaA2P4elVJNVjEZZGiOTnjqDWGyXMjuJp2LHqqjFCaY74ZomZj1OcGpuS6jZqjXY4yd2M+jdD7Co5dfabDxwn5ep6DHvmoodPkCbFjADdRjkfj2qxHpmQp8vkc465/Gi4rtlA6ldzOWRAB0y54qNpLt2DIzHP8ACPlA961zaOp+4pA7t0X6etWIoY4wFRAx6lgMY+tF30C3cwhpjuvmTRl+/XNTLp7bSVCr6A810ccaY/eOuM42qad5AyCUyue5xSsw5TnY9PmVwSiMD/DnFXYrMJ8rIMk4Xb29q3Et2wT5TqD3Ap0VvnKGOUjqGXnNOw7GS1n5eAQwDHoTnJqwlqoPzK2f9mtFrc/3WIB5VhjP49qkNo8IUgttY4y3JFFhmeltvJKM7Begb+oNTG0AXLRMT/smrvkyqpMkLNjo68j8qeCJlPmZxnGFOAD7ii1wsUI7doyFX5s8j5uR+dKVaP5mQ88EONwrS+zxlOnPqx6UeSQm4MNwGPlp8qEZgIIG5EPHy8dBUhjVSrAYbsFGMiry26MVwTk/3wCB+NSiLaoAcH0GAaOWwGf8pJVvNGeu5c0phwhIhO31VQa0PJePqXAPTK8Gq9zGWBZEOR14IoasVFXZmOSSBGFfuCF20z7HcykEkBiegH860YlVhhtq/U8flV6LyUjIYDd1B96SjzGskoHPLbXELFGLK46EdKswiRXCyjcD/eUZNbVxGXQHBx2I4qJUhznfnnneO9PlsHMpLYREwp2bfUjGMUiL32qPfPFSttMmNhz2IqXbJkEqFXHeqsjGxVYqBvdAEHvTB5agNJsXJ+UBcnFXREWkzICMD+9nmqum6jZ6ibo2M8bm2na2mOOUdcbl/DIpcorjfIyzMFDA9VzjNeQ/E34gXFzfDwt4KDyX0j+VLPA245/uIfX1bt+ZEfxM+IVzrt6PCvgkm5lnbypbmEYL+qIf7vXLenfGTXafC74cW/g+1M9zJBPrEy4km27hGP7ie3qe9axiormkc8puq+SG3Vmn8O9J1jw/4VtbHWbs3F0gycgMIlPSMHvj1/oBXUK6t1lO4evansoHBcsfYdaarqGYfMQOgGOaz5ne7N4xSVgZVmTbHsKjk8dTUZs1aNWRUz/EAODUhcFxguMnG1Rxj608mRHBTOe/0oTuUVvKKLtbBb6EEfjUEynkPucdwFq9IyvE6yoee7dfyqjC0kBbyRuAbp7UM0p9yusXIcxvnPAPH41YZXlOW+VR6NStIGdlcYXOTzVpcs3ADR46k96EuwTbH2VxLFEIltbeRN33nXJxUx1B42YraWjY6DZjmq8LurEsgVDwOeppiuodRNtRWOAc9PerTMnq9iGa6cuWdB+8JOEP3aKbcyosrm3lWTt93biipb8zRRQEruIckDsacrZ46kdPeiXYxzkEg9KjDICQDjua3aM0iSFAq5K8E/rTm54GePWoXvIo9xaRCeD14x61Tl1aMA4AA6gk1LshWbNDIQfNxk45pjyxqoBG7BwMVjT65BwJGIJGCwGaoS67EQArKQOcjv8AX0qeZBaxrXcwDPwqhuy8mqE86rxvYjGAF61h3niANLsyAQeu4AVUk1hmIKLkjjIGVH5Vmx3SNqa7VFJERBHYN0qCLV2bI+QgDn5sGuemvrh3LKrhhxkrwR61EIbq5cElF78Lzj61Icx0A1XMpWKF5Mjt0FV5b4E5kJUr2Y5BrPitJwpTeynPBWrS6a7Mm9pGBPf1o0FzMWXVVGVLxHuCoPJ+hpg1LczFQVYcHGQPwpw0/ZLsYKu0fxDPNXYLIlGI2qM7eTj8qTYJszvt08jDykIHQZAzTTBLkB+OxwcYroINOiXG1VOPapo7AbtyhUJ5yV601cLHPpbTsVYyNgZ5A/Sj7AHXazMefxrp4bTZJuMqqW4wvAqf7AAcqdxH3mB/zmizK5Uc/b6OI/u7QW7Oc1Yh0v5gHK5z3HStcWikbE3Ke5UcfjnvVpLSKED72/qcDJI96aVxNGD/AGZ5ZDkoyA9CASfwqzBp+FwM9TgsMjFakaxeYQ0LHA5KjPFS7GG7ytip1w+SaOVD5TPhsihYv1JyCi9KQwiNiWJYkZGOCPwq7LI8ZCrIqs3QR8/iasWkblMtGjA8FlXlj+NFuiDlaVyjDBgHZbnceA24ZNWRaud373a391F6fWtNbYSDCrHuBwVK8j6e9N8lI3KMHkI5Gz+Rp8rJMySBLVFzGJD1BaliQSBnjbqM/J8qj6+takNrE2SE3HPpirUdlAGyqxpJ6qMcenvS5XcLmTCix4cCMknGSPmBq2kUgxw7A+mM1alsxIjBcBh0Kg80wRyiEFEV+MEA4NPlsNMq7IklVkZ45M4ZQDz9RUxBwcREgchsdfyq2uzGxYmJPBB6/WpAGMe3PtnGM07AVgAUxMuH6D3pYoZUKqybh0wTnIqSO1MoO4mMjpuOcUk8giXEZ3noCtD7lcr6BK6gkvub3HUVm3FzE7ECJiBySwxT2SaZj5pjdvc4OP6VatbdsgKNyg9xjH+NK7excYJK8jOB8wBkOCP7xAz+VTpjPzRDcvOARz9K05LWIowKNnH3Txn6VntCgPyplRxhScik4tFx5ZbFyN88BT1zgjvSpEzhiNgXPK5xiooWIAMTMCvZmGf1q4zzugARX3DAIXIHuSK0RlKFnoMKhDtJZ26YA4pjRLIuHDLt44NP3OkeP3e8jBDZNQO7p1hKuePkbOTQCiyA2MeS2xj+nPrToWaMHeCyjnOK0LRvMQAo+4deKsGFJsb0wV/ChQ6lOa2kYzF52IXtyAODUkVk55mVMfXJrY+yqg3RBDx35xTTFJzu29OwxT5O4nU6RM9IowSRLxnAwe1SLBE+ASrgnuTmruFdVCgc9drVXmtlwSysAOeeaXKZXu9Tm/HusReGPC+paswiMkEeIlYdZDwg/Mj8K+TNN8VaxZ6VqWl2t6Y4NTkV7hyfmJ5B+bsGzz64+ufZvjhb6v4m1ax8OeG7O5u44MXF06/6tZCMIrMflUhSTyf4hWf4W+AkkgSbxNqscS9Wt7M7mHsXYYH4A/WtoWitTjrxnOdo9Dt/hH4Q0HQNFS8sLm31XUZ0/fXcLb19diegHfue/YD0EEZGYkDdACP51jeGvCGi+FIHj8PWscMkgAeRjud/qx5x7dK3SjfLlmcj0IrGTu7nXTjyxSIfJAz5f8RyTjPHsKWRYlOMknuFHP5U1kLSHKyEH7z8flSTSLBD+6kI+vNQaJXJJAm0ZO0fxMTiqjXAIIEmEB6jk0wo8qbpG3EngY4NI0RCDgHHJpXNFBLcc10kXzqW44GeTmlMqSjHyqRySTjNU/KlLnOPVec5pNxicyOgYildlci6CXFvljlScj7wNPt5gyKHZU5xgHH51LJIZhEp4VhkheTVWS2L5JMbHkDJ4xSdx8yktTTsCJL+JJfuM4GO1XlBiWJZbSNp7qYgQlM7Ixxxnp9aw7ONru8ihWYIWYL7j3rQlNkTbShrz98725keTLegPsMnpVxehhNJPQzHVEnnSMlo1kZVAwcqDgc0VUvR9mmeKWXmNijBBxkGiouPc5u98SSTRZRLhHPRQRjP+FUTrN0RuhhdWI678Y+lSxWPOWXPYYGBUiae6tyqxhvTnNU53M0mZ899fz/NIAsZ/h5O4+poH2ycArK2AeAgxgVrpZFBlZQN3Y1aS0Koud5Pptxz7UXYWZzT2kpbBmkUep70o0ogjed+e5bg/h2rqEtGYFWCsB1A6inpawrjem09iRkH8aVmwsc6mlRnqmB6jjHtUy6YsfKnI9PT3FdJHbpG5dAAD1yeKkSFWJEcXmE/xZwKLeY0rHPx6dJuJVST1zjGatCwwoZlJHZTxj3reS2fawIReOMHmniDcxBHI79qOQaMeOGKPAAPJyPWrCRJyfMUAde+auNAmAFHf726pxpwP3YUfPOduCaOWwaFCKxhcE7VYE447fWnraoh2P8AOo7dMGtC1B3NGEyF9BgD8adcIWn2l0UY4wMmrSGlqVltVwQsak9hjpUv2feUThRjgD+tTw25bLSSKMdFqdTsUZUBf7xFNIGVpbALHs+UE9RjJqO3tvJY5LN6KT/KtFztb5nXaewOc/iKWKGJhv8AJcDOPQfrTaBS0Kf2d2OTIoy2QvofQ0sUcrowjDKDksQQcmtMRReWQI1LDqAATTlsgItsUXk5GMA4xT5SEzPFsZExyD1BHGPwqRLMRrksjH+HzByKutbFSPOD5xyfM61FOoilzE5Vv9olgKLWGncjeBZAFITA9tuaVbaVMJa9AOOcirlvCs6sZwOOPu8H6VY+zbVCw/c/uhsU1HqDl0MdxHBIjXEL7shd65bFWXZTjaxIB528VamKKGjkA5HQtxWW0UhJaOMAdxnke4qZe6VGHNqXi8RjLTBgy/dIHX8aVbpCg8uVJDn7p5NUvJZ5dplO7H8Z4/8Ar0545bX5WhXH9+PqPyp36l+yRdRpHkxyi7eNo/XmknUEuHLEOM+Z3+lVoZS3Ec7hwfunqR9DUkzTMwWQ/P8A3dtAlTEkUIm2WTKdmAzVm3SAYHmk8dVbn8qprHG6MDIcj1UrtP8AhVm2ECglVGf72Bg0JDcNC1JFG6FBOSPZcn8apT2caNlCSexVSD+VXvtCxIqpcRuPQdvxpn2nzOkqOe+0HJHpVtJ6ERUkZzx+Y+DE20dcjBqxZxRmYny5FA/hPAp8kMbEMFnYgep5p8YZeEdlYDgYzn86hJJmr96I+6VDFiRWYEdMZA9/pVCKAKQpWaP3HNaLM8wG7zG2/wAORUTwLAm4b8nk7mwB+dOS6ippJWJYbbJUAvI3Zio/I1aS2YKw+ZM9sVUsbxG+Rt6gnHy85P1q8Ud35W4WLtjnNXGxjO6ZGkKcAbi/IyOMVVFtmQrI+Af7xzmtEQFYydwYdgxqF4icGMkuO+3g0NIUZNbDIYQpOCAMYwFPFMmfb85J9ADjNO2O7EPLGV75BX9aryTL91kVVJxkdPzpMaTbI52dgGjUgdTg5qKR52QNudge2OlX4I41i3EjP+yeM0hiQMoIwW7A5qbGilFdClGZxE2AzEcZxjFQvJOv945HV+K1ywjCqWUv79RUMsCGMYAlcj72TgUNXGpK+qKNnJuyAqhs8njBqw+wcPsLY4Cjk1nTKLdhsG07sAAdT6/Sr0LKkbO+GfjLY5z/AEqUxVI21BxnLmI+nAHApjxoJMKpT3qQSBsYz14/+uar3UwQ7Sc5OCq9vfNJmaTb0HAck7icdyMVSuGDTpvZcMOAAM9abJe4ygjZmzwzcD8qqTTAuvmqFI5DAdPbPrUuSN4QaepfdCkbOrsGPCjA4qttGWLzHcecselR+c0jKqrk55zxxS+akaMG24JACgYqA5bbkqeWF37856tnoKqFj+8jiGS5yHbnaPb3qSVUVzvQFcckngfhUBmCpvfCjJGRwT9KAincW2k8tP3jqQvDEjGakJjEI3BMnJ4OcE1RugTLgZIPAA6YqrJAMgxluu44bAFLYfLc0YlZruE2jBbuNgUIIzu9PpW2y3vyLHpECzRszqzSj5WPVgua5uxuRa31vO2ZIUcFtpya0Eit4tQS6OrQsit5jFSTIw64x6npVRehhUjqZOqWktrOGuo5EaQFt27O49yCODzRVnUp4m02CJX8wtO9xsUZ8lT/AA/WioY0+5n7EAJ2LtTnJOAPekRVdt2Qo9eufwqd38wozbPLXoM4/E1GCjOcpvGeAq4z+Na2EiWNYlbCgFm/DHrUiw7WO1zx+Aotkk2g4EWTwqkEj61L5Lv8pdjjqxFMWwxFlbLb146c4qSJd3E0b+nqKe8SqgDTFh6A8U+IIBhQzE8HnrT3Aa1rBMQiqqj+Jiv8qki0+NHB8x9v93dViOOIAKAWfHIHarCRJ1PCjrSshldhEnC4yOrHmnYK8ooYc8HAx71GyFkZ0XYgPXuaiQJvCMpaXBwXahuxSj3JUZPKIklAIJ2gUCa3CgEylse/WmxWKswkAG88nB5P0qy1v5TAtgk85Ipe8zXlh1Fs9hYCLherE1bFnHkOIUG7+I96hgh3zARyqCe2K0TDgAI52gddvFaR1RnU02KjWpY/Kg4PTOKcYRGRI7IFxkAtkCrUFtDh94diOMFvm/Km3NukcfyAEZzhh+lOxnHV2KUEkhdlM2B7LWhHLCiqHZXYdNo5xVe3Qn545FViMkf0xU32LIbY2zuGcZH4Ulc2mouwy5dSQ0KkY/hVsE1OAzJmQryM7M85posXJGGiznk7f51YBSJeIpzIeAyn5frVa9TKaS2EEULFSSwdRnB5JqCe3X/WPFIg7/Ln8a0IWMvG4IAfmOzJ6dPpSBIlDvIWQdNzZxVNXQouzKkNxAyCNZcFeMMmc/SpfMUKwlZeMdF5qB7dVZHSUDnnaMg1YuI0khXMSrn+93+lCLcFfQoNi5kIZ4SP4VIz/KrkVnEpjcIpKjA+QjP40WkKLOm0YcdAq4x+VassphzmRSvUFnwc0ox6sKjtoik0EJADAKW/hKZGaabQImY3QsOdvp+FWS0wZWQJtPJMjcflTVdEkJaSLceMBsVdkZqTRnlHZSJYQxx95cjFWYovKRfLSUxjhi68/nUruYsZYRk9fmJJp0dy7sVGCDyDI5z+VTZXNOaT2GzRtIu5UUheQTxk1QltWOZJYck9NlXbmdVjHmyoDkEngc+wqkoNyT9ndlToS0mf0odi4JrUSytgZCqwHB5Py4wfr0pJvMiYhFRQOcr1pzExuVkYsDx94gfQClhj3glItpz0HNK/QvzZZtn8+LcHbI4IPB/OieJ1YlIzuA6scg1ct43j2rEnPck8H86juljXiZkAJ/iJwTTtpYwU7MzYmWKT51VCeS+49fwqw88SxYZ0bPTPzE/hVeWJzLtRUAfgE9h9KaIjAwXzI3J4GE5/Olc1sm7jiH3KVjAAHXIGD9BV9X3piXKkDGATVCIH7RtMShSM5L/pWmkpYgpt2j7xFOJFURCpdVSZgw56d6jMqLKEkZ2ZeMk05p7h2dCqnPIZedtVWgkeVT80h65PShkRS6mg6K0bfKoBHUmshkG8LIm4qcjmr00qg4aE5Ayfm4+lZk0pWXdgIp6kn8qTLpJ6mowRNm9sei9abJKAd2W442sv+eKjhlUKMHzJMenapiARk9+TlqDNqzIVlIHLLux60S4WE4LN7gYFTugZPlOcc8dDVN0LDDOWU/eXFK4JmXcuryEBS3GOucVPCZSi7VQKOv8Ak1FdhEkXa3HZT0qZXAiAcgngj1/Ks+up0VLtKxITIEJOMdgO9Zd47A58xIyAeNvSr/nwvuUOeR0HOP8ACqN+oKoqFfc4yD7VMtETTTTIIGcg7iMkdBxx+NSTEEbZQuR0UfN+NMDkZVM+hG3IH41G8xRgPLZC3IcCovYp3uQ3H7sAo5PH3c8Cq/nOdvyhs9AKvSEybXVeD97is+Z181ig/dqcMR1Yj+lKxamtgkkkVTtIZj1DHOPYVBE4ULvUsc8KDmnhhJnylBJ5I7ge9Q7kiKonLn+L0pA5FpWaR3eRSMDHPP5UhO4sy/QLnp9age5SMblJwBt+tQSXsSRsVJBPtz+NO6MmzR01YW1G1imC7GkHXufT861k1CYpbM1jCWN0YJo1gGVBxtPsRXKWMRv9RtIVJjV3AMmenuPetNNR022nmaK61VXkOJHEigvjjmri9DCpqzN1FsX88bsrssrDcBwTk80VWkeMyOYywUklQcZx7+9FLluK5NFAxuCm4HnAJq6lqwGJHZmzyq8CrK2waXkDcOlWTa7wvJGD61fKasoRQuAOAijgCrlrEBksAx7lqk8pEH3m/GpY4fMXI5jHJHrVJWJY6LYxxtjcH+ILxQUjDklwR/sAED8BSMhkYqiEL0y3GfarcMQjUgxxrnrgYxTSYrCQthgDGCP7xOM08ASMyhDGOxPNOMMR7Ddj05qFFZAdkoVQejDmhlJdR6qY4mLMuQCckURoTuAkXD4O4jJpkm4sWUMzY4xyB9amjV3XDthvRRxU2uUWYsKOZAQOpHanStmFypEg7HtSRwKqEsMDvikMKFC5ViB0Pt9Kuz2JvqVo9rsmVUjOCTWnKy7R5JLnb1PCiqhRSQ0SADqcdKmMLqQ8bqv+yeQacb2NJJPUbEJGO4tt7fL3qdIyZVTyiM8k5zmq7RSg72Vhxgjj9Kt20XlgNwCfUc00hNJaolkQwrvKZIyCduCKWMiTyyibm7AjjP1PFWVmLIEAYvnneMZqR/unzo8HsiMOauxhcprbrJMQysH64UYqwsLNIEaRueQMdqik3ISTHsyc5d8YqMS3kaZkaNYzx5q8/pS0AdcCGNWBUuQT0BHNMjmdlCLDMBnrwMfiadDLGIspKS/clDUgic7iAxJ5DO2KYyCW0L/6q3Ifrvdhz+XWqUiXDM6yTx4AIYRjnP41sTHaqgnc/GQpxn1qhcMqTlYdvBJ9vqfepkka05X0I7C3TzNkdwCf7r8AVqI0cKYKQvJ6Aisp53Vv3ixSsCCB0x70onlCkpGsRbk4WknYqUObUuySQMDi3aVj2OcYqF/LTJNuoGeBnHT1qFd6nLbj6ktn8BipYLdppCf3keed7tyad7haMdyN2hXEiW8rSMOctwPxqGbOQQQrfw8Z/SrkdtFvYMrTY5UBySfrVkP8rh/KjQccDJH40WuJ1EtjMgtpCCCN5PBYrzVyCJQubkMxPIjX5Rj+tTRo6xjYoDE/ec4yPwqWJnVtrsp45C+nuaI6ETqNjXtl2mUQoq9gGyaIYyuHEUqgjoTUjFlLcqJex7AUgYuiEDe3XczcAfSh7kXewuyEckMAeCSdvNDCLK4bIU4yefyprrlgspXaeyjA/WqkpZFfyZflz3XP86L2HBOTsizNcPkgmNEHtlv0rPuMSxKYZst0Pr+VVzuYgzMqyZ4O7r74ogdwzM8qMR26c/hUt3Ojk5dRDHFHjec7cZ5zmpxMCBt/dx9ML1NQzNLztEQ9xjAquseZFMpUN67jU31sNpPVm1b7WXgF+Oj8VJvWFcgZ9AO1VIViVAWzuPbPH1qdhuw7AnI4OentVnMxAXKnagjPXJPeqckYMuGbczcsTzVqUDywSOP7o5qNXVQSBtz2xzSGnYFCIAicEDnPQ01SvJc7gP4VU4pJHUgpjeW60m4LliTkcBcUhsnVwesfOOh4xUFy21WLJjHGM0zzgP8AWE5I2gDpUE7R7G5Iz6nmlcFuUrjmXZkKSO3WkMSlywJIA5Yt3prRu7fLwO5PHFTFj5QACJHjgnq1Z2ZvOWmhSuQyjPmKq9Scdqhjbz49nmMePlZsgVYuix4+96IgANUZo3JBVgcDHzGpY1JNak0hCrgEyMOMkYFV5HkciMYIz0xwB/WpgdqgrJl8YKsQAKikuRyoYA45PoaQuboiCZVVWYO6uOPlOKYZtuQNu3qAB1/GnuRJwxGMfjVWURHOXPy4AA60g5l1CVSCXcESHnj+tQK6IcOWOOpHzEmny7TxuB7MxOaQbTuJUqOyjg0WM5SIZfMfYI8RjqxJ5+mKhlfa2W2hegONxNSXFwAjbSBnpntWdLcAENklRwTjqfaqsZuRo6SFl1ezSVS0XmglVzx6dPetaebWjcSGbQbRmDZ4tS2fxzzWFp8VpPCJrnVXsJFYkIkZY49SRVvzLMMu7xRc7R0xC/8AjWkVoYSldmXcXDmaRWXy5C5DKvG3npRVC8lxM+JGkTeQHPWTnr/n1oo5Q5j0ZU2sWIIOcCnBZM4Gee9WmMbALxx2o/deYBng+natLI6OZEUMSx5Bzjoc0QxLJLnblVPT+8fWrBBYMqgKM5z1NRQoqSnGSeOO9ND3RbS1WMAMCO5FSS2MJZXZSG9RUPmyM4K7xt+8wOcVYgmyfus5/OnozN3HrDIMqhK8dcc1nT2pW8G9jhuMtyM1qsxGDuCDvtPQ/jUFw8Trskcbv5j+lTKKY4ysVtrIyDcEb0xnFTQxg5+cFuzZOTUUo2RnMmVx1Xkim21w2452EkcDJB/GlErc0QNwwjE+hIxTt6pFtd0Vyex5+tUny+PNIB/urUkUUew+cqp7AcmquSQSyI0hVVM64xkn5a0bO4gUbJFZ2bkfLwPamTFvLPkxoiY4PANVbSZlmPlbdvU55pLQvmUo6mjLcQtMiwxNIxGeRtFMRSjBSzrKOgB4pJLqRwFRN3ru4x9KjF1hz0RsYCjljV3M1cteW7K29gidNzHB6dqkRJDGilzEo4APLH3qp9sifYHUbweN2fzqQ3TZyhJOeGIyPwouIur5armT58d3OacGDsytEVU+pHP4Cs0mRWMkjHP8IPH1xTmncJtZVJPQZPA96OYLFyRkQFmO3njBzVJ7mRn2KjtyNpBxj61XBM0vySbyvTH3RSXTLFsWUksOQicA0X6lxVy7HIyBjMxLPztQZJ5onxICMLGP4c8HPvWcjbmJRTCx5OwnP/1qYXABSUBjkEDJJ/GpbKSaehYmXZGNrYdjtLIegpscq7jGEZwOST3rPkuDudIAVTPzNtp8E27GwMwH3uOanm10NU9NTWi85F/cKI0z90kEn2HpSyN8haWaLA9Ac/Sq8crjCpCckcFzVbULmQr5QAc99g6fWqvbUyS5mXkv4UUKrxq2OQoORVtJ43AZQeDncflGfpXNwS8FdgBHBb+I1YlkfCpFuzjoD0qVMp04t2OhkvGGFQhmPIPYetRpcbFZmI3t0OMk1ziTtEwUkDvt3Ek1oW0gaTLDn164FHPcmdPlL8WEIZn3Y/vnJP4Uszhp0dy5KjnJ2qKqCcFwvmnB7KMAVWuJ0EhCqd38Ic9fenewowbZqtMHj3M6hBwB61Sv0ZkDeZIq55GMflVIXzll3sSy9DxTZdQCMVB3yHg46D3pcyNYU3HYniMcZ4UlfVhzTp5y2GwiqOenP41nI+/5VjLSep4H1pbgy7AzkY6bQOKnm0Nba6kzfOeU8126YbirUTJGg8xFQjueap287JGF3hW75H8hRIkkkoPmb9v8R7fhRcUn3LrXAJ3xMF9yM7j608XUgIZ1Uq3fdx+tZ7xSxsTuEqngL0xTTLKqED5VB/i5NO5HKnsaD3JLYJYZ7ZwBTTclyAHRUzyO5NZpuRuwzBj2HeojdFcMWGc+lLmH7M2C7vlQfl7Z6U93baoA4H92qcM25fmJZh0VR0+tKGQFWdju/u5ouYtEhYscEYHY9TSoSV9COpNQOzKP4myfu9KYzKq/OS3tnj6UiSVwvzEuM9SfaoHYbWaM8Y+91zUE8rDkjEXGQB0pkjMwwcBTyeensKQ0x0jhsbVbJ4wByKgeX5QiIvPUL2qC7lVOE3c9celVydoby2McY6vn+VS0N6FhztGMqqDggD9aqSyZbBwSei+gqCRi7L83HUA8n6mo5ZUjOQ5kc4JA4PHr7UrApdiWSYJudmXanU/4e9VfPaONWKgEk4U9T7mqkkgJztJHXbnAHuaieZ2kycDAA3HoPehITkXZpApPCIepIFV5ZsxYZmwOh6ZqhPdFpAA7FuijHHuarz3IVQjSBm6jFaKJk5osTzAKfLJD52tt5/Kq8snlkbnII5x6Vn3F/wDKyIMKTyTwBWRe6xBDkvIGOOueB+FWqbZk6h11lo97qduJrWBXt9xVm8xVyfQ5NSS6Bq6kLHZoee0yD6c5rgdH1Nda8Q6fpwd44riULJIOoHJOPfArch/4Re+t9OuX07Uktr28ey3Ndn5HXG0tjscjp0rohQbOeWIS6mbqWreTcSRzkI0bFGG7oQcHmiuR1TTpodVu4JU8po5nTyg24R4YjaCeuPWiuhYGbWxg8VY+n0n2SFACSOWGenpU6O8gOBgdOajTEaF1IOeCSOf/ANVK9wkQ2RHzJMY2qR+ZNeZc9hkjh1IVvLHHXJPFQO7RLkONo77sZNNMjCHEhQHuM5xVWIhJH8sSPj7o4Ip3Q4su28zzMNo+XvxgD2/+vWhECgAZ1CjsD1/Gsf7TMkg4ZSRnbjr+NRSXU8h2sPKHccZP49qalYGalzekyFYtvHV2/oKZHtjzI4bB7k/yqnFcwxt+5IBHXd2pxvVm3bA2McyMMj8BRzAnZFxp2lXMagYPA6Z+tSMkztumIx0IUVnNKBHsC4b1Y/z96ljuCG4chAMEZzk0kU2uhpGWMKCBtUH0zT4XDMXHJxwvfHrWPIfIjLEAjPc9KZBfCchUjPA4J4zRzC5dLo2prsuRBEM56t1xUUG+CXLM57fKMZFZxnKsjSEBem0Dr9KlN+uckEvjnHagW2iNVdib2ZWYe45oVwIyUjCH071i/wBpMmFwCW/hPJNSxzjG52Kseg7mhSuHLymk0qKclcsvHr+FKLg7S0q7R0BLcj2rNbdswg2u3OWbpUQDtJ8z/uwOFBxz607sVjWF0AC2QQo4Oe3vURuPPctI58rPyhTy31qgBbYJVwwBwVLEAetQTXXljai8MflOcUuaxcIcxs/bmiO2OIbSOMkDNUZJpNpEakS5++Wzj6VRUpGpcsTIepB/WgMzEMx2/QZ/GlzNmqiosu75s4kZSRzycc+tI80jRgSFVTkcdTVMyQo5WOZycclj1NQM6sON4x6HJb/61S3YIyUmXTKDhfMQ/wCyoxV21c4AXOAOeOD+NY9swxh3RSeSMc1pLJ8nMgLEYABwAKcURUfQtSybVzIMZ6En+QqhPMS/y5AzlvmPFBjPO6R+BksD/SqJQx48zkHoGPNOTbCm1salucp5jsqIOg3YJ+pqSQxSrhBnjqorNS9RFOSBjuf5U2W9llPyBmX1Y7VX29TSuhOLuWtsdqxxtXvjqWP1qzDeNIgYKFXodxxn2rCkkbftDKCBycZwKuWMibt2HkkIxuIyBSTZpKzWptmYpzkDI6AdBWflJJWzI8qngKq9qpXrvI5VpDt7gnG6pIXMUf3gsa8AYxTbQ0uVXRcWGNcCXy8DoFBz9KVlfd+7t8DHGelMW8jIRgy5I+UdaQSkKTJOmSe/UU9GZ8zvqRtLJAw3MATyQo5omuDKAzgpwcDrUE80QBBZju5wOrGqayEscRgHp1zgVL7GyfMrl9Hcg8FRjIJq9DLuj+RgTkcZxn61mwBwT5rbVH8IPWraThCW2nb0AUULQyqST2LxdnwWYYPYVHL8ylZXA9P/AK9UxOsh3g78cLk8CiSVkBwVJIxjFUncyTsQ3LRxPtVs55JA6elQpK0sodVOBwM0sil25YbmHzHFNQgEENuxxk1NjZVNC2u4jDOT6461YSUKD904HHPP41QjuEwSBtxxk0x593yx9euTxTMpNmklyApZzgdz1/Kq5u+QScJ1+7zVGa4JcBiQgGcDv9KrNd7SdxfnkewoJuarXCY5PPYetVJJ+CRjeOQv+NZr3v8AEpz/AFqpJelgeTk9BxgCgLk32gvcy5dlViMev0qQyhFUKVIHIVj0+tZzTJBhSx3n8arPejcdrFmHGB2/GmlchyNSa72jKE5I5bt+FUJJ0DB3ByckAn9TVCS6CkMw3nsCeKyLzUgZMb8qBgt1AqlTuR7SxtS3nmPtj+ZO/OM1TvbshSM7mPp0OK5u81yCLIaYYPLBT82PTHas261m5lgEdpbsI2BG5x1/DriuinhpS6HPUrxj1OnuNRVIyDJnjk7sAewrn77xGI1Ih+cscZX/AD+tZv2C8um3XM5CdcLnFXYdMgtwNq7hzk4Oa9Cll8n8WhxVMYvsmZNdX99gRAxx+uaZHpe4lp3LsRwvJGa3JFKrgEgDnIxj6AVWcdCFYDqQTXfTwlOHS5yyrSkLoNnOmr2Q0hQb3zl8kgcq3rz2rsdKvbpfEd/pyPoUzyT/AGiDeh+zm5GAPKx0J9+Miua0KW6sNUsb+2tJp2jmwg2HEp7oD3OPSumhstHt7xLyPTPETskglSye2wm4HIG8c4B9s1c0lpYlXOK1BbiW9uWuz/pXmMZQwwd+fmz+NFW7+WW51C5nuAVnllaSQDjkkkj8KK1WxFz6CniRwcY39OO9R/ZBBHtiRQDyccbjVd7iIuwRjnrg9vx9RUT3EhUhklbPQlv6dq+OZ9QkxbgeWS+/ax6KcYpgE5iLTXAReoVABUKyqmSUy3q3IFRSlWxuZSW6dvxxSbKLKlQMqXkduScEk/U0jz44ygGeQOWP0rNyzttiLFB3MnFNEzBisLqTjluwH1oA044lLEzY9kB/U+9SXEnlpu8wD/ZxisxJViwFbfJjOT2FVJbncSxDMvQEnGT7UCNQM7FnkOXIzuOMCmG8CYwhwT06ZrON2HjLFwvYDrUSsBukMpMh6HPNTqO5s+d5wPnKHA52L91f8aiN0EU+UMZ/iznH0qj5qxoFD43ctk4wKalyg+Y8J2yKeoc3Qv29xIpyxZie+efp7VYSba3LLG3oDn86xJLxdmG+71GDyajMylSclSeMK3WizC6OjFwv+sZ1Oey9SKmju23AKD6A5/Sua+2pEoVshugyevvUsd2iYCMxJ65/nVK4uY3TOrnLuxUHvxz7U8XQxhZAXJxhedornXuCy7mfaw4AXpTxcqihVI3d8d/c0xcxu3FwhAGUCjkjHJNUXu0DbRyc9T2rNe5fpJKoU/Niq6XY78nOPrUO5tB2Whuyz7YztwR/ET0xUMd2GIeZmB6BQcVUe7LRkKVOOgU5xVZpYxlAzbzyxpWYlVS0ZtveQqCYo8sevy/1qk11858tSpzlmPf2rLadQdjOxI6lB/OpBLEgzvK+hPIH/wBeizEqkVsbFvLyzueDwABirBuFU/vJ+fRRjaK58Xvyny5mIxlmI/lTBeDDZkKDqVyNx/wp6kudzoWuI8g7jnoBzzQ81uF5LNJ25zk1grexBjg5bHUNz+tPjvQCcMmR1AGcfjRqTzGkzIwQmM7skliTwPpVkTDbtQM7Hu4x+lY5vz0RlLn+7zinidi43uQvG7Z3pWZbqPY2EaGMYkA3H+E9Sak+2BUIiVlHQse3tWGbsQ5ZdyD1HJI9z2qEXe5SRjbnkjPNO7Q1rqzVe7UuTF07u1DFncmRXkX+6TwPwrOFwAu0kgkY2r2HvTGuvKJMjDaD2OaTTNFURvR3Pl8lAuAPlxzTvtYyWcKWPTNY/wBuUqVVyGPU56VTNwkbYSQYPU56U7Mz5k3qbst8mMJHg9ie1VoLjEuQHPrk4BrME7yuGLYHQYqQzxI+0vz6E0rNl+1S2Nia+aTC/wASjg56UxLojIDkhuSM1lSyxknk59M1B9oYZAY5Y8CnqT7SPU30uFA5VVUcYHpTBeksRjCHgN3rnzMpzvl37TnBB5pzXQlBZ5NvJwq09SeeJvTah85O4lscqBVWTUCzFeBx90VitMrcszDHHXGabJf28HAX5/QUkmw9pHoa4veMHA7HNOe/wSFHzdAAM4rmJ9UL7dq9fWs6TWPLDDIAAyScmrUJCdSPU7J79FbLN8x7df8A9VVLjUDxg5I6k1xdzrkeDl+nXLVn3XiOExhfNOPr/StI0WznlXijtZL4SOfm4z2qtPqccIJ3/e4APX6159P4kfkQqwHTJ/8ArVQF/eXLEIQM8E4rWGGbZjPFeZ3txrcavhm6dfesy48TQKNsW5sf3etc7bae8xU3DyEkdN2BnsK37HR4FiUlflKgAdOe9ehTy++stDjqY57Ipy6pe3ePJiKg8jcc5/Cg6Tf3DD7ZMyqeSifLXRWcSLwihOew5bFSSNt4DEjAGD2PYn3rup4OlDpc454ic+pjwaHBAiblDuTkD19qtrEnlhVQYxg4HerCsfM2Esp9/Wk3LjKE98jPJHqK6VFLYxcm92QFX7gnBwrZwB60xsc7eMDKmpm+dVIXjd1BzUBDKQdp45Bxz7c1RJGD8o3AFMfd6VVkCmXC4Cr3A5BqeXCbfl4PGS3Q/Somzuz8uO5Uc0FWLmh/a7nVNOsIru5gjM4aPyuTE54LgZHOO/pXVwPbXGpCxi8c6wZnfy0k8s7GbPQNu9eK4/Sriew1K1u7UZuYnUqpXO7npjvnpXbnSVsn/tK28KXH2+I+atsb1WWI9d3lj5sA/wANYVdH/wAN+ppA5PxDpSWkUd7aXsl9BJcSRStLH5bxzL94OvqeTmik1LVftmlQWaQOkgme6uZmbJnlbqR/dAHaitI3tqS7dD1W5uYQFQB8njcozj8arO6sThpserHiuOvPGWnRcfaFGePlPasa78b2ZJRFdwOhA618mqUnufRyrwW7O6nvmEvkxlWOc4x0qOa4KZaZmcngADaK83m8aMObeBhnjG4DmqE3i27kkyq4JGMs9WqDM3ioo9Ma7kb5Q5WIf3cZqE6lHHHxhQo7tnca8vm8SXzjaWTHqDVSTVruRgZJeKaw/cn62j1Q6wv3gjnI6Zx/kVHPqjGMeY+0n0xXlsuqXRPyzsVHHpUZvrg4zcSZ7DNUqCJ+tnqL6sFwTICgHrzTYtYUENnLdga8se6mIAaZye/NKLqQLgTy5xgAHGKfsET9a8j1c6tCrN5xDSHsRxVeTXYvmbcA3RUA7V5f9pnzk3Dk/U1I00yQKTctub+AMc49T6U/YxF9aPRxqwf72Cfb+VSSazGoUJIit0YeleWi5kycyv8AnSmd8jErt36nFHsYh9aZ6gdYjzvMxK9OQKk/tyBY/wDWAnoBntXlnnvkb5HP400SN1LEn3Jp+yiL6yz09NajL/NIMDjr3qwmuxc4ZPz615Q0zFMeZIW+vFKZJQM5K8YGOM+9P2MA+ss9Pl1yJpMhgQD36E1ANXBLszBQeflrzj7TNsAWU7B1APX60n2iUj5nf86XsolfW2eoLrUKqFB2nqSMUw6zEWwWKhuo3da8xaWTH+sbn3pPOkwPmbj3o9jEX1pvoenDWoI1OWAP93JqKTW14AkTZ6V5sZ5CeXY/VjTd59T+dHsoi+svselHWlcnMxx2xjioBrcQRlQpg+/NeemRm4JP0oZwOB+nFCpRF9ZZ6LHqiPnaibAPmOc1I2qxKPk2KfTsK82ErAEIXTPoaXzpAchiDQ6URrE+R6WuspGmN8Z/4FgmrEetyED95GBnBwK8u898HMjnPXJpwu5ACC+7P6UvYxGsV5HqD6qX4cjnqM0NrGxQTgAdh1xXmC38yfckYfrTv7Rugf8AWknOeQKXsYlLF+R6WNWG4rGuc9Dnk0smplSOMv6k8D6V5udVucDEgAFNXU7lejgr6EZp+yiP60elx6op5JJC9zxUi6mCQQ6r6nGS1eZ/2xcgjayjH+zSyaxeOzEyY3cnaMUvYrqS8SmelnUmZjskbHbIANV49QKs0nQk4wBnjvzXm/8Aad2RzO59MmlTU7tMATNj0pqlHuH1mx6S+tEbskr6ZNRT62sagbsHbkfNyQa82a+uGI3SnjtUf2iYHPmNnv70/ZRIeIbPQzr0SgEkjucnrVW58TxcEk/L0A71wTOzHJY/nSc+tPkj2J9vLodhP4oUgBVYgHk561Rl8SMeY4yT2JNc4TRmjlS2Qvbz7mvPrt3KpAYLn86oS3k0n3pXI69ark0lMzcm92OZix5JoCknim1IpxV048z1JbsSwxqWBk6E8/StOH5doAxg9B3wOtZ0P3hkA8+tX4HB68nuPwr16MFFaGE3c1bLl1AJwxJ5Hb1roLOZCig5A6gdz74rnbcFQSpz0T862rNNmMj7gwWz3roSMWWIph5sgTLdx221JJtAO7aDgdBzj1qKQrHMWVTlgeWPJxQys0eEYx+ueeKoljZidwYk+lRtlWGMM2cgds9x9KkCZAGVIUbS3r6GnN8oJLfL6oeTQSQByTgK6BuOnT3zTiWbOAWPPU8CnqF+cIBg8nP8PvSOflBbBYYGR6+tA9ClIilMogIXpjk/jSLl3AGxSRkj0q0yYYkgg9R7+tQMjR/d5wxyCM0AmanhuePTda0+7uMvDHKHYBclR/eA9uv4Vrw6L9l1qLVZdesfs0Uwn+1JcZlcA5xs65PTHvXNW9jfXUQltLW6njVjzHGzAe2QK0NF0TUP7asTJpt2qC4jLFoGAA3Drx0rKfV3LWpm6m8d1fXdxGhijkmeRFA+6rNkCin65Mqa3qKKAFF1JgY6fOelFWtge5wq2N0/3LeTHuMU9tOuwR8qgn/aFdUcFcgurYycdqVQCd5DdfQVyLA00ae3ZyY0+5DYKLnvzUn9lXARSVOCO3NdTHCrHegQEckY5p4BHG7DL3H+FWsFTQe2Zyn9lydiwIHTHNMbTpeoR2Xqe1dc2Ttzknvz1FQScKVzlcYHFP6pS7B7VnL/AGFskbHX/e4qVdLkJHPLccc104yyhW3/AC8cLUixhWwC4B6gDFNYWn2F7ZnNw6HI7BckY4qRdCffhicDrgV0ixFvmAbAPAxzn3p2yRhhs46EdzVfVqXYn20jmX0PaeHZlPTtSNoW3qzDPTjOa6IIImLCPAztwDVlo8gjbluoyeCKPq1PsHtpHLf2AcL+8UZP1qx/wjYPPmMxPQ9BW9G+xySikj16flTyVckKTgHkevej6tT7C9rI5ZtBIdlXcwA6hhQNFUcOkpPsRxXTMCVyy5JyfrTgwfOe3TjrT+r0/wCUPayOak0BlUsu7gcqTVdtGcoHy5wOfYV1xALbstkdPSmeXkDqWB5CcdaX1al/KP20jj/7MduELnHtxTf7MlD4xgdc5zXYT26oMkYHfrz9KiEaxyFRGu0Zznkml9Vpdh+2Zy/9iznlfmHUk8AUq6FdnOQPwNdYWYjEe3HB24x+dMjHPGTnPNL6pS7C9tI5UaJcHIVWJHFDaHcoAXKrnoC2TXXPuA6ZOOc9qiDs4I2rxx1yTT+qUuwe2kcm2kXEYBZefQU0aXO3zKuSO1dUqMPuHBJ28Hj/AOtVogLyvygEHcOefap+p0uw/byOKOk3YxiMsMZzUL2NxH96NvyrvdhKg7gAehA6/WomiQtghd/Sk8HTD27OD8iQH7p/Kk8pz/Dmu5NqrsNyn8eaHtYhkkANjoBzU/UafmP25wrQyA8ocU0xuOoNdu1uCVMcYwex71FJEuAQN5PJ6cVP9nw7lLEM41Q6sCFP86GBLEnqa65rffgbVGerbaDaR4+VF9+OaP7OX8we3OR2N/dPHtS+W+PuGuu8hVB3plh681GYgxBwWxxgHOPrR/Z6/mD2/kcoEfsp/KlEUuRhGP4V2McCcNsUADB44qSKFBhtij6ihZfHq2H1hnGG2nPSJ6X7JcYH7p/yrsnjG3OOcZ+U0IgGXVSCcFlJ6iqWAp9yfbs5Eaddn/lnge9SDS7kg5VRg+tdW+EI2gMMcHHBP9DTWwTggKR+h9apYCl1E68jmRpE5xkqO/WnLpBPWUflW+43Ke5B6+tHA69yMDFaLB0l0F7aRhtpSIoy5b9Kq3NssSnHWuhkQEYAPAH4+1ZGojnGCD1we1E8PTUdEVGo2Y5qRBnFRt1xUsR+UCvJor32jolsTx8E8+narcGQM4+UccVTQ4bpVqAEON2QDgf1r1KfYwkakOVVcHBQ4AHv71rWhB6NkfTqax4GBIYrkk7j+PWtqxwCoAIGME4/Kt0ZstTQPhWbDAHNTlRgkk9MmnOo2sBnn8P0p4CtGAgBz17YpiK8YwxBJbnK8YyPWhhk5yoB6k96lykeWG8nAxnnikeNmGGxtHT1xQTYh2kg8FWPTnj6VJ5a4IYZVvWhVYkbfTOT61KEXA5fJ5yelAiCVQVA4xjKgVWdCVLbgQeM9Kt7CzAliGPHTANQMpDYIzjIIFABZ6nqNinlWt9dW0WdxWKTAz34HrU51/WMknVb9fUecetX9E0Sz1O1u5JNT+zyW6l3hEBcmMfxDB59/Snrpeg7SF8Q9wwP2J8gfnWbcL7fgWr2OUuC7yFpCXZySxY5LHOck+tFWbyNEaVYpPMQMdrYxvGeDjtRVk3IEy3rgH7vbFSfc6kbeuSM06XYrDa2XODjH9aQyYJYZz2I7VQhU2D3J5x0NO3ckHH++ByPpUalWDABce3JJpWlGBv2kjsOlACEMVAI+UdMdRTFzkIxIUHr2/CrDsTJklcEYAXt9aYYmBUknPTkUBcVCN/3s56c/rVhVIkHBwOc+1QgYTLL8w9PX3qRcqNpwAeACecd6AJTjC5JLH36CoHbGMryOo5I+tT8E529sEZzgVGWDMMlTtYA470ANHLITnI6cdfU1MhBDFW46bTUUuAwUBenI70ZcgKNysTyCOKABipYhep56fpUy54wAxHJHpUfC4HzDjqOtOVcYDZXOOO5/GgCV4mYDDEj06Zpuwo43MOuMA9KmilERw20KSOA3NVpXIkZQVwxzkjk8UAWEKFgM569RRlVHT5jwMdqrI4Vshm6Zz6mngsVUbsjoPUUAOlfK4ZWGehIqJYz/cye5NS7ZApZT869h/Q07eyYyGJ67epGfWgCIx54XaSf4iagcBiFHAB9OntU7T/OeB0pNyldo4x+H/66dgBguOhJY9gKiwQ5BX5vRe1TDyiAqYGcY55NWFjCqNuMe/U/Wk0BSaJmbEgBOeEHU/SnkbScj5cDK+lWAiKcghQf4h1WmvAeWRgCw5yBzQBGo3JhSMemePxqNehACt1OB/KpNjEYOCP0FP8AJGccbcU0gKyscBQfLzyM9B+NPRAFIxk55J9KfIu3lhwMkqO9CPleTnjGG6UWFchlyxUEZC8k9xUaxZZSG29enOasOc52hl+XJ4/pSEMy/Ice/TNFgGMuDuGGHc+vtiojDk7gcg9PWrGHjUEHkHBx2/xpyFcbjnbnkngg07AUJUKkZJUE4znp61EqkAZBz+VaN2qvnJTPUc9apYLHKqeuSD0oGNHysCWI+lSBchB8vTJyaGC4UN8ufm+tIFLLhcngjjvQIWX7pUrgZzkGmjLchskAkUvzAAEexNAbYvTjjtk0ACx5GFBGefm7+1RMpVc9c+p6/X3qyimTkgbehJ70wo5LE44ODigCFUKqvJ5HGP8APWlAJUEE8dmH86lZQCWIwFPOe9CsCQEIyOaAIJgcHgY9u3vmsq9jHPXoT9PrWtLlRxj3A71m3oyCeOetJ7FRepzki7ZHB6iiA9aW5G2U54yM02EjfXhpcld+p3bxLWDirEQyQAcgnnj1qBf6VNAcNknoc16cTBmraEg9VUHnrwOcVr2hBboQuNzHPvxWJC2OCeADwfpWrakgY3HYBg+ufWtkZs2wS6IW5LfoO2abbyKU54JJBx2I7U2LmJtxwD8oAOOnbNJEv3127cNu4PT60yLj3bL5TBIPIqRiRxkZHJyOo9aad2QVB29cr3pz5O05JK84PoaBEbqzYAY8frSK7FBz05CngGnyOEbb2759faoeQcNwucg+maBAhJJUnI6DnFGQy/dIJHQ+o60EfINwUqpzkd6a5PzCPgYJGf1FDA0tPs9TlK3Wl2t04GV8y3Q4zjkZHscYoHh/V9oVdIvfQDyTUegald2ZngtoZ7iK4jKy20RIPP3XBHIIPem3R8QWkZe6XVI0HJdt4H1zWbbv0KsrGZco0blZEMcina6nqDnBFFRtKXXcx3nOdx53e+aKskGwoXG5ST3PX6UhZsdMDoDnJNPJwOnXjcD/AJxT8bsEEK3rjJqgIVHXLHnOABzTDjlCVyOuB0qyGBZQGwCM7sVGqHzNud69CwWgBFTJJBA5Hf8AlUrDepbABHXHenRqGK9M/dBK0/nYCGU/3sjpQAyNx8u44B6gHrS7pDvbepxwfTFIybcEAsHPTgD86ekbsygknYO3A/OgCNUfbzhieQecGpChBztGMAkE/rihiQfmyPYc5FKvBAAPrkHt7mgBBGpBYr3zuPf6VMIVAGFC5OBvNN3IpDHaA3HPOKA/BGVc5zvHSgB4V+ASNpOCQMAD27005UEksy4xngYNCliyktvHbNKzFpMhVJHGOgoAZsMSqyLwemOTULKF4IO4DqeauDODl2LDkHHH0FRldylMBPc0AU1J2Md2D35/Sphwy7s4x3OcflTX3qW4IxwfemiMhemAPmPrVWAtIy85LZA+Ummv8zbgC3OOScmowWyTtwD1B7fWpIWD4/vMM5NFgFdcDhsjqc/40xUJdSuCM43HoakIPyjG5Tk7R2pQAUVSMjGVH+NAERjA+cZA7+/0qRX2uFbJOMbmz+FOZ1wSGBLL90DOBnpUZH8ZBA9uTQBIVcHJc7em0cimTFolGUBLHnJxipfM2rhiOwI7t6fjSPHlwWzkDJOOtFgGQy7lMYHPXBPX6VJJKAMkYPHJHFQzh1BChQR3J6/SnrtZMuGZvXGKAB8OMAZP94GmNjJXJHsT1pxj52gcnjgc+1NA+YFs8Z56596AGFWzkbd2ONwPIqLLKSexPfpVh4iVK7irD5sg8VELZmAIYADnJPX8O1ADQCc527FHTutMA+bPD9cN6/UVYlhRc7QynqcH+ftUIUgnHCkZyORQAMzFG+8cjnH8VMEaDChsKG4x24605AwXIOUHUKeQfWpS+QBhQTyDjk+tAFby9zEja2Tzz1/+tUa5XIYqcDHFWI9pY4xnHXOB7UsqcZQ54644J9KAIOMHIKnGOR3qTKOp4BYce9MA4yMqQc4PXPtTSSehwBz7mgCRQNvBBYLuwMClcPxvBz3HsKVXGQMfNnjkVIyqY2yPb3p2ArRBowRngcEdcj3pzgHG3k44bFKGI+Xcu4j5eOv1qJwCCwzkclRxQBHIAwxuAGPoRWdcgfMFbAPIBq/82OvB5Ge4qpdkoCW7+lDGjnNRX95mqsXDir2ojIJ9DiqKdQa8TFLlrXXkdsHeJdSp4gPb15NQL0BqSLgE4zgd69COxkzRtGOQc4GM7vTua1bEZYBsjuTWVb+nXHPTqO9a1mVQHlhuBJ559hjt1rZbGbNm3DEKAN2QTgnjIp5UpNs5VGB59T3plnwM85IGOPu4/rU8oAdGZ84JbnnqKZmNbKY2sFXufY1IG3L8mcg43eooZFKkj0x7f/qpMFhtbHTHHTpTGiOUblPGR3x0BqD5wFK4ZfQnqO9TOnRlOAv1yKHXHAA39R2JzQSMiRSCDkfUcYpzoAo5U85HPINLHI28DI391PGaHkypDAc9DQBvaH9pn8Py2ugXMdpqJuCZ18wRySR7flCseoBzkZqTSLLxPY38VxfXbWlorg3DXNyrRlAeRtyc5GaoW1tp1vo39o6tay3jzTm3iiWTyguACWLDv6VIdEtrnUNMvdP3z6Tc3KQzxynLwsTyj/Xsw61zytd/5Gi6HMak1u+pXMlmhW0aVmiQjohJwPyoqTVI0g1S9ij+WKO4kRVzkgBiBRWy2M2Jvy2xgF5wFUdfqacrKAPm2AHJ2jJFRghlJdgoBxs7mlUkjOAmO5PSrsA/H9zO70JFOEZYgk5A7dKarBiq7RnnI7mpMBBtcAZ5Crzn8aLAG5VYAA7x1701nAds84/hBwBQSSpPyq2Oi8UyRGzgBTgZOPWiwCluGOQWHb+lG5nVS4ZjyT3p8aFDsdlVD1HoaJBujH3mAO3A4oQDFd1wxIQsMYAGSKaWG5QAWIPyjNPaEHhVwrY4J5+lSiJg2Q4B6DoT+NMCPGXY4KhvvgVIMMn3jz04oMfzDc546HFSmNlbJfg5zxQBGCzDceo65GamRNzkbW7deOaj2AHjJ7j3FWIj5j7gWJ6k0DSBbf127c8EcmnSQBQ3Vnzz2zVxmBH8Hvio2wc55B6ZPNBVkZzqFJKgsffqahdQCecKR8xA/Kr8qryxyR2yP0qE4IAddqH8MUE2Kyk4ORnbzjFLG2Tyfm9QeB/hT2U7l2ngcEn+dLhFUZGVA3AKOnvQIfEwO5OcE9adGAAuwb8jG73qHdnIRVOTkGrIfDDI3DGc44YigCCTCtiPcMHoOQfanxJtO4MoHYgckU6UxIAyyADqOxU1CkvybuQucE47+tADZ90ZIRQS/wDe7ilSRigBXdtHVjkVNN/pES5JXHPoag2hc5Ib0/2h70ALsy4zlz79PwND7k4zjPUelPUqMYDMPYcfhUkqeZGwDEkditMCFCu3bjkgf/rpTIc7EbPTBNVowobaEIHHXIHX1qYn5lEg2BvukDJFACnLMD8qL3B9fpTkR2kYryD3PH4GgkEAkhT/ABHqamQ4VTjcCOATnd9aAHeX5nJJYU2SPaRjB9iM0/fng7c9Rj196cW+fnGOh9aBlZ4lAJwu/p6Zqq0caksgGSd3fPv/APqq3KN24ZwMY+lQnBGQCqggnb1BH60CZWBG/I5PXlcYpHnIBJwxJwQO1Suig7juKdd3f8aYybQWyAmeMDv/AIUAV5G3FTv9hxjApm4nO0FRjnHNOWPeAAGIJ4JPC/hRuKrkngdTigBGOAoIypxwR+tT+YyRnacBe/uKgQnB/iXkDPGas7c5PAc8DOMYNAFaWQ5IOdpPI6n60YVicABjyR7UOnUgqR19KaIso2CQyjkimxC4OM4DAnqaoXWRktggnp6VqlDtIwQucjpgcdKqXEeRnC9M4Hp/jQikcxqAwCcdazU7fStnUkO1l5446ViA9MV4+OjaaZ10ndF9GGAKnhPIGM45NVYiNoPfNW7fhg2ORXXSd1ciRct2MaludoyCR2B6CtW1KkopXDcYwepz/Ksm2cDBxlcYHtzwa07QkOCDu+UjOO/pW5mzetJCUUl8ruyffNSvvGRkhQePeqdmciMZGQFDD2NXzHuVgCy8flTMxC42BTgqeD3xR5g2rtxjHJPrTVXGQeDxwep9+KeiFCUyNrHdnHQVVhDt+5g3G7sB2HenAJsweF/vHnFNyMYOOvBJpyjaSGPOB0pgVzDvXClWCnkN3oeMAf3VJ6deasS+Wd2SDng4PSonbKsMEhSCAR2NKwEkOpz2dhdWTrHLaynDpKoba2MBlz0b3qHR9autFuPO091JIG+N/nSQA9CP61uaPZRvafaXjgeSXf5X2nmKJIwC8jD+LGQAPWobCYataO+pi0aON1R/LgEU0CsdqyqVADKCRlT2rGTWqt6lpPuc1cyG6vprhwPMmdndccfMc8fnRUk1u9reSW9y2ZYGaNmUcEgkA0VovIggaIH5cqqHqSecU9QoQAlT6BRgD60+IAy8gdaeQPNIxxk1YBjIIG2NfQDp+NIPlGURSO3P64pmSZ8EnGOlQ5zcKD0oAsJnJHLN1BB4qeNT1K7eOee9RIAHkIAzmmwEljnnk/yoAlDbWL4KEHDccfWrIUcDzOvdRWfGcl884I61ahY/aI+T09feiwxTCm/Cjcx6HPWpYxwMBQQe4/nUzDEORwaIf+PcHvt/rQA1VHIBxnkj/ChwDxuOTxtxVpgBuIFMUff+lAFYoyjO8gDgEdqYG8tQWzjOcimMTuxnimj7v40APN2QV5U4/D8alWc7Aclnxnp0/GqqgbhwO1SMT++5/wA4oAm8zccOQZF5AB6/4UFTnnGewOCc1EOImI6+tSAfIf8Ad/rQA0xszBioJJwRnAFQgMNysygrj2BFTTf6g/7tIADtyB2/lQBDGx4AfA54HT8as28qruRQTgEE54xUUQGF4/ipbxmGMEjPvQBI0e9ztXgHucg1HKMpkquzPB42j6CnZOxeeuf5VE/K4PIwOKBEvOwMxLMBhcHrQrkRgBBx2I5/OmxAfZlpWJ8hee4pgN2SMzP/AAnkKMUwMULcKRjnPWlk4PHoaSD7zfQUAOk53Y3ADkENjio0Y42qiqRyBu3GrLAZ6D7tQKOPzoAVdgOW2lyc8HDEd+KsKYwm1GCnqCf5VWYAJkAZz1oBOG570ASiRGO1W+QEdRz9aVphnK544AB6/hUC/cU9yxpJ1GAcDO0fzoAcXLsBnIA6NxSDO9XLEsc496gP8H1qZOXwem4UADQ4bdk5C4J6ginfLg8cYwQTSMT5/X+KnOB58nH8NAECoo3LxnGdy1C6lWxnj3qVP9Sv40rgFDkelAFQAbOFyfQmnZPl4U5AGcUkfO/NWbYDyX4HWmBAijILZ3c49wakIBUbiAAMkkcmnr98/T+tRdh/vH+dDJY5nTfhfmf0C56d6ryqcsQQOSV45zVuQAScDHJqo3+oz32jn8aOg0YWpgFSBkjrk9q5l/lYgdjXUaj0H1Nc3N/rG+teZmCVkzrw+xNbHcnNW4yT04PWqdp9z8auR/eFaYf4EwnuW425jwOSCDj9K2LMgoHIGSuQoOPY1iADenH8Valvwox/fYfpXUZM3bTbsK5PX73fHatBflJbZ8xGQ3vWXD1i/wB3+tXrfmYZ5+c1SMxzFixbLDBzk8U4EqhUNtDdSOab1mcHpUjAean+7TExVG9QNvyjuaYW3cLxg4Y4609vv47YFNuvvD/eoAaQ+TsTBPvyaj5EiyZ54BJ44qY/6nPemyj5JaANnR76OO1W1klgimgdjCZgTFKrgB43PYHAIPrUkT2liknnwWdrAxWZore7NzNc7TuCA/wJkAkmsC4+5F9D/KqUQw8eOOD/ACqHTvqVz2H3E7XV5LcT7RLI5eQc4OTnA/Oiol/1DHvtH86KrlIuf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lesion identified by the arrow represents an arcuate lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40931=[""].join("\n");
var outline_f39_62_40931=null;
var title_f39_62_40932="In vitro fertilization (IVF)";
var content_f39_62_40932=[" <h1 id=\"patTopicTitle\">",
"  Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/62/40932/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40932/contributors\" id=\"au5323\">",
"       Richard Paulson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/62/40932/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40932/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/62/40932/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40932/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/62/40932?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      IN VITRO FERTILIZATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     In vitro fertilization (IVF) is a treatment for infertility in which a woman's eggs (oocytes) are fertilized by sperm in a laboratory dish. One or more of the fertilized eggs (embryos) are then transferred into the woman's uterus, where it is hoped they will implant and produce a pregnancy.",
"    </p>",
"    <p>",
"     This topic will discuss the reasons IVF might be recommended, the medications used to prepare for IVF, and the outcomes of treatment. Other topics that discuss infertility are available separately:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Diagnosis and evaluation of infertility (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"        \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Treatment of infertility (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=see_link\">",
"        \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=see_link\">",
"        \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"        \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHO SHOULD CONSIDER IN VITRO FERTILIZATION?",
"     </span>",
"    </p>",
"    <p>",
"     IVF is usually considered by couples who have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Absent or blocked fallopian tubes",
"      </li>",
"      <li>",
"       Severe male factor infertility (sperm counts or sperm motility is low)",
"      </li>",
"      <li>",
"       Advanced reproductive age, as time to conception is critical and pregnancy rates with other therapies are low",
"      </li>",
"      <li>",
"       All other causes of infertility, after failing treatment with other therapies (eg, endometriosis, ovulation disorders, unexplained infertility)",
"      </li>",
"      <li>",
"       Ovarian failure, although donor eggs would be required in this case",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Although IVF has a high rate of success in helping couples to become pregnant, it has some disadvantages as well, including high costs, potential risks from fertility medications and invasive procedures used, as well as an increased rate of multiple gestation (ie, twins or triplets). There may also be an increased risk of some pregnancy complications, such as preterm birth. Ectopic pregnancies can occur after IVF, although the risk is much lower than with other fertility therapies.",
"    </p>",
"    <p>",
"     Women who are considering IVF should discuss the risks, benefits, and alternatives with their healthcare provider and partner before treatment begins. In most cases, several cycles of a less expensive and less invasive infertility treatment are recommended before considering IVF.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      IN VITRO FERTILIZATION PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     The IVF procedure consists of several steps that take place over a period of weeks:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Education of the couple about the complex steps involved in IVF, its risks and benefits, and techniques for giving injections at home.",
"      </li>",
"      <li>",
"       Stimulation of the ovaries to produce several eggs",
"      </li>",
"      <li>",
"       Retrieval of the eggs from the ovaries and obtaining a semen sample",
"      </li>",
"      <li>",
"       Fertilization of the eggs with sperm and growth of the embryos in the laboratory",
"      </li>",
"      <li>",
"       Transfer of one or more embryos into the uterus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More than one cycle of IVF treatment is often necessary before pregnancy occurs. Unfortunately, some women will not become pregnant despite multiple IVF attempts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Ovarian stimulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first step of the IVF procedure involves the use of fertility medications to increase the number of eggs (follicles) that develop in the ovaries and control the time of ovulation [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/1\">",
"      1",
"     </a>",
"     ]. The stimulation regimen is selected based upon the woman's diagnosis and the physician's preferences. It is possible to perform IVF without ovarian stimulation. This is known as &ldquo;natural cycle IVF&rdquo; or &ldquo;unstimulated IVF;&rdquo; usually only one egg is retrieved. However, the vast majority of IVF cycles worldwide are performed with some type of ovarian stimulation.",
"    </p>",
"    <p>",
"     The ovarian stimulation regimen described below is an example and may differ from that recommended by your doctor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Many clinicians will prescribe a birth control pill for the woman to take for one or more weeks before beginning IVF. The pill helps to prevent the woman's body from releasing hormones that could stimulate natural ovulation.",
"      </li>",
"      <li>",
"       The woman will start giving herself injections of a medication (a GnRH agonist) that helps to prevent the body from releasing hormones that could stimulate ovulation or allow premature ovulation. This medication is called leuprolide acetate or Lupron&reg;, and is started approximately one week after starting the birth control pill. The injection can be given under the skin in most cases and is not painful.",
"      </li>",
"      <li>",
"       Most programs ask that you call on the first or second day of menstrual bleeding to schedule an appointment for blood tests and an ultrasound. The first day of menstrual bleeding is considered day one of the cycle.",
"      </li>",
"      <li>",
"       On day three to five, you may be asked to have a pelvic ultrasound to evaluate your ovaries and blood testing to measure hormone levels. If these tests are OK, you will be given a date to start giving yourself injections with FSH to stimulate the growth of egg follicles.",
"       <br/>",
"       <br/>",
"       In most cases, you will give yourself an injection of FSH once per day, generally in the evening. The injection can usually be given under the skin, rather than deep into the muscle.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       After a few days of injections, you will be asked to have a pelvic ultrasound to measure follicle growth, and a blood test to measure hormone levels. Depending upon the results of these tests, the dose of FSH may be increased or decreased. Blood testing and pelvic ultrasound may be repeated several times during a cycle.",
"      </li>",
"      <li>",
"       In some cases, a class of medication called a GnRH antagonist",
"       <span class=\"nowrap\">",
"        (abarelix/Plenaxis&reg;,",
"       </span>",
"       <span class=\"nowrap\">",
"        cetrorelix/Cetrotide&reg;,",
"       </span>",
"       or",
"       <span class=\"nowrap\">",
"        ganirelix/Antagon&reg;)",
"       </span>",
"       will be recommended instead of the GnRH agonist. In this case, stimulation with FSH is started immediately after stopping the birth control pill and the antagonist is added once the follicles have reached a certain size (often around 14 mm). This medication helps to prevent premature ovulation [",
"       <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/2\">",
"        2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       The goal of stimulation is to have at least two follicles that are approximately 15 to 18 mm in size. The number of follicles that develops depends on the ovaries and hormone levels of the individual patient. In most cases, more than 2 follicles develop; in some cases, more than 20 may develop. When blood testing and ultrasound measurements show that the follicles are \"ready\", you will be instructed to give an injection of hCG to trigger ovulation. hCG stands for human chorionic gonadotropin, with brand names including Ovidrel&reg;, Pregnyl&reg;, and Novarel&reg;. hCG is usually injected under the skin at a particular time in the evening. This allows the follicles to be ready for egg retrieval during a window of time, approximately 36 hours later.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Side effects of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;FSH injections do not cause side effects directly. However, the ovaries become enlarged during treatment, which can cause abdominal swelling and discomfort, and in more severe cases, nausea or even vomiting.",
"    </p>",
"    <p>",
"     Ovarian hyperstimulation syndrome (OHSS) is a condition in which the side effects of ovarian enlargement and abdominal swelling become extreme. The woman may develop severe abdominal pain, vomiting, and if untreated, blood clots in the legs or lungs and fluid imbalances in the blood. Mild forms of OHSS occur in 2 to 6 percent of women undergoing ovulation induction for IVF. Severe cases of OHSS occur in approximately 1 percent of cases, typically in association with the retrieval of more than 20 eggs.",
"    </p>",
"    <p>",
"     The risk of OHSS can be reduced by canceling the IVF cycle when blood estrogen levels become too high or there are too many follicles seen on ultrasound. The IVF cycle may be cancelled before hCG is given or after the oocyte retrieval. If the cycle is cancelled after oocytes are retrieved, they are often fertilized and cryopreserved for use in a subsequent cycle. Because symptoms of OHSS peak approximately three to five days after egg retrieval, the decision to freeze all embryos may be delayed until this time. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Storing unused embryos'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Egg retrieval",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 32 to 36 hours after injecting hCG, a procedure is performed to retrieve the eggs. The physician inserts an ultrasound probe into the vagina and then uses a needle to withdraw the egg from each follicle. The procedure takes approximately 15 to 30 minutes, depending upon how many follicles are present. This is generally done while the woman is sedated.",
"    </p>",
"    <p>",
"     Serious complications of oocyte retrieval are uncommon, but side effects such as pelvic cramping, light bleeding, and vaginal discharge often occur. If these problems are persistent or become severe, it is important to call a healthcare provider as soon as possible. Abdominal swelling and discomfort may also be signs of early ovarian hyperstimulation syndrome (OHSS), so close contact with the healthcare provider(s) is a good idea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Postprocedure care",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the retrieval, the patient will be monitored in a recovery area for a few hours and then allowed to go home. Due to the effects of the anesthesia, the patient should not drive or return to work for approximately 24 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Fertilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the retrieval procedure, the eggs are combined with sperm in a laboratory dish so they will fertilize. In general, approximately 50 percent of oocytes become fertilized.",
"    </p>",
"    <p>",
"     In cases of severe male factor infertility, fertilization is achieved by intracytoplasmic sperm injection (ICSI). ICSI is an option for all men with severe male factor infertility, regardless of their sperm count. Only mature oocytes can be injected. Fertilization rates with ICSI range from 50 to 70 percent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Embryo transfer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately two to five days after the retrieval, one or more eggs that have been fertilized (embryos) are placed in the woman's uterus using a thin, flexible catheter inserted through the cervix. Most commonly, embryo transfer is performed on day 3 after egg retrieval. The catheter is inserted as gently as possible to minimize uterine cramping; traumatic transfer procedures are associated with lower success rates. Anesthesia is not usually needed for this procedure.",
"    </p>",
"    <p>",
"     Following the transfer procedure, the woman is generally encouraged to rest at home for several hours. Although studies do not show that rest increases the chance of pregnancy, many women prefer not to resume their normal activities immediately.",
"    </p>",
"    <p>",
"     Most clinicians will prescribe a progesterone medication to improve the chances that the embryo will implant inside the uterus. This medication is started either on the day of retrieval or the day of transfer. There are several ways to administer progesterone, with the most common being a vaginal gel or suppository, or an injection given into a muscle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      How many embryos to transfer?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The number of embryos transferred depends upon the woman or couple's preferences, the previous history of pregnancy and miscarriage, the woman's age, and the quality of the embryos. Younger women (under age 35) in their first cycle of IVF are often encouraged to have only one or two embryos transferred. If multiple attempts of IVF are not successful in achieving pregnancy, a physician may recommend transferring more than one or two embryos to increase the chances of pregnancy. However, this may also increase the risk of multiple gestation (twins, triplets).",
"    </p>",
"    <p>",
"     The rate of implantation is lower among women over age 40 years; as a result, more embryos (eg, up to five) are often transferred in these women. However, older women who are receiving eggs from younger donors (eg, donor eggs) have a rate of implantation similar to that of younger women, and are generally advised to transfer no more than one or two embryos (",
"     <a class=\"graphic graphic_table graphicRef56555 \" href=\"mobipreview.htm?6/39/6780\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Storing unused embryos",
"     </span>",
"     &nbsp;&mdash;&nbsp;Embryos that are not transferred may be stored by freezing them (called cryopreservation). Because some embryos do not survive the thawing process, the chances of a successful pregnancy using frozen embryos is usually lower than that when using fresh embryos.",
"    </p>",
"    <p>",
"     The embryos may be cryopreserved for an unlimited period of time. However, most couples are encouraged to choose one of the following options [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/4\">",
"      4",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Transfer the embryos at a later date",
"      </li>",
"      <li>",
"       Donate them for research or for use by another couple",
"      </li>",
"      <li>",
"       Dispose of the embryos",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TESTING FOR PREGNANCY AFTER IN VITRO FERTILIZATION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Blood testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately two weeks after the embryo transfer, a blood or urine test for hCG, the hormone that signifies pregnancy, can be done. Home urine pregnancy testing is not as sensitive for detecting an early pregnancy as blood testing.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the first blood hCG level is &lt;5",
"       <span class=\"nowrap\">",
"        IU/L,",
"       </span>",
"       the woman is not pregnant.",
"      </li>",
"      <li>",
"       If the first hCG level is &gt;10",
"       <span class=\"nowrap\">",
"        IU/L,",
"       </span>",
"       the test is usually repeated 48 hours later to confirm that the levels are increasing. The hCG level should approximately double every 48 hours during the first 21 days after embryo transfer.",
"      </li>",
"      <li>",
"       If the second hCG level does not double or decreases, the blood test may be repeated again 48 hours later. Depending upon the situation, there is a possibility that the pregnancy is not viable. hCG levels do not increase or begin to decline when the pregnancy is not progressing normally. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'When in vitro fertilization is not successful'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the hCG levels increase as expected, a pelvic ultrasound may be done three to four weeks after the transfer. At this time, it is usually possible to see a gestational sac inside the uterus. The gestational sac is a fluid-filled sac containing the embryo (",
"     <a class=\"graphic graphic_diagnosticimage graphicRef76430 \" href=\"mobipreview.htm?10/21/10583\">",
"      image 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     At five to six weeks of pregnancy (four to five weeks after the transfer), the yolk sac is usually visible. The yolk sac provides nourishment to the embryo early in development. A heart beat is usually visible by 6 to 6.5 weeks of pregnancy (4 to 4.5 weeks after the transfer).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Pregnancy care",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, prenatal care begins at 6 to 10 weeks of pregnancy. At this time, the woman will begin to see her obstetrical physician or nurse on a regular basis. These visits allow the obstetrical provider to monitor the woman and baby's health and to answer any questions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHEN IN VITRO FERTILIZATION IS NOT SUCCESSFUL",
"     </span>",
"    </p>",
"    <p>",
"     In vitro fertilization has a reasonable rate of success in most cases. Overall, approximately 27 percent of IVF cycles will end in a live birth, and the cumulative chances of success are higher when more than one cycle of IVF is done [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     However, an individual's chance of success depends on several factors, including the woman's age, cause of infertility, and treatment approach. For example, in the United States, the live birth rate for each IVF cycle started is approximately 30 to 35 percent for women under age 35; 25 percent for women ages 35 to 37; 15 to 20 percent for women ages 38 to 40; and 6 to 10 percent for women over 40. The success rates of individual infertility clinics in the United States is published on the internet at the Society for Assisted Reproductive Technology (",
"     <a class=\"external\" href=\"file://www.sart.org/\">",
"      www.sart.org/",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     It can be difficult to deal with the emotional highs and lows of infertility treatment. This is especially true if the woman (and her partner) have been trying to conceive for a long time, if treatment is not covered by insurance, or if there are any underlying problems in the couple's life (eg, medical, family or partner, job, financial).",
"    </p>",
"    <p>",
"     Support groups and counseling services are available at many infertility treatment centers, as well as on the internet. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Where to get more information'",
"     </a>",
"     below.) To find a reputable group, talk to your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      COSTS OF IN VITRO FERTILIZATION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The costs of IVF treatments can be high, depending upon what tests are required, the type and dose of medication(s) used, and the number of cycles required to become pregnant. The average cost of an IVF cycle in the United States is more than $10,000. Insurance policies cover the costs of infertility treatment in some states, although this varies by location and individual insurance policy. Less than half of the states within the US have laws requiring insurers to cover infertility treatment.",
"    </p>",
"    <p>",
"     More information about a state's laws can be obtained by calling your state Insurance Commissioner's office. Information can also be found by visiting the website for the American Society of Reproductive Medicine (",
"     <a class=\"external\" href=\"file://www.asrm.org/insurance.aspx\">",
"      file://www.asrm.org/insurance.aspx",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413248836\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150909\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11523?source=see_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/42/40610?source=see_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/25/6547?source=see_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=see_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/20/35138?source=see_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/20/32065?source=see_link\">",
"      Patient information: Turner syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150901\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=see_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=see_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"      Evaluation of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"      Surrogate pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"      In vitro fertilization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15546?source=see_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38136?source=see_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/52/22343?source=see_link\">",
"      Psychological stress and infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29256?source=see_link\">",
"      Techniques for preimplantation sex selection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"      Treatment of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39865?source=see_link\">",
"      Use of assisted reproduction in HIV and hepatitis infected couples",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Reproductive Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asrm.org/\">",
"      www.asrm.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Resolve: The National Infertility Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.resolve.org/\">",
"      www.resolve.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The International Council on Infertility Information Dissemination",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.inciid.com/\">",
"      www.inciid.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Infertility Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://infertility.about.com/forum\">",
"      file://infertility.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/62/40932/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/62/40932?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40932/abstract/1\">",
"      Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006; 27:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40932/abstract/2\">",
"      Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; :CD001750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40932/abstract/3\">",
"      van Rumste MM, Evers JL, Farquhar CM. Intra-cytoplasmic sperm injection versus conventional techniques for oocyte insemination during in vitro fertilisation in patients with non-male subfertility. Cochrane Database Syst Rev 2003; :CD001301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40932/abstract/4\">",
"      American Society for Reproductive Medicine. Guidelines for cryopreserved embryo donation. Fertil Steril 2004; 82 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/art/art2005/ (Accessed 2/13/2008).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_62_40932=[""].join("\n");
var outline_f39_62_40932=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           IN VITRO FERTILIZATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHO SHOULD CONSIDER IN VITRO FERTILIZATION?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           IN VITRO FERTILIZATION PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TESTING FOR PREGNANCY AFTER IN VITRO FERTILIZATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHEN IN VITRO FERTILIZATION IS NOT SUCCESSFUL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           COSTS OF IN VITRO FERTILIZATION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          DIAGNOSTIC IMAGES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/21/10583\" title=\"diagnostic image 1\">",
"           Ultrasound image of embryo in gestational sac",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/39/6780\" title=\"table 1\">",
"           ASRM revised guidelines for embryo transfer",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40933="Lipseal-nasal prong NPPV";
var content_f39_62_40933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Lipseal-nasal prong NPPV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Bach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40933=[""].join("\n");
var outline_f39_62_40933=null;
var title_f39_62_40934="Innervation of the kidney";
var content_f39_62_40934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic depiction of the innervation of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sympathetic, parasympathetic and sensory enervation supplying the kidney. The solid line represents the sympathetic component. The dotted line reflects the parasympathetic nerve supply. Afferent (sensory) fibers are represented by the dashed line and travel with the autonomic nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vasavada SP, Comiter CV, Raz S. Painful Diseases of the Kidney and Ureter. In: Bonica's Management of Pain, 3rd Edition, Loeser JD (Ed). Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40934=[""].join("\n");
var outline_f39_62_40934=null;
var title_f39_62_40935="Ketamine poisoning";
var content_f39_62_40935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ketamine poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Robert J Hoffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40935/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/62/40935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    was synthesized in 1962 by Parke Davis and first used in humans in 1965 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The United States military used ketamine as a field anesthetic during the Vietnam War, and the agent gradually gained popularity for use in brief surgical procedures as both an induction and maintenance agent for general anesthesia.",
"   </p>",
"   <p>",
"    By the 1970s,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    became a widely used recreational drug, with street names such as K, Special K, Kitkat, Vitamine K, Ket, and Super K. Ketamine abuse is closely associated worldwide with the use of other \"club drugs\" including \"ecstasy\" (3,4-methylenedioxymethamphetamine or MDMA), gamma hydroxybutyrate (GHB), and methamphetamine, often in the setting of large dance parties (sometimes referred to as raves) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is produced by a complicated, multistep synthesis that essentially precludes clandestine drug production. Most if not all ketamine sold illicitly is obtained by diversion of legitimate supplies. &nbsp;",
"   </p>",
"   <p>",
"    This topic review will discuss the presentation and treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    intoxication. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef69157 \" href=\"mobipreview.htm?40/22/41324\">",
"     table 1",
"    </a>",
"    ). Discussions of the use of ketamine for procedural sedation and induction for rapid sequence intubation (RSI) are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H20#H20\">",
"     \"Procedural sedation in adults\", section on 'Ketamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is an arylcycloalkylamine that is structurally related to phencyclidine (PCP). Ketamine is a dissociative anesthetic and hallucinogen. It acts primarily as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, but also possesses some opioid receptor activity and sympathomimetic properties. The latter results in enhanced central and peripheral monoaminergic transmission and inhibition of central and peripheral cholinergic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary site of ketamine's CNS activity appears to be the thalamocortical projection system, where it causes depression of certain cortical and thalamic functions and stimulation of parts of the limbic system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two phases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    distribution can be distinguished following intravenous administration. The first phase corresponds to the anesthetic effect of the drug and is characterized by rapid distribution (half-life of 10 to 16 minutes), and a large volume of distribution, due to the drug's high lipid solubility. The second phase represents redistribution from the central nervous system (CNS) to peripheral tissues, with an elimination half-life of two to three hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    undergoes significant first pass metabolism. The drug is metabolized by hepatic enzymes through demethylation, hydroxylation, and glucuronidation, and then excreted in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOSAGES AND FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common therapeutic dosages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    are 3 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for intramuscular (IM) use, and 0.5 to 4.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for intravenous (IV) use depending upon the procedure and the patient&rsquo;s age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/2\">",
"     2",
"    </a>",
"    ]. The usual induction dose is 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Recreational doses typically range from 75 to 125 mg via the IM or subcutaneous route, 60 to 250 mg intranasally, 50 to 100 mg IV, and 200 to 300 mg orally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of designer drugs that are analogs of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    has increased and includes methoxetamine, methoxyketamine, and others. There is limited clinical experience with the toxicity of these substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], but the relative ease with which such drugs can be purchased via the internet is expected to lead to an increase in poisonings from these substances. In the absence of more definitive data, we suggest that clinicians manage poisoning from designer drug analogs of ketamine in a manner similar to that described below for ketamine poisoning. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;At low or therapeutic doses (less than 5",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    may cause slight elevations in heart rate and blood pressure. Higher doses (over 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    have inconsistent cardiovascular effects and may result in hypertension or hypotension, tachycardia or bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/10\">",
"     10",
"    </a>",
"    ]. Massive overdose or use with other sedatives may result in respiratory depression or apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/11\">",
"     11",
"    </a>",
"    ]. One case of malignant hyperthermia has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Central nervous system (CNS) effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is capable of causing a spectrum of CNS effects, ranging from mild agitation to coma, depending on the dose and patient susceptibility. Agitation and other psychiatric disturbances caused by ketamine are much less common and less severe than those caused by phencyclidine (PCP).",
"   </p>",
"   <p>",
"    The desired clinical effect of iatrogenic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    administration is conscious sedation or anesthesia. Reflexes, including those involved in airway protection, are maintained. In overdose, ketamine, like PCP, is capable of inducing coma and deep anesthesia. In smaller doses (ie, those of most abusers), ketamine alters sensory perception. Effects include slight depression of mental status, diminished alertness, ataxia, and nystagmus. In abuse and with emergence reactions, patients may also experience extreme agitation, fear, and psychiatric disturbance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The typical presentation of ketamine abusers who present for medical evaluation is impaired consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergence reactions occur as the effects of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    dissipate following sedation. The phenomenon may involve vivid dreams, &ldquo;out of body&rdquo; experiences, and illusions, and can be associated with excitement, confusion, euphoria, or fear. The incidence of emergence reactions may be lower than previously thought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following manifestations may also be seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    intoxication:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amnesia (not as prominent as with benzodiazepines)",
"     </li>",
"     <li>",
"      Moderate dilatation of pupils",
"     </li>",
"     <li>",
"      Increased muscle tone",
"     </li>",
"     <li>",
"      Petit mal seizure-like activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory and airway effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is an attractive anesthetic because in therapeutic doses it does not cause cardiopulmonary depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/17\">",
"     17",
"    </a>",
"    ]. In massive doses or in combination with other sedative agents, however, respiratory depression and apnea can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Independent idiosyncratic effects seen after iatrogenic administration include laryngospasm, hypersalivation, and bronchorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/11,21-23\">",
"     11,21-23",
"    </a>",
"    ]. The cause of these phenomena is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In therapeutic doses,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    can exert a mild sympathomimetic effect on the cardiovascular system with slight increases in blood pressure and heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/24\">",
"     24",
"    </a>",
"    ]. Hypotension and bradycardia have been reported, but are rare. Ketamine increases myocardial oxygen demand, and may increase the risk of acute coronary syndrome, particularly in patients with additional risk factors for cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51338108\">",
"    <span class=\"h2\">",
"     Ocular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;While less common in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    than PCP intoxication, nystagmus may be seen, and may be rotatory, vertical, or horizontal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    abuse may lead to neuropsychiatric impairment and ulcerative cystitis, according to a small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Presentation after iatrogenic administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When administered correctly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    is generally a safe sedative. Nevertheless, respiratory depression, apnea, hypotension, bradycardia, myocardial infarction, and death have all been reported after ketamine overdose or overly rapid infusion.",
"   </p>",
"   <p>",
"    The most common adverse events after iatrogenic administration include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychiatric",
"      <span class=\"nowrap\">",
"       disturbance/emergence",
"      </span>",
"      phenomenon",
"     </li>",
"     <li>",
"      Respiratory depression",
"     </li>",
"     <li>",
"      Laryngospasm",
"     </li>",
"     <li>",
"      Salivation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects occur after intravenous (IV) use. Since most abusers insufflate (ie, \"snort\")",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , the complications listed are rare outside of the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Presentation after illicit use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    abusers are typically adolescents or young adults. However, according to one case series, the age of abusers ranges from 13 to 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/10\">",
"     10",
"    </a>",
"    ]. Overwhelmingly, impaired consciousness is the presenting complaint. A sizeable number of patients may have white powder in or on their nose at time of presentation. Symptoms from ketamine abuse appear to resolve quickly in most instances. In another small case series, half of patients who abused ketamine were asymptomatic by the time a clinician evaluated them in the emergency department, while half complained of anxiety, chest pain, or palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/24\">",
"     24",
"    </a>",
"    ]. Hallucinations usually resolved prior to evaluation. Tachycardia was the most common physical finding; hypertension was also noted.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is frequently abused in combination with other illicit drugs, such as amphetamine, MDMA, and cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Toxicity from these other agents is common. In New York City between 1997 and 2000, 12 deaths occurred in people abusing ketamine, but in all cases multiple drugs were involved. Death following intravenous injection of ketamine alone has been reported, but such events are likely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/17\">",
"     17",
"    </a>",
"    ]. Animal data suggest that combined use of caffeine and ketamine exacerbates toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/28\">",
"     28",
"    </a>",
"    ]. This may be important in some cases, as use of highly caffeinated energy drinks is common in the nightclub settings where ketamine is often abused.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    toxicity varies with the major presenting symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coma can be caused by many toxins, including opioids, alcohols, and sedative hypnotic agents. The clinician must also consider neurologic injury, hypoglycemia, and hypoxia in any comatose patient (",
"    <a class=\"graphic graphic_table graphicRef59515 \" href=\"mobipreview.htm?21/48/22284\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"mobipreview.htm?39/19/40254\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis for psychomotor agitation or hallucinosis includes intoxication with drugs such as phencyclidine (PCP), lysergic acid diethylamide (LSD), cocaine, and amphetamines. Withdrawal from ethanol or sedative hypnotic agents may also cause such symptoms. Psychiatric and other medical causes are far more common etiologies of psychomotor agitation than is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal neurologic findings, such as nystagmus and ataxia, can be caused by intoxication with such drugs as PCP,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    , and anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and by injury to the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=see_link\">",
"     \"Overview of nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    intoxication is based on history and clinical evidence; no definitive laboratory test is available. Although ketamine and phencyclidine are structurally similar, there is no reliable cross-reactivity between ketamine metabolites and available phencyclidine (PCP) detection assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should obtain additional tests based on clinical findings. In patients experiencing chest pain, cardiac enzymes may be indicated. Muscle rigidity and severe agitation from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    overdose can cause rhabdomyolysis. If this is a concern, serum creatine kinase and urine myoglobin should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of problems commonly encountered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    intoxication is described below. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef69157 \" href=\"mobipreview.htm?40/22/41324\">",
"     table 1",
"    </a>",
"    ). A general approach to the poisoned patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Airway and breathing support",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Laryngospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    -induced laryngospasm is rare, but most frequently occurs in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/21\">",
"     21",
"    </a>",
"    ]. It is typically self-limited, usually lasting less than one minute. Respiratory support should include administration of supplemental oxygen and positive-pressure ventilation by bag-valve mask. In circumstances when laryngospasm does not resolve with basic airway support, endotracheal intubation may be needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Respiratory depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia during administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    for procedural sedation most frequently occurs from positional airway compromise; respiratory depression or apnea is much less common. Clinicians should provide supplemental oxygen and ensure airway patency with basic maneuvers, such as head-tilt chin-lift or jaw-thrust. For apnea or respiratory insufficiency, clinicians should provide assisted ventilation using a bag-valve mask. Rarely, endotracheal intubation may be needed, if apnea persists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Salivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extreme sialorrhea is a known complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    administration. Suction and proper positioning should be performed to prevent aspiration. Pharmacologic treatment is needed if respiratory compromise develops, continual suctioning is necessary, or excessive saliva interferes with a necessary procedure (eg, laceration repair). Such treatment involves use of an anticholinergic agent, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    may be repeated once every two to three minutes; maximum single dose is 0.2 mg; maximum total dose is 0.8 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.01 to 0.02",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    minimum dose 0.1 mg; maximum dose 1.2 mg). Glycopyrrolate may be more effective at reducing secretions than atropine, although this has not been well studied, and it is less likely to produce cardiac and central nervous system effects. &nbsp;",
"   </p>",
"   <p>",
"    When providing procedural sedation, some clinicians coadminister",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    to prevent salivation, but there is little evidence to support this practice. Coadministration is not a necessity, but atropine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    should be available at the bedside when ketamine is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cardiovascular support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant cardiovascular complications are uncommon and may be managed using standard treatments. After securing the airway and breathing if necessary, clinicians should treat bradycardia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.01 to 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, minimum dose 0.1 mg IV, may be repeated every five minutes to a maximum total dose of 3 mg). Tachycardia from psychomotor agitation is treated with benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H11#H11\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Bradycardia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Psychomotor agitation, muscle rigidity, hallucination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of hypotension begins with intravenous (IV) boluses of crystalloid. Hypotension requiring treatment with vasopressors is uncommon, but sympathomimetic agents such as norepinephrine and dopamine may be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once airway, breathing, and circulation are secured as necessary, supportive care is typically the only treatment necessary for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    toxicity. The adverse effects of ketamine typically last between 15 minutes to several hours, and prolonged care is rarely needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Psychomotor agitation, muscle rigidity, hallucination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric disturbance from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    toxicity is generally short-lived. Minimizing stimuli, such as light and noise, is helpful. When restraint is needed, physical restraints should only be used until adequate chemical sedation is provided. Benzodiazepines are the mainstay of such treatment. They are helpful in managing fear, panic, hallucinations, and emergence reactions.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    may be used in 1 to 2 mg intravenous (IV) doses, until the desired level of sedation is achieved. Alternatively,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    in 5 to 10 mg IV doses may be used.",
"   </p>",
"   <p>",
"    Muscle rigidity can occur with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    use, but is generally without consequence.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    may be given in identical doses for muscle relaxation if needed.",
"   </p>",
"   <p>",
"    Butyrophenones (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ) and other antipsychotic agents should not be used to treat agitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40935/abstract/31\">",
"     31",
"    </a>",
"    ]. They interfere with heat dissipation, may prolong the QTc interval, and may reduce the seizure threshold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) decontamination is almost never indicated. When used illicitly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    is usually snorted, and occasionally injected intravenously or intramuscularly. Toxicity from these routes of administration would not be affected by GI decontamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Enhanced elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;No enhanced elimination technique is available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    overdose. A risky and outmoded method of enhanced elimination of phencyclidine (PCP), urine acidification, has never been tested in ketamine and should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    -induced laryngospasm occurs more commonly in young children than adults. Management is discussed above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Laryngospasm'",
"    </a>",
"    above.) Child protective services should be consulted for children too young to have abused ketamine intentionally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In extraordinarily rare instances of end-organ toxicity, such as myocardial infarction, patients require admission to an intensive care unit. In most cases, patients may be discharged after symptoms have resolved, usually within six hours. No specific follow-up is needed for most of the adverse events previously mentioned. Drug abusers should be referred for drug counseling and rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90350064\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Presentation and evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      is a dissociative anesthetic and hallucinogen. Patients who use ketamine illicitly usually insufflate (\"snort\") or ingest the drug. They often have no medical complaints. Some describe anxiety, chest pain, palpitations, or hallucinations. Tachycardia is a common physical finding. Massive overdose or use with other sedatives may result in respiratory depression or apnea. Ketamine is capable of causing a spectrum of CNS effects, ranging from mild agitation to coma, depending upon the dose and patient susceptibility. It is frequently abused in combination with other illicit drugs, such as amphetamine, MDMA, and cocaine. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administered correctly,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      is generally a safe sedative. Nevertheless, patients given ketamine intravenously for medical purposes can develop problems, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Psychiatric",
"      <span class=\"nowrap\">",
"       disturbance/emergence",
"      </span>",
"      phenomenon",
"     </li>",
"     <li>",
"      Respiratory depression",
"     </li>",
"     <li>",
"      Laryngospasm",
"     </li>",
"     <li>",
"      Salivation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory depression, apnea, hypotension, bradycardia, myocardial infarction, and death are rare but have been reported after iatrogenic overdose or overly rapid infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      intoxication is based on history and clinical evidence; no definitive laboratory test is available. Tests obtained as part of the evaluation of a patient with suspected ketamine poisoning are described in the text. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      -induced laryngospasm is rare, but most frequently occurs in infants. It is typically self-limited, usually lasting less than one minute. Assisted ventilation using a bag-valve mask should be provided. In circumstances when laryngospasm does not resolve with basic airway support, endotracheal intubation may be needed. Hypoxia during administration of ketamine for procedural sedation most frequently occurs from positional airway compromise, but respiratory depression or even apnea may occur. In such circumstances, clinicians should provide assisted ventilation. Rarely, endotracheal intubation may be needed. A summary table to facilitate emergent management is provided (",
"      <a class=\"graphic graphic_table graphicRef69157 \" href=\"mobipreview.htm?40/22/41324\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Airway and breathing support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extreme salivation (sialorrhea) is a known complication of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      administration. Suction and positioning should be performed to prevent aspiration. We suggest pharmacologic treatment be given if respiratory compromise develops, continual suctioning is necessary, or excessive saliva interferes with a necessary procedure (eg, laceration repair) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mcg/kg,",
"      </span>",
"      may be repeated once every two to three minutes; maximum single dose is 0.2 mg; maximum total dose is 0.8 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      (0.01 to 0.02",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      minimum dose 0.1 mg; maximum dose 1.2 mg) may be given. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Salivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant cardiovascular complications are uncommon and are managed using standard treatments. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Cardiovascular support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychomotor agitation can occur with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      overdose. When necessary, we suggest treatment with benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In adults,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      may be used in 1 to 2 mg intravenous doses, until the desired level of sedation is achieved. Butyrophenones (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      ) interfere with heat dissipation, may prolong the QTc, and may reduce the seizure threshold. We suggest that butyrophenones",
"      <strong>",
"       not",
"      </strong>",
"      be used to sedate patients with ketamine toxicity. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Psychomotor agitation, muscle rigidity, hallucination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the majority of cases",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      intoxication produces no significant adverse effects, and patients may be discharged after a period of asymptomatic observation, usually within six hours. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/1\">",
"      Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     Miller RD. Miller's Anesthesia, 6th, Elsevier Churchill Livingstone, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/3\">",
"      Weir E. Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 2000; 162:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/4\">",
"      Adams HA. [Mechanisms of action of ketamine]. Anaesthesiol Reanim 1998; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/5\">",
"      Miyasaka M, Domino EF. Neural mechanisms of ketamine-induced anesthesia. Int J Neuropharmacol 1968; 7:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/6\">",
"      Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87:1186.",
"     </a>",
"    </li>",
"    <li>",
"     Report on the Risk Assessment of Ketamine in the Framework of the Joint action on New Synthetic Drugs, European monitoring Centre for Drugs and Drug Addiction, September 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/8\">",
"      Ward J, Rhyee S, Plansky J, Boyer E. Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 2011; 49:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/9\">",
"      Shields JE, Dargan PI, Wood DM, et al. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 2012; 50:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/10\">",
"      Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010; 16:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/11\">",
"      Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     Martindale: The Complete Drug Reference, 34th, Sweetman S.  (Ed), Pharmaceutical Press, London 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/13\">",
"      Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med 2000; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/14\">",
"      Garfield JM, Garfield FB, Stone JG, et al. A comparison of psychologic responses to ketamine and thiopental--nitrous oxide--halothane anesthesia. Anesthesiology 1972; 36:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/15\">",
"      Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/16\">",
"      Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Am J Emerg Med 2005; 23:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/17\">",
"      Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol 2004; 28:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/18\">",
"      Green SM, Clark R, Hostetler MA, et al. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Ann Emerg Med 1999; 34:492.",
"     </a>",
"    </li>",
"    <li>",
"     Dillon JB. Clinical experience with repeated ketamine administration for procedures requiring anesthesia. In: Ketamine, Kreuscher H.  (Ed), Spring-Verlag, Berlin 1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/20\">",
"      Smith JA, Santer LJ. Respiratory arrest following intramuscular ketamine injection in a 4-year-old child. Ann Emerg Med 1993; 22:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/21\">",
"      Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 1998; 31:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/22\">",
"      Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993; 40:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/23\">",
"      Pandey CK, Mathur N, Singh N, Chandola HC. Fulminant pulmonary edema after intramuscular ketamine. Can J Anaesth 2000; 47:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/24\">",
"      Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/25\">",
"      Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007; 69:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/26\">",
"      Wood DM, Nicolaou M, Dargan PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse 2009; 44:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/27\">",
"      Gill JR, Staj&iacute;c M. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci 2000; 45:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/28\">",
"      Hsu HR, Mei YY, Wu CY, et al. Behavioural and toxic interaction profile of ketamine in combination with caffeine. Basic Clin Pharmacol Toxicol 2009; 104:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/29\">",
"      Pruitt JW, Goldwasser MS, Sabol SR, Prstojevich SJ. Intramuscular ketamine, midazolam, and glycopyrrolate for pediatric sedation in the emergency department. J Oral Maxillofac Surg 1995; 53:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/30\">",
"      Toft P, R&oslash;mer UD. Glycopyrrolate compared with atropine in association with ketamine anaesthesia. Acta Anaesthesiol Scand 1987; 31:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40935/abstract/31\">",
"      Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients. Acad Emerg Med 2000; 7:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 298 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-D6D24912BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40935=[""].join("\n");
var outline_f39_62_40935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOSAGES AND FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Central nervous system (CNS) effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory and airway effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51338108\">",
"      Ocular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Presentation after iatrogenic administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Presentation after illicit use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Airway and breathing support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Laryngospasm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Respiratory depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Salivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cardiovascular support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Psychomotor agitation, muscle rigidity, hallucination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Enhanced elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90350064\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Presentation and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/298|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/22/41324\" title=\"table 1\">",
"      Ketamine intoxication - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/48/22284\" title=\"table 2\">",
"      Drugs causing coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/19/40254\" title=\"table 3\">",
"      Causes of coma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40936="Approach to the patient with suspected choledocholithiasis";
var content_f39_62_40936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with suspected choledocholithiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Martin L Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Mustafa A Arain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40936/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/62/40936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H972627641\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choledocholithiasis refers to the presence of gallstones within the common bile duct (CBD). According to the National Health and Nutrition Examination Survey (NHANES III), over 20 million Americans are estimated to have gallbladder disease (defined as the presence of gallstones on transabdominal ultrasound or a history of cholecystectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/1\">",
"     1",
"    </a>",
"    ]. The exact incidence and prevalence of choledocholithiasis are not known, but it has been estimated that 5 to 20 percent of patients have CBD stones at the time of cholecystectomy, with the incidence increasing with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Western countries, most cases of choledocholithiasis are secondary to the passage of gallstones from the gallbladder into the CBD. Primary choledocholithiasis (ie, formation of stones within the common bile duct) is less common. It typically occurs in the setting of bile stasis (eg, patients with cystic fibrosis), resulting in a higher propensity to the formation of intraductal stones. Elderly patients with large bile ducts and periampullary diverticular are at elevated risk for the formation of primary bile duct stones. Patients with recurrent or persistent infection involving the biliary system are also at risk, a phenomenon seen most commonly in populations from East Asia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=see_link\">",
"     \"Recurrent pyogenic cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of primary choledocholithiasis affect the biliary tract diffusely and therefore are often complicated by extrahepatic and intrahepatic biliary stones. Intrahepatic stones may be complicated by recurrent pyogenic cholangitis.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the diagnostic and management approach to patients with suspected choledocholithiasis. Other topics related to gallstones and the endoscopic techniques employed in the diagnosis and treatment of choledocholithiasis are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=see_link\">",
"       \"Epidemiology of and risk factors for gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=see_link\">",
"       \"Uncomplicated gallstone disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14582?source=see_link\">",
"       \"Patient selection for the nonsurgical treatment of gallstone disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link\">",
"       \"Dissolution therapy for the treatment of gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22905?source=see_link\">",
"       \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627859\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CBD stones may be asymptomatic or present with pain and liver test abnormalities with or without evidence of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627867\">",
"    <span class=\"h2\">",
"     Asymptomatic presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with choledocholithiasis are occasionally asymptomatic. In such patients, the diagnosis is typically made when imaging studies are obtained for unrelated reasons, when a patient is being evaluated for abnormal liver tests, or when an intraoperative cholangiogram is obtained during cholecystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627875\">",
"    <span class=\"h2\">",
"     Pain and liver test abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated CBD stones typically have pain and abnormal liver tests, but are afebrile and do not have other abnormal laboratory tests. (See",
"    <a class=\"local\" href=\"#H972627928\">",
"     'Laboratory evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms associated with choledocholithiasis include right upper quadrant or epigastric pain, nausea, and vomiting. The pain is often more prolonged than is seen with typical biliary colic and resolves with either spontaneous passage or removal of the CBD stone. Some patients have intermittent pain due to transient blockage of the CBD. Transient blockage occurs when there is retention and floating of stones or debris within the bile duct, a phenomenon referred to as a \"ball-valve\" effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627896\">",
"    <span class=\"h2\">",
"     Complicated choledocholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major complications associated with choledocholithiasis are acute cholangitis and acute pancreatitis. These conditions can vary from mild to potentially fatal, and prompt diagnosis and appropriate management are essential. Given the risks of these complications, complete removal of all bile duct stones is recommended in virtually all patients.",
"   </p>",
"   <p>",
"    Patients with acute cholangitis often present with Charcot's triad (fever, right upper quadrant pain, and jaundice) and leukocytosis. In severe cases, bacteremia and sepsis may lead to hypotension and altered mental status (Reynolds' pentad). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute cholangitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with biliary pancreatitis typically present with pain, nausea, vomiting, elevated liver tests, elevations in serum amylase and lipase (by definition &gt;3 times the upper limit of normal),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging findings suggestive of acute pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627928\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations are typically elevated early in the course of biliary obstruction. Later, liver tests are typically elevated in a cholestatic pattern, with increases in serum bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase (GGT) exceeding the elevations in serum ALT and AST.",
"   </p>",
"   <p>",
"    Studies have attempted to estimate the predictive value of liver chemistry tests for CBD stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 22 studies",
"      <strong>",
"      </strong>",
"      evaluated the predictive role of multiple examination findings and tests used in the diagnosis of CBD stones, including serum bilirubin and alkaline phosphatase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/9\">",
"       9",
"      </a>",
"      ]. An elevation in serum bilirubin had a sensitivity of 69 percent and a specificity of 88 percent for diagnosing a CBD stone. For elevations in serum alkaline phosphatase, the values were 57 and 86 percent, respectively.",
"     </li>",
"     <li>",
"      A study of 1002 patients who underwent laparoscopic cholecystectomy for cholelithiasis evaluated five liver-related biochemical tests for predicting choledocholithiasis: serum GGT, alkaline phosphatase, total bilirubin, ALT, and AST [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/10\">",
"       10",
"      </a>",
"      ]. The sensitivities ranged from 64 percent for AST to 84 percent for GGT, and the specificities ranged from 68 percent for ALT to 88 percent for bilirubin. Independent predictors of a CBD stone on multivariate analysis were elevations in serum GGT (odds ratio [OR] 3.2), alkaline phosphatase (OR 2.03), and bilirubin (OR 1.41).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since liver tests may be elevated due to a wide variety of etiologies, the positive predictive value of elevated liver tests is poor. On the other hand, the negative predictive value of normal liver tests is high. Thus, normal liver tests play a greater role in excluding CBD stones than elevated liver tests play in diagnosing stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627978\">",
"    <span class=\"h1\">",
"     IMAGING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several imaging modalities can be used for the evaluation of patients with suspected choledocholithiasis, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transabdominal ultrasound",
"     </li>",
"     <li>",
"      Endoscopic ultrasound",
"     </li>",
"     <li>",
"      Magnetic resonance cholangiopancreatography",
"     </li>",
"     <li>",
"      Endoscopic retrograde cholangiography",
"     </li>",
"     <li>",
"      Intraoperative cholangiography or ultrasonography",
"     </li>",
"     <li>",
"      Abdominal computed tomography",
"     </li>",
"     <li>",
"      Percutaneous transhepatic cholangiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972627986\">",
"    <span class=\"h2\">",
"     Transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial imaging study of choice in patients with suspected common bile duct (CBD) stones is a transabdominal ultrasound (TUS) of the right upper quadrant. TUS can evaluate for gallstones, CBD stones, and CBD dilation. It is readily available, noninvasive, permits bedside evaluation, and provides a low-cost means of evaluating the CBD for stones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21992?source=see_link\">",
"     \"Ultrasonography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of TUS for CBD stones ranges from 20 to 90 percent. TUS has poor sensitivity for stones in the distal CBD because the distal CBD is often obscured by bowel gas in the imaging field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. A dilated CBD on TUS is suggestive of, but not specific for, CBD stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. A cutoff of 6 mm is often used to classify a duct as being dilated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/17\">",
"     17",
"    </a>",
"    ]. However, using a cutoff of 6 mm may miss stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/18\">",
"     18",
"    </a>",
"    ]. One study of 870 patients undergoing cholecystectomy found that stones were often detected in patients whose ducts would have been classified as \"nondilated\" using the 6 mm cutoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the probability of a stone in the common bile duct increased with increasing CBD diameter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 4 mm: 3.9 percent",
"     </li>",
"     <li>",
"      4.1 to 6 mm: 9.4 percent",
"     </li>",
"     <li>",
"      6.1 to 8 mm: 28 percent",
"     </li>",
"     <li>",
"      8.1 to 10 mm: 32 percent",
"     </li>",
"     <li>",
"      &gt;10 mm: 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, a definite CBD stone (one that casts a shadow) can be imaged by TUS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62309 \" href=\"mobipreview.htm?31/53/32593\">",
"     image 1",
"    </a>",
"    ). In a meta-analysis of predictive factors for choledocholithiasis, TUS had a sensitivity of 38 percent for detecting a CBD stone and a sensitivity of 42 percent for identifying a dilated CBD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628121\">",
"    <span class=\"h2\">",
"     Endoscopic retrograde cholangiopancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, endoscopic retrograde cholangiopancreatography (ERCP) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59987 \" href=\"mobipreview.htm?2/62/3043\">",
"     image 2",
"    </a>",
"    ) was used as a diagnostic and therapeutic procedure in the management of patients with gallstones seen on TUS or in patients with suspected choledocholithiasis in whom the diagnosis remained unclear after laboratory testing and ultrasound. The sensitivity of ERCP for CBD stones is estimated to be 80 to 93 percent, with a specificity of 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/20\">",
"     20",
"    </a>",
"    ]. However, ERCP is invasive, requires technical expertise, and is associated with complications such as pancreatitis, bleeding, and perforation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS), magnetic resonance cholangiopancreatography (MRCP), and intraoperative cholangiography during cholecystectomy have replaced ERCP as the diagnostic tests of choice in the evaluation of patients with choledocholithiasis because of their similar test performance and, in the case of EUS and MRCP, less invasive nature. In our practice, ERCP is reserved as an initial diagnostic and therapeutic procedure for patients in whom there is a high level of certainty for ongoing or worsening biliary obstruction due to CBD stones, especially if there is suspicion of ascending cholangitis based upon clinical presentation and laboratory findings. Since the goal of therapy in these patients is to establish biliary drainage, ERCP is also an appropriate therapeutic procedure if the diagnosis of choledocholithiasis has been confirmed by other imaging tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628153\">",
"    <span class=\"h2\">",
"     EUS and MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60410 \" href=\"mobipreview.htm?34/1/34838\">",
"     image 3",
"    </a>",
"    )) and magnetic resonance cholangiopancreatography (MRCP, (",
"    <a class=\"graphic graphic_picture graphicRef70857 \" href=\"mobipreview.htm?12/17/12575\">",
"     picture 1",
"    </a>",
"    )) have largely replaced ERCP for the diagnosis of CBD stones. EUS is less invasive than ERCP, and MRCP is noninvasive. Both tests are highly sensitive and specific for choledocholithiasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deciding which test should be performed first depends upon various factors such as ease of availability, cost, patient related factors, and the suspicion for a small stone. The potential advantages and disadvantages of each modality are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef73388 \" href=\"mobipreview.htm?22/51/23356\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EUS and MRCP for the diagnosis of choledocholithiasis have been evaluated using ERCP as the reference standard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 27 studies with 2673 patients found that EUS had a sensitivity of 94 percent and a specificity of 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 13 studies found that MRCP had a median sensitivity of 93 percent and a median specificity of 94 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have prospectively compared the accuracy of EUS with MRCP in the diagnosis of choledocholithiasis. These have been reviewed in two systemic reviews, both of which showed no significant differences between the two modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a pooled analysis of 301 patients from five randomized, prospective, blinded trials that compared EUS with MRCP, there was no significant difference in aggregated sensitivity (93 versus 85 percent) or specificity (96 versus 93 percent).",
"   </p>",
"   <p>",
"    MRCP is preferred to EUS for many patients because it is noninvasive. However, the sensitivity of MRCP may be lower for small stones (&lt;6 mm, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60410 \" href=\"mobipreview.htm?34/1/34838\">",
"     image 3",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/25\">",
"     25",
"    </a>",
"    ], and biliary sludge can be detected by EUS, but generally not by MRCP. As a result, EUS should be considered in patients in whom the suspicion for choledocholithiasis remains despite a \"negative\" MRCP (ie, no visualization of a CBD stone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628315\">",
"    <span class=\"h2\">",
"     Intraoperative cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era prior to laparoscopic surgery, patients with gallstone disease and suspected choledocholithiasis underwent open cholecystectomy including cholangiography and palpation of the CBD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    open exploration of the CBD to diagnose and treat CBD stones. As laparoscopic surgery replaced open surgery as the preferred method for cholecystectomy, exploration of the CBD for removal of intraductal stones became technically more challenging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=see_link&amp;anchor=H22#H22\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Evaluation for choledocholithiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6440?source=see_link&amp;anchor=H813094#H813094\">",
"     \"Common bile duct exploration\", section on 'Intraoperative cholangiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With improvements in cholangiography technique and the use of fluoroscopic rather than static cholangiography, the successful completion rate and accuracy of intraoperative cholangiography (IOC) have improved over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/26\">",
"     26",
"    </a>",
"    ]. In practice, the use of IOC is highly operator-dependent and may be technically unfeasible in patients with a severely inflamed gallbladder or with a tiny or inflamed cystic duct.",
"   </p>",
"   <p>",
"    Studies of IOC during laparoscopic cholangiography have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 13 studies with 1980 patients, 9 percent had CBD stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/27\">",
"       27",
"      </a>",
"      ]. The success rate for technical completion of IOC during laparoscopic cholecystectomy ranged from 88 to 100 percent. IOC had a sensitivity of 68 to 100 percent and a specificity of 92 to 100 percent for diagnosing CBD stones.",
"     </li>",
"     <li>",
"      In a more recent prospective population-based study, IOC was routinely attempted in 1171 patients undergoing cholecystectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/28\">",
"       28",
"      </a>",
"      ]. The cholecystectomy was carried out laparoscopically in 79 percent. IOC was successful in 95 percent and CBD stones were identified in 134 patients (11 percent). The sensitivity and specificity of IOC were 97 and 99 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is ongoing debate about the routine use of IOC in all patients undergoing laparoscopic cholecystectomy versus selective use in patients at high-risk for intraductal stones, and practices vary widely among surgeons. Proponents of routine IOC argue that it permits delineation of biliary anatomy, reduces and identifies bile duct injuries, and identifies asymptomatic CBD stones. Opponents argue that IOC adds to procedure time and expense. In addition, they argue that asymptomatic CBD stones may pass spontaneously",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a low potential for causing complications, such that their identification may lead to unnecessary CBD exploration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conversion to open surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/29-39\">",
"     29-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2008 study examined the frequency with which surgeons employ IOC. In a survey of 1417 surgeons, 27 percent defined themselves as routine IOC users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/40\">",
"     40",
"    </a>",
"    ]. Among the routine users, 91 percent reported using IOC in more than 75 percent of laparoscopic cholecystectomies. Academic surgeons were less often routine users compared with nonacademic surgeons (15 versus 30 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628573\">",
"    <span class=\"h2\">",
"     Intraoperative ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another intraoperative approach for the evaluation of CBD stones is intraoperative ultrasound. During laparoscopy, an ultrasound probe is inserted into the peritoneal cavity though a 10-mm trochar and is used to scan the bile ducts. The reported sensitivity and specificity are over 90 percent and it has been suggested that the routine use of intraoperative ultrasound followed by selective IOC leads to the accurate diagnosis of CBD stones, while reducing the need for IOC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of intraoperative ultrasound may also decrease the rate of bile duct injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/42\">",
"     42",
"    </a>",
"    ]. Compared with IOC, intraoperative ultrasound has the advantage of being noninvasive with regard to the bile duct. However, it is associated with a longer learning curve and is currently not as widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/27\">",
"     27",
"    </a>",
"    ]. The decision regarding IOC or intraoperative ultrasound depends upon patient selection and the surgeon's expertise and comfort with the technologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628617\">",
"    <span class=\"h2\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT and percutaneous cholangiopancreatography are alternative methods for diagnosing choledocholithiasis. Unenhanced abdominal CT is neither sensitive nor specific for CBD stones. However, both sensitivity and specificity can be improved with the use of intravenous contrast media combined with a helical cholangiography protocol, increasing from 65 to 93 percent and from 84 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]. If a CBD stone is clearly visualized on CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64701 \" href=\"mobipreview.htm?0/28/451\">",
"     image 4",
"    </a>",
"    ), the finding is highly specific. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18950?source=see_link\">",
"     \"Computed tomography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous transhepatic cholangiography is typically performed in patients who are not candidates for ERCP, who have failed ERCP, who have surgically altered anatomy preventing endoscopic access to the biliary tree, or who have intrahepatic cholelithiasis. Due to its invasive nature, it should be generally considered a therapeutic procedure rather than a diagnostic one. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628735\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of multiple diagnostic modalities with differing levels of sensitivity, specificity, and invasiveness provides clinicians with various options in the evaluation of patients with suspected choledocholithiasis. The aim of the diagnostic evaluation is to confirm or exclude the presence of common bile duct (CBD) stones using the least invasive, most accurate, and most cost-effective imaging modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/49\">",
"     49",
"    </a>",
"    ]. The specific approach is determined by the level of clinical suspicion, availability of imaging modalities, and patient factors (eg, contraindications to a particular test).",
"   </p>",
"   <p>",
"    In a 2010 guideline, the American Society for Gastrointestinal Endoscopy (ASGE) proposed a strategy to stratify patients based upon their risks of having CBD stones. Patients were stratified using the following predictors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Very strong\" predictors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of a CBD stone on transabdominal ultrasound",
"     </li>",
"     <li>",
"      Clinical ascending cholangitis",
"     </li>",
"     <li>",
"      A serum bilirubin greater than 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (68",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Strong\" predictors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A dilated CBD on ultrasound (more than 6 mm in a patient with a gallbladder in situ)",
"     </li>",
"     <li>",
"      A serum bilirubin of 1.8 to 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (31 to 68",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Moderate\" predictors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormal liver biochemical test other than bilirubin",
"     </li>",
"     <li>",
"      Age older than 55 years",
"     </li>",
"     <li>",
"      Clinical gallstone pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with at least one very strong predictor or both strong predictors are considered high-risk. Patients who do not qualify as high-risk, but who have at least one of the strong or moderate predictors are considered intermediate-risk. Patients with no predictors are considered low-risk. A flow-chart for the management of patients based on their risk of a CBD stone is presented in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef66945 \" href=\"mobipreview.htm?26/3/26686\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Our approach to patients with suspected choledocholithiasis is similar to the approach outlined in the ASGE guidelines. After performing a history and physical examination, we obtain serum liver tests and a transabdominal ultrasound. Based upon those results patients, patients are risk stratified according to the ASGE definitions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628784\">",
"    <span class=\"h2\">",
"     High-risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proceed directly to ERCP (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22905?source=see_link\">",
"       \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628809\">",
"    <span class=\"h2\">",
"     Intermediate-risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is a surgical candidate, proceed to laparoscopic cholecystectomy with intraoperative cholangiography or ultrasonography. (See",
"      <a class=\"local\" href=\"#H972628315\">",
"       'Intraoperative cholangiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H972628573\">",
"       'Intraoperative ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient refuses surgery, is not a surgical candidate, or is post-cholecystectomy, further imaging with an MRCP or EUS is recommended. (See",
"      <a class=\"local\" href=\"#H972628153\">",
"       'EUS and MRCP'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If no CBD stones are seen on MRCP but suspicion remains for bile duct stones, proceed to EUS.",
"     </li>",
"     <li>",
"      If no CBD stones are seen by EUS, proceed to laparoscopic cholecystectomy in patients who are surgical candidates (assuming cholelithiasis has been confirmed by transabdominal or endoscopic ultrasound). Alternative therapies, such as medical gallstone dissolution, may be considered for patients who are not surgical candidates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link\">",
"       \"Dissolution therapy for the treatment of gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a stone is seen on MRCP or EUS, proceed to ERCP, followed by laparoscopic cholecystectomy (in surgical candidates) either during the same hospitalization or electively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628881\">",
"    <span class=\"h2\">",
"     Low-risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If stones or sludge are present within the gallbladder and the patient is a good surgical candidate, proceed to laparoscopic cholecystectomy without imaging of the CBD preoperatively or intraoperatively. Alternative therapies, such as medical gallstone dissolution may be considered for patients who are not surgical candidates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=see_link\">",
"       \"Dissolution therapy for the treatment of gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is no evidence of gallstones on imaging, look for alternative explanations for the patient's pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628921\">",
"    <span class=\"h2\">",
"     Incidental CBD stones found during laparoscopic cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine intraoperative cholangiography or ultrasonography is not performed in all patients undergoing laparoscopic cholangiography. When obtained, some patients are found to have CBD stones that were not suspected prior to surgery. (See",
"    <a class=\"local\" href=\"#H972628315\">",
"     'Intraoperative cholangiography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H972628573\">",
"     'Intraoperative ultrasonography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The choice of treatment for patients with CBD stones found incidentally during surgery includes intraoperative ERCP, intraoperative CBD exploration (laparoscopic or open), and postoperative ERCP. At our center, intraoperative ERCP is performed if consent was obtained preoperatively. Otherwise, ERCP is performed at a later time during the same hospitalization, as is standard in most practice settings.",
"   </p>",
"   <p>",
"    Intraoperative CBD exploration is performed selectively based upon surgeon preference and local expertise. In selected centers, laparoscopic CBD exploration and stone removal is routinely performed. There are relatively few indications for open CBD exploration, but cholecystectomy in patients with altered anatomy may be an example of an appropriate setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63650557\">",
"    <span class=\"h2\">",
"     Cost-effectiveness analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent to the ASGE guidelines, a cost-effectiveness analysis was published that looked at five treatment strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40936/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Laparoscopic cholecystectomy alone followed by expectant management",
"     </li>",
"     <li>",
"      Preoperative ERCP followed by laparoscopic cholecystectomy",
"     </li>",
"     <li>",
"      Laparoscopic cholecystectomy with intraoperative cholangiography &plusmn; CBD exploration",
"     </li>",
"     <li>",
"      Laparoscopic cholecystectomy followed by postoperative ERCP",
"     </li>",
"     <li>",
"      Laparoscopic cholecystectomy with intraoperative cholangiography &plusmn; postoperative ERCP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The analysis found that if the probability of a CBD stone was between 4 and 100 percent, then laparoscopic cholecystectomy with intraoperative cholangiography &plusmn; postoperative ERCP was the most cost-effective approach. If the probability of a CBD stone was 0 percent, then laparoscopic cholecystectomy alone was the most cost-effective approach.",
"   </p>",
"   <p>",
"    However, for patients at high-risk for CBD stones, and particularly those with evidence of ascending cholangitis, we prefer to perform preoperative ERCP, as outlined in the ASGE guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"       \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972628953\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choledocholithiasis refers to the presence of gallstones within the common bile duct (CBD). It has been estimated that 5 to 20 percent of patients have CBD stones at the time of cholecystectomy, with the incidence increasing with age. (See",
"      <a class=\"local\" href=\"#H972627641\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CBD stones may be asymptomatic or present with pain and liver test abnormalities with or without evidence of complications. (See",
"      <a class=\"local\" href=\"#H972627859\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are typically elevated early in the course of biliary obstruction. Later, liver tests are typically elevated in a cholestatic pattern, with elevations in serum bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase (GGT) being more pronounced than those in ALT and AST. (See",
"      <a class=\"local\" href=\"#H972627928\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several imaging modalities can be used for the evaluation of patients with suspected choledocholithiasis. (See",
"      <a class=\"local\" href=\"#H972627978\">",
"       'Imaging tests'",
"      </a>",
"      above.) Available tests include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transabdominal ultrasound",
"     </li>",
"     <li>",
"      Endoscopic retrograde cholangiography",
"     </li>",
"     <li>",
"      Magnetic resonance cholangiopancreatography",
"     </li>",
"     <li>",
"      Endoscopic ultrasound",
"     </li>",
"     <li>",
"      Intraoperative cholangiography or ultrasonography",
"     </li>",
"     <li>",
"      Abdominal computed tomography",
"     </li>",
"     <li>",
"      Percutaneous transhepatic cholangiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aim of the diagnostic evaluation is to confirm or exclude the presence of CBD stones using the least invasive, most accurate, and most cost-effective imaging modality. (See",
"      <a class=\"local\" href=\"#H972628735\">",
"       'Approach to diagnosis and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic and management approach chosen for a particular patient depends in part upon the level of clinical suspicion. Factors associated with a higher likelihood of choledocholithiasis include elevated serum bilirubin, elevated serum alkaline phosphatase, dilated bile duct on ultrasound, and a clinical picture of cholangitis. (See",
"      <a class=\"local\" href=\"#H972628735\">",
"       'Approach to diagnosis and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic ultrasound (EUS), magnetic resonance cholangiopancreatography (MRCP), and intraoperative cholangiography during cholecystectomy have replaced endoscopic retrograde cholangiopancreatography (ERCP) as the diagnostic tests of choice in the evaluation of patients with choledocholithiasis because of their similar test performance and, in the case of EUS and MRCP, less invasive nature. ERCP should be considered a therapeutic procedure and only be used prior to other imaging modalities in patients with a very high likelihood of choledocholithiasis, in patients with confirmed or suspected cholangitis, or when EUS and MRCP are not available. (See",
"      <a class=\"local\" href=\"#H972627978\">",
"       'Imaging tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/1\">",
"      Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/2\">",
"      Collins C, Maguire D, Ireland A, et al. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg 2004; 239:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/3\">",
"      Hunter JG. Laparoscopic transcystic common bile duct exploration. Am J Surg 1992; 163:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/4\">",
"      Petelin JB. Laparoscopic common bile duct exploration. Surg Endosc 2003; 17:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/5\">",
"      Neuhaus H, Feussner H, Ungeheuer A, et al. Prospective evaluation of the use of endoscopic retrograde cholangiography prior to laparoscopic cholecystectomy. Endoscopy 1992; 24:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/6\">",
"      Houdart R, Perniceni T, Darne B, et al. Predicting common bile duct lithiasis: determination and prospective validation of a model predicting low risk. Am J Surg 1995; 170:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/7\">",
"      O'Neill CJ, Gillies DM, Gani JS. Choledocholithiasis: overdiagnosed endoscopically and undertreated laparoscopically. ANZ J Surg 2008; 78:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/8\">",
"      Prat F, Meduri B, Ducot B, et al. Prediction of common bile duct stones by noninvasive tests. Ann Surg 1999; 229:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/9\">",
"      Abboud PA, Malet PF, Berlin JA, et al. Predictors of common bile duct stones prior to cholecystectomy: a meta-analysis. Gastrointest Endosc 1996; 44:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/10\">",
"      Yang MH, Chen TH, Wang SE, et al. Biochemical predictors for absence of common bile duct stones in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2008; 22:1620.",
"     </a>",
"    </li>",
"    <li>",
"     Sox HC, Blatt MA, Higgins, MC, et al. Medical decision making, Butterworths, Boston 1988. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/12\">",
"      Einstein DM, Lapin SA, Ralls PW, Halls JM. The insensitivity of sonography in the detection of choledocholithiasis. AJR Am J Roentgenol 1984; 142:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/13\">",
"      Laing FC, Jeffrey RB, Wing VW. Improved visualization of choledocholithiasis by sonography. AJR Am J Roentgenol 1984; 143:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/14\">",
"      O'Connor HJ, Hamilton I, Ellis WR, et al. Ultrasound detection of choledocholithiasis: prospective comparison with ERCP in the postcholecystectomy patient. Gastrointest Radiol 1986; 11:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/15\">",
"      Wermke W, Schulz HJ. [Sonographic diagnosis of bile duct calculi. Results of a prospective study of 222 cases of choledocholithiasis]. Ultraschall Med 1987; 8:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/16\">",
"      Pasanen PA, Partanen KP, Pikkarainen PH, et al. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis. Eur J Surg 1993; 159:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/17\">",
"      ASGE Standards of Practice Committee, Maple JT, Ben-Menachem T, et al. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc 2010; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/18\">",
"      Urquhart P, Speer T, Gibson R. Challenging clinical paradigms of common bile duct diameter. Gastrointest Endosc 2011; 74:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/19\">",
"      Hunt DR. Common bile duct stones in non-dilated bile ducts? An ultrasound study. Australas Radiol 1996; 40:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/20\">",
"      Prat F, Amouyal G, Amouyal P, et al. Prospective controlled study of endoscopic ultrasonography and endoscopic retrograde cholangiography in patients with suspected common-bileduct lithiasis. Lancet 1996; 347:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/21\">",
"      Tse F, Liu L, Barkun AN, et al. EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc 2008; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/22\">",
"      Kaltenthaler E, Vergel YB, Chilcott J, et al. A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography. Health Technol Assess 2004; 8:iii, 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/23\">",
"      Verma D, Kapadia A, Eisen GM, Adler DG. EUS vs MRCP for detection of choledocholithiasis. Gastrointest Endosc 2006; 64:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/24\">",
"      Ledro-Cano D. Suspected choledocholithiasis: endoscopic ultrasound or magnetic resonance cholangio-pancreatography? A systematic review. Eur J Gastroenterol Hepatol 2007; 19:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/25\">",
"      Zidi SH, Prat F, Le Guen O, et al. Use of magnetic resonance cholangiography in the diagnosis of choledocholithiasis: prospective comparison with a reference imaging method. Gut 1999; 44:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/26\">",
"      MacFadyen BV. Intraoperative cholangiography: past, present, and future. Surg Endosc 2006; 20 Suppl 2:S436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/27\">",
"      Machi J, Tateishi T, Oishi AJ, et al. Laparoscopic ultrasonography versus operative cholangiography during laparoscopic cholecystectomy: review of the literature and a comparison with open intraoperative ultrasonography. J Am Coll Surg 1999; 188:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/28\">",
"      Videhult P, Sandblom G, Rasmussen IC. How reliable is intraoperative cholangiography as a method for detecting common bile duct stones? : A prospective population-based study on 1171 patients. Surg Endosc 2009; 23:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/29\">",
"      Cuschieri A, Shimi S, Banting S, et al. Intraoperative cholangiography during laparoscopic cholecystectomy. Routine vs selective policy. Surg Endosc 1994; 8:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/30\">",
"      Shively EH, Wieman TJ, Adams AL, et al. Operative cholangiography. Am J Surg 1990; 159:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/31\">",
"      Vezakis A, Davides D, Ammori BJ, et al. Intraoperative cholangiography during laparoscopic cholecystectomy. Surg Endosc 2000; 14:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/32\">",
"      Jones DB, Dunnegan DL, Soper NJ. Results of a change to routine fluorocholangiography during laparoscopic cholecystectomy. Surgery 1995; 118:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/33\">",
"      Woods MS, Traverso LW, Kozarek RA, et al. Biliary tract complications of laparoscopic cholecystectomy are detected more frequently with routine intraoperative cholangiography. Surg Endosc 1995; 9:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/34\">",
"      Soper NJ, Dunnegan DL. Routine versus selective intra-operative cholangiography during laparoscopic cholecystectomy. World J Surg 1992; 16:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/35\">",
"      Hauer-Jensen M, Karesen R, Nygaard K, et al. Prospective randomized study of routine intraoperative cholangiography during open cholecystectomy: long-term follow-up and multivariate analysis of predictors of choledocholithiasis. Surgery 1993; 113:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/36\">",
"      Kullman E, Borch K, Lindstr&ouml;m E, et al. Value of routine intraoperative cholangiography in detecting aberrant bile ducts and bile duct injuries during laparoscopic cholecystectomy. Br J Surg 1996; 83:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/37\">",
"      Stuart SA, Simpson TI, Alvord LA, Williams MD. Routine intraoperative laparoscopic cholangiography. Am J Surg 1998; 176:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/38\">",
"      Snow LL, Weinstein LS, Hannon JK, Lane DR. Evaluation of operative cholangiography in 2043 patients undergoing laparoscopic cholecystectomy: a case for the selective operative cholangiogram. Surg Endosc 2001; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/39\">",
"      Nickkholgh A, Soltaniyekta S, Kalbasi H. Routine versus selective intraoperative cholangiography during laparoscopic cholecystectomy: a survey of 2,130 patients undergoing laparoscopic cholecystectomy. Surg Endosc 2006; 20:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/40\">",
"      Massarweh NN, Devlin A, Elrod JA, et al. Surgeon knowledge, behavior, and opinions regarding intraoperative cholangiography. J Am Coll Surg 2008; 207:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/41\">",
"      Machi J, Oishi AJ, Tajiri T, et al. Routine laparoscopic ultrasound can significantly reduce the need for selective intraoperative cholangiography during cholecystectomy. Surg Endosc 2007; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/42\">",
"      Machi J, Johnson JO, Deziel DJ, et al. The routine use of laparoscopic ultrasound decreases bile duct injury: a multicenter study. Surg Endosc 2009; 23:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/43\">",
"      Soto JA, Velez SM, Guzm&aacute;n J. Choledocholithiasis: diagnosis with oral-contrast-enhanced CT cholangiography. AJR Am J Roentgenol 1999; 172:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/44\">",
"      Soto JA, Alvarez O, M&uacute;nera F, et al. Diagnosing bile duct stones: comparison of unenhanced helical CT, oral contrast-enhanced CT cholangiography, and MR cholangiography. AJR Am J Roentgenol 2000; 175:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/45\">",
"      Ishikawa M, Tagami Y, Toyota T, et al. Can three-dimensional helical CT cholangiography before laparoscopic cholecystectomy be a substitute study for endoscopic retrograde cholangiography? Surg Laparosc Endosc Percutan Tech 2000; 10:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/46\">",
"      Polkowski M, Palucki J, Regula J, et al. Helical computed tomographic cholangiography versus endosonography for suspected bile duct stones: a prospective blinded study in non-jaundiced patients. Gut 1999; 45:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/47\">",
"      Jim&eacute;nez Cuenca I, del Olmo Mart&iacute;nez L, P&eacute;rez Homs M. Helical CT without contrast in choledocholithiasis diagnosis. Eur Radiol 2001; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/48\">",
"      Tseng CW, Chen CC, Chen TS, et al. Can computed tomography with coronal reconstruction improve the diagnosis of choledocholithiasis? J Gastroenterol Hepatol 2008; 23:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/49\">",
"      Tse F, Barkun JS, Barkun AN. The elective evaluation of patients with suspected choledocholithiasis undergoing laparoscopic cholecystectomy. Gastrointest Endosc 2004; 60:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40936/abstract/50\">",
"      Brown LM, Rogers SJ, Cello JP, et al. Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. J Am Coll Surg 2011; 212:1049.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13922 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-49D3304717-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40936=[""].join("\n");
var outline_f39_62_40936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H972628953\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972627641\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972627859\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972627867\">",
"      Asymptomatic presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972627875\">",
"      Pain and liver test abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972627896\">",
"      Complicated choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972627928\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972627978\">",
"      IMAGING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972627986\">",
"      Transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628121\">",
"      Endoscopic retrograde cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628153\">",
"      EUS and MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628315\">",
"      Intraoperative cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628573\">",
"      Intraoperative ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628617\">",
"      Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972628735\">",
"      APPROACH TO DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628784\">",
"      High-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628809\">",
"      Intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628881\">",
"      Low-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H972628921\">",
"      Incidental CBD stones found during laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63650557\">",
"      Cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972628953\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13922|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?26/3/26686\" title=\"algorithm 1\">",
"      Patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13922|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/53/32593\" title=\"diagnostic image 1\">",
"      Ultrasound showing stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/62/3043\" title=\"diagnostic image 2\">",
"      Common bile duct stone on ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/1/34838\" title=\"diagnostic image 3\">",
"      MRCP and ERC versus EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/28/451\" title=\"diagnostic image 4\">",
"      CT scan bile duct stone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13922|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/17/12575\" title=\"picture 1\">",
"      MRCP stone post Roux-en-Y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/51/23356\" title=\"table 1\">",
"      MRCP and EUS for choledoch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6440?source=related_link\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18950?source=related_link\">",
"      Computed tomography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=related_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14582?source=related_link\">",
"      Patient selection for the nonsurgical treatment of gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21992?source=related_link\">",
"      Ultrasonography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40937="Rotavirus vaccines";
var content_f39_62_40937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rotavirus vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     David O Matson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40937/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/62/40937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotaviruses were among the first viral agents to be identified as important causes of viral gastroenteritis, particularly in children between the ages of six months and two years. Extensive surveys have established rotavirus as the single most important viral cause of severe gastroenteritis in children worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rotavirus vaccines will be discussed below. The pathogenesis, clinical presentation, and laboratory techniques available for specific microbiologic diagnosis of rotavirus gastroenteritis are discussed separately, as are general measures to prevent viral gastroenteritis in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9912?source=see_link\">",
"     \"Prevention and treatment of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal infant immunization against rotavirus is recommended by the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the European Society for Pediatric Infectious Disease (ESPID), and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rotavirus vaccines have been developed from animal rotavirus strains, human-animal rotavirus reassortants (genes from human and animal strains), attenuated human rotaviruses, and subunits of rotavirus virions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The need for reassortants was prompted by poor growth of most human rotaviruses in cell culture (at levels insufficient for development of standard vaccine lots for large-scale immunization programs). Monovalent vaccines prepared from animal rotaviruses have not been promising.",
"   </p>",
"   <p>",
"    Several oral rotavirus vaccines have undergone large trials of safety and efficacy; two are currently licensed in the United States and other countries (",
"    <a class=\"graphic graphic_table graphicRef70478 \" href=\"mobipreview.htm?20/22/20844\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pentavalent human-bovine rotavirus reassortant vaccine (RV5, PRV, RotaTeq) is licensed in the United States and Europe for universal use in infants younger than six months (Europe) to eight months (United States) of age, as described below. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pentavalent human-bovine reassortant rotavirus vaccine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A monovalent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       rotavirus vaccine",
"      </a>",
"      derived from the most common human rotavirus strain attenuated by serial passage (RV1, HRV, Rotarix) is licensed for use in the United States, European Union, and many countries in Latin America, Africa, and Asia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Attenuated human rotavirus vaccine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An oral tetravalent human-rhesus rotavirus reassortant vaccine (RRV-TV, RotaShield) was licensed in 1998 and recommended for universal immunization of term infants in the United States in 1999 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/12\">",
"       12",
"      </a>",
"      ]. It was soon withdrawn from the market because of an epidemiologic link to intussusception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/13-16\">",
"       13-16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Human-rhesus rotavirus reassortant (RRV-TV, RotaShield)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV5 is an oral vaccine that contains five human-bovine reassortants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RV5 is based upon the bovine strain, WC3, which by itself is naturally attenuated for humans, but not broadly cross-protective. Each reassortant component contains a single gene encoding a major outer capsid protein from the most common human serotypes: G1, G2, G3, G4, and P1[8]. This vaccine is administered in three oral doses, with at least one month between doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy/effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV5 is efficacious in preventing rotavirus gastroenteritis in infants, even when administered near the end of its shelf-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In the Rotavirus Efficacy and Safety Trial (REST), a phase 3 trial, 68,038 healthy infants from 11 countries were randomly assigned to receive three doses of vaccine or placebo at 4- to 10-week intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/18\">",
"     18",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first rotavirus season after immunization, efficacy against severe G1-G4 rotavirus gastroenteritis was 98 percent (95% CI 88-100 percent), and against G1-G4 rotavirus gastroenteritis of any severity was 74 percent (95% CI 67-80 percent). Severe rotavirus gastroenteritis was defined by an established clinical score based upon intensity and duration of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/17\">",
"       17",
"      </a>",
"      ]. Rotavirus gastroenteritis was defined as the production of &ge;3 watery or looser-than-normal stools within a 24-hour period, or forceful vomiting, along with detection of rotavirus by enzyme immunoassay in a stool specimen obtained within 14 days of onset of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RV5 reduced hospitalization for G1-G4 rotavirus gastroenteritis by 96 percent (95% CI 90-98 percent) and for any gastroenteritis by 59 percent (95% CI 52-65 percent).",
"     </li>",
"     <li>",
"      RV5 reduced emergency department visits related to G1-G4 rotavirus gastroenteritis by 94 percent (95% CI 89-96 percent) and clinic visits by 86 percent (95% CI 74-93 percent).",
"     </li>",
"     <li>",
"      In the second rotavirus season after immunization, the efficacy against severe rotavirus gastroenteritis was 88 percent (95% CI 49-99 percent), and against rotavirus gastroenteritis of any severity was 63 percent (95% CI 44-75 percent).",
"     </li>",
"     <li>",
"      In an extension study of 20,736 original participants followed for up to 3.1 years after the last dose of RV5, the efficacy against hospitalization and emergency department visits related to rotavirus gastroenteritis of any serotype was 94 percent (95% CI 91-96 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RV5 was added to the routine infant immunization schedule in the United States in 2006. The effectiveness of rotavirus immunization is difficult to determine because many children with rotavirus gastroenteritis do not seek medical attention. However, the number of stool samples sent for rotavirus testing and the number of positive samples can serve as a marker of vaccine effectiveness. Such laboratory surveillance indicates that during the 2007 to 2008, 2008 to 2009, and 2009 to 2010 rotavirus seasons, rotavirus activity was delayed in onset and diminished in magnitude compared with the 2000 to 2006 rotavirus seasons (",
"    <a class=\"graphic graphic_figure graphicRef58821 \" href=\"mobipreview.htm?9/49/10000\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a national insurance database indicate that receipt of three doses of RV5 was 100 percent effective (95% CI 87-100 percent) in preventing rotavirus gastroenteritis hospitalization and emergency department visits and 59 percent effective (95% CI 47-68 percent) in preventing all-cause acute gastroenteritis, although the study methodology was biased toward increased effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/27\">",
"     27",
"    </a>",
"    ]. Additional studies confirm a dramatic decrease in rates of hospitalization, emergency department, and outpatient visits for rotavirus infection and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/28-32\">",
"     28-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43376967\">",
"    <span class=\"h3\">",
"     Herd immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from more than 1000 hospitals in the United States indicate that rotavirus immunization of infants has been associated with a reduction in diarrhea hospitalizations in older children and adults, suggesting that immunization of infants provides indirect protection for unvaccinated individuals (ie, herd immunity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/30\">",
"     30",
"    </a>",
"    ]. As an example, compared with 2006, rates of hospitalization for rotavirus infection in 2008 were reduced among children younger than three years, whether or not they were vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/31\">",
"     31",
"    </a>",
"    ]. There was an 87 percent reduction in the 6- to 11-month age group (with vaccine coverage 77 percent), a 96 percent reduction in the 12- to 23-month age group (vaccine coverage 46 percent), and a 92 percent reduction in the 24- to 35-month age group (vaccine coverage 1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV5 is administered orally. Each dose is 2 mL. The vaccine has a 24-month shelf-life at 2 to 8&ordm;C and should be administered as soon as possible after being removed from refrigeration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no need for dietary restriction, including breastfeeding, before or after the vaccine is administered. Doses that are regurgitated need not and should not be repeated, as this condition applied in the study of the vaccine's efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV5 is administered in three oral doses at two, four, and six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5-7,33\">",
"     5-7,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the first dose should be given between 6 and 14 weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Two subsequent doses are administered with a minimum interval of four weeks between doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/34\">",
"     34",
"    </a>",
"    ]. The third dose should not be administered after eight months, zero days of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The vaccine series should not be initiated in infants who are older than 14 weeks and 6 days of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. The safety of the first dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    in older infants was not studied in the prelicensure trials. However, for infants in whom the first dose is inadvertently administered at 15 weeks or older, the rest of the rotavirus immunization series should be completed as described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. The timing of the first dose should not affect the safety and efficacy of the second and third dose.",
"   </p>",
"   <p>",
"    In Europe, the first dose should be given between 6 and 12 weeks and the full schedule completed by six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RV5 may be administered at the same visit as the other routine inactivated infant immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,33,35\">",
"     5,6,33,35",
"    </a>",
"    ]. However, in countries where oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/57/33684?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    (OPV) continues to be used, the European Society for Pediatric Infectious Disease (ESPID) and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) suggest that RV5 and OPV not be administered at the same visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whenever possible, the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    series should be completed with the same vaccine product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. However, vaccination should not be deferred if the product used for previous doses is not known. A total of three doses of vaccine should be given to infants who received RV5 for any dose and infants in whom the vaccine product for previous dose(s) is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Special situations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RV5 can be administered to premature infants who are clinically stable, at least six weeks old, and are going to be or have been discharged from the nursery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,36\">",
"       5,6,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The vaccine also can be administered to breastfed infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,37\">",
"       5,6,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The RV5 series should be initiated or completed in infants who have had rotavirus gastroenteritis before receiving the full three-dose series because the initial infection frequently provides only partial immunity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     RV5 contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV5 is contraindicated in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,38,39\">",
"     5,6,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Who are allergic to any of the ingredients of the vaccine",
"     </li>",
"     <li>",
"      Who had a severe allergic reaction after a previous dose",
"     </li>",
"     <li>",
"      With severe combined immunodeficiency",
"     </li>",
"     <li>",
"      With a history of intussusception",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RV5 can be administered to infants with latex allergy because the RV5 applicator is latex-free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43377109\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotavirus vaccines are live virus vaccines and should not be administered to infants with known severe combined immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/38\">",
"     38",
"    </a>",
"    ]. Vaccine-acquired rotavirus disease within one month of the first, second, or third dose of RV5 has been reported in seven infants who subsequently were diagnosed with severe combined immunodeficiency (five cases reported in the literature and two reported to the Vaccine Adverse Event Reporting System [VAERS]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/38,40-42\">",
"     38,40-42",
"    </a>",
"    ]. An additional case of vaccine-acquired rotavirus disease following RV1 has also been reported to VAERS. Rotavirus disease in these infants was associated with prolonged viral shedding.",
"   </p>",
"   <p>",
"    Clinicians should consider the potential risks and benefits of administering",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    to infants with known or suspected alterations in immunity; the Advisory Committee on Immunization Practices advises consultation with an immunologist or infectious disease specialist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,38,43\">",
"     5,38,43",
"    </a>",
"    ]. There are few data regarding the safety or efficacy of rotavirus vaccine to infants who are potentially immunocompromised.",
"   </p>",
"   <p>",
"    The author of this topic review suggests that vaccination of infants born to mothers known to be HIV positive is safe provided that perinatal prophylaxis against HIV transmission was provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. There is no evidence that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    causes disease in HIV-infected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/44\">",
"     44",
"    </a>",
"    ]. In a randomized trial, administration of RV1 was safe and immunogenic when administered to HIV-positive infants in a three-dose schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rotavirus vaccines can be administered to infants living in households with immunocompromised persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. They also can be administered to infants living in households with pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and American Academy of Pediatrics (AAP) suggest the following conditions are precautions for the administration of rotavirus vaccines, because the safety and efficacy of the vaccine were not specifically evaluated in infants with these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute moderate to severe gastroenteritis &ndash; Immunization of infants with acute, moderate to severe gastroenteritis should be deferred until the illness resolves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. There is a concern that the antibody response may be diminished.",
"     </li>",
"     <li>",
"      Moderate to severe febrile illness &ndash; Immunization of infants with moderate to severe illness of any type should be deferred until the illness resolves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Deferral of the immunization makes it easier to differentiate possible adverse effects related to the vaccine from manifestations of the underlying disease.",
"     </li>",
"     <li>",
"      Pre-existing chronic gastrointestinal disease &ndash; Infants with pre-existing gastrointestinal conditions (eg, congenital malabsorption syndromes, Hirschsprung disease, short-bowel syndrome) who are not receiving immunosuppressive therapy should benefit from rotavirus vaccines, and the benefits outweigh the theoretic risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Receipt of a blood transfusion or blood products, including immunoglobulin &ndash; Rotavirus vaccines may be administered at any time in relation to the receipt of blood products, including antibody-containing products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     RV5 adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the prelicensure studies, the rates of death and serious adverse events were similar among vaccine and placebo recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. In the seven days after administration of dose 1, vaccinees had a small but significantly greater rate of diarrhea and vomiting than placebo recipients (1.3 percent increase for each symptom). After administration of dose 2, vaccinees also had a 1.8 percent increased rate of diarrhea. These symptoms were of mild intensity. The rates of fever and irritability were similar between groups.",
"   </p>",
"   <p>",
"    Any clinically significant or unexpected adverse events that occur after administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    should be reported to the Vaccine Adverse event Reporting System (VAERS,",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H8#H8\">",
"     \"Standard immunizations for children and adolescents\", section on 'Adverse event reporting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intussusception after RV5",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of intussusception is a contraindication to RV5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/39\">",
"     39",
"    </a>",
"    ]. RV5 continues to be indicated for infants without a history of intussusception. In the prelicensure studies of RV5, the number of cases of intussusception was similar between vaccine and placebo recipients: 12 cases among 34,837 vaccine recipients and 15 cases among 34,788 placebo recipients in the year of follow-up, with six and five cases among vaccine and placebo recipients, respectively, occurring within 42 days of any dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/18\">",
"     18",
"    </a>",
"    ]. Postlicensure studies conducted by the CDC, the Vaccine Safety Datalink investigation group, and the manufacturer have confirmed the prelicensure finding of vaccine safety with respect to the occurrence of intussusception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cases of intussusception following administration of the first, second, or third dose of RV5 have been reported, the number of cases does not exceed the number of cases expected based upon background rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Secular trends in rates of hospital discharges for intussusception did not change after rotavirus vaccination was reintroduced to the routine infant immunization schedule in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/50\">",
"     50",
"    </a>",
"    ]. The RV5 label and patient product information have been updated to include the postlicensure reports of intussusception, but there have been no changes in the recommendations for vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents should contact their infant's healthcare provider immediately if the infant has abdominal pain, vomiting, diarrhea, blood in the stool, or change in bowel movements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35145?source=see_link&amp;anchor=H9#H9\">",
"     \"Intussusception in children\", section on 'Clinical manifestations'",
"    </a>",
"    .) Cases of intussusception and other adverse events should be reported to the Vaccine Adverse Event Reporting System (VAERS",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known cause and effect relationship between RV5 and Kawasaki disease (KD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/53\">",
"     53",
"    </a>",
"    ]. Six cases of KD were reported during the Phase 3 clinical trial, and several additional cases have been reported to the VAERS in postmarketing surveillance. However, the number of cases of KD reported after administration of RV5 does not exceed the number of cases that would be expected to occur in infants who did not receive RV5 vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The label of RV5 was updated in June 2007 to include the postlicensure reports of KD, but there have been no changes in the recommendations for vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. Cases of KD and other adverse events should be reported to the VAERS (",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for transmission of vaccine virus was not evaluated in prelicensure studies. However, among subjects enrolled in phase 3 trials who were evaluated for fecal shedding of vaccine virus, the following results were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      9 percent shed vaccine virus four to six days after the first dose",
"     </li>",
"     <li>",
"      0 percent shed vaccine virus four to six days after the second dose",
"     </li>",
"     <li>",
"      0.3 percent shed vaccine virus four to six days after the third dose",
"     </li>",
"     <li>",
"      Shedding was observed as early as one day and as late as 15 days after vaccine was received",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transmission of vaccine-derived rotavirus from an infant to an older sibling resulting in symptomatic rotavirus gastroenteritis has been reported, but this case is unique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/56\">",
"     56",
"    </a>",
"    ]. To minimize the risk of transmission of RV5 if transmitted by the fecal-oral route, individuals who change the diapers of infants should wash their hands after changing a diaper. Particular care should be taken with this precaution for at least one week after the first dose of RV5.",
"   </p>",
"   <p>",
"    In the event that an infant requires hospitalization after administration of RV5, standard precautions should be utilized to prevent the spread of vaccine virus in the hospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/6\">",
"     6",
"    </a>",
"    ]. No additional infection control measures are necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Porcine circovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 2010, RV5 was found to contain components of porcine circovirus 1 (PCV1) and porcine circovirus 2 (PCV2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/57\">",
"     57",
"    </a>",
"    ]. However, given the established safety record of RV5 and the lack of evidence that PCV1 or PCV2 poses a safety risk in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/58\">",
"     58",
"    </a>",
"    ], the FDA recommends continued use of RV5. The known benefits of the oral vaccination outweigh the theoretic risk related to PCV1 or PCV2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    updated information is available through the",
"    <a class=\"external\" href=\"file://www.fda.gov/\">",
"     FDA",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ATTENUATED HUMAN ROTAVIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV1 (HRV, RIX4414) is a monovalent vaccine derived from the most common human rotavirus serotype (G1P[8]) specificity that has been attenuated by serial passage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/11\">",
"     11",
"    </a>",
"    ]. Similar to natural rotavirus infection, immunization with RV1 provides at least partial cross-protection against most other serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Route and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV1 is administered orally; each dose is 1 mL. It is administered in two doses at two and four months of age.",
"   </p>",
"   <p>",
"    In the United States, the first dose should be given between 6 and 14",
"    <span class=\"nowrap\">",
"     6/7",
"    </span>",
"    weeks of age and the full schedule completed by eight months, zero days of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The minimum interval between doses is four weeks.",
"   </p>",
"   <p>",
"    In Europe, the first dose should be given between 6 and 12 weeks and the full schedule completed by six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RV1 can be administered at the same visit as the other routine inactivated infant immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, in countries where oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/57/33684?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    (OPV) continues to be used, the European Society for Pediatric Infectious Disease (ESPID) and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) suggest that RV1 and OPV not be administered at the same visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whenever possible, the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    series should be completed with the same vaccine product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"     5",
"    </a>",
"    ]. However, vaccination should not be deferred if the product used for previous doses is not known. A total of three doses of vaccine should be given to infants who received RV5 for any dose and infants in whom the vaccine product for previous dose(s) is unknown.",
"   </p>",
"   <p>",
"    There is no need for dietary restriction, including breastfeeding, before or after the vaccine is administered. If the infant spits out or regurgitates most of the vaccine dose, a single replacement dose may be administered at the same vaccination visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539692945\">",
"    <span class=\"h3\">",
"     Special situations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RV1 can be administered to premature infants who are clinically stable, at least six weeks old, and are going to be or have been discharged from the nursery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,64\">",
"       5,6,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      RV1 can be administered to breastfed infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,65\">",
"       5,6,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The RV1 series should be initiated or completed in infants who have had rotavirus gastroenteritis before completing the two-dose series because the initial infection frequently provides only partial immunity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     RV1 contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV1 is contraindicated in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5,6,38,39\">",
"     5,6,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Who are allergic to any of the ingredients of the vaccine",
"     </li>",
"     <li>",
"      Who had a severe allergic reaction after a previous dose",
"     </li>",
"     <li>",
"      With severe combined immunodeficiency",
"     </li>",
"     <li>",
"      With a history of intussusception",
"     </li>",
"     <li>",
"      With severe (anaphylactic) allergy to latex (the applicator contains latex) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link&amp;anchor=H12#H12\">",
"       \"Allergic reactions to vaccines\", section on 'Latex'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43377178\">",
"    <span class=\"h2\">",
"     RV1 precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precautions for RV1 are the same as those for RV5. (See",
"    <a class=\"local\" href=\"#H43377109\">",
"     'Precautions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     RV1 efficacy and effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV1 is efficacious in preventing rotavirus gastroenteritis in well-nourished and malnourished infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/20,66-73\">",
"     20,66-73",
"    </a>",
"    ]. It was evaluated in a phase 3 trial that included 63,225 healthy infants from 11 countries in Latin America and Finland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/69\">",
"     69",
"    </a>",
"    ]. Infants were randomly assigned to receive RV1 or placebo at two and four months of age. Episodes of severe gastroenteritis were identified by active surveillance of 20,169 infants from two weeks after the second dose until one year of age. Severe gastroenteritis was defined by the passage of &ge;3 loose or watery stools within a 24-hour period, with or without vomiting, that required overnight hospitalization or rehydration therapy in a medical facility. The following results were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy against severe rotavirus gastroenteritis was 85 percent (95% CI 72-92 percent) and against severe gastroenteritis from any cause was 40 percent (95% CI 28-50 percent)",
"     </li>",
"     <li>",
"      The efficacy against gastroenteritis caused by G1P[8] strains was 92 percent (95% CI 74-98 percent) and against strains sharing only the P[8] antigen (G3P[8], G4P[8], G9P[8]) was 87 percent",
"     </li>",
"     <li>",
"      The efficacy against hospitalization for rotavirus gastroenteritis was 85 percent (95% CI 70-94 percent) and against hospitalization for gastroenteritis from any cause was 42 percent (95% CI 29-53 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of RV1 during the first two years of life was assessed in a subgroup of patients and found to be similar to that during the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/73\">",
"     73",
"    </a>",
"    ]. However, protection against severe gastroenteritis caused by heterotypic G2P[4] strains was only 39 percent (95% CI &lt;0-84.2), highlighting the need for prospective surveillance of vaccine effect and circulating strains. Subsequent study has revealed significant efficacy against heterotypic G2 strains in some settings.",
"   </p>",
"   <p>",
"    Additional trials and postmarketing surveillance confirm that rotavirus vaccines are also efficacious in less developed countries with greater burden of rotavirus disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/44,74-76\">",
"     44,74-76",
"    </a>",
"    ]. In one such trial, conducted in South Africa and Malawi, the pooled efficacy of RV1 in preventing severe rotavirus gastroenteritis was 61.2 percent (95% CI 44-73.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/74\">",
"     74",
"    </a>",
"    ]. Although the efficacy in Malawi was lower than that in South Africa (49.4 versus 76.9 percent), the number of episodes of severe rotavirus gastroenteritis that were prevented was greater (6.7 versus 4.2 episodes). In a postmarketing study in Mexico, introduction of RV1 was associated with decreased diarrhea-related mortality among children younger than five years (from 18.1 to 11.8 deaths per 100,000 children, a 35 percent reduction [95% CI 29-39]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/75\">",
"     75",
"    </a>",
"    ]. These findings support the World Health Organization Strategic Advisory Group of Experts on Immunization's recommendation for worldwide use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/44,77\">",
"     44,77",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     RV1 safety",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Intussusception after RV1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of intussusception is a contraindication to RV1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/39,63\">",
"     39,63",
"    </a>",
"    ]. Fatal intussusception after the second dose has been reported in infants with a history of intussusception after the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'RV1 contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    RV1 continues to be indicated for infants without a history of intussusception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/79\">",
"     79",
"    </a>",
"    ]. In the phase 3 trial, the number of cases of intussusception was statistically similar between vaccine and placebo recipients (9 cases overall in vaccine recipients and 16 in placebo recipients during the entire safety surveillance period [median duration 100 days after the first dose]; with six and seven cases in vaccine and placebo recipients, respectively, occurring within 31 days of any dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postmarketing surveillance studies suggest an increased risk of intussusception after administration of RV1 in some populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/49,80-83\">",
"     49,80-83",
"    </a>",
"    ]. These studies must be interpreted with caution. The pattern of increased risk varied depending upon the country (after the first dose in Mexico and after the second dose in Brazil, where the first dose of RV1 is coadministered with oral polio vaccine) and similar patterns of risk have not been observed in safety studies of RV1 in other countries. Moreover, because intussusception is rare, the number of excessive cases attributable to RV1 is small (approximately 1 in 51,000 infants in Mexico and 1 in 68,000 infants in Brazil) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/81\">",
"     81",
"    </a>",
"    ]. The absolute number of estimated rotavirus deaths and hospitalizations prevented by rotavirus vaccines (1300 deaths and &gt;80,000 hospitalizations) far exceeds those for intussusception associated with RV1 (5 deaths and 96 hospitalizations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In September 2010, the warnings and precautions section of the label of RV1 was updated to include intussusception as a potential adverse effect. Pending additional investigation, the United States Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) continue to recommend rotavirus vaccination. The risk of intussusception after rotavirus vaccination is much lower than the risk of severe rotavirus gastroenteritis in children who do not receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents should contact their child&rsquo;s healthcare provider if the child develops signs of intussusception (ie, stomach pain, vomiting, diarrhea, blood in the stool, or change in bowel habits) anytime after vaccination, but especially within the first seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35145?source=see_link&amp;anchor=H9#H9\">",
"     \"Intussusception in children\", section on 'Clinical manifestations'",
"    </a>",
"    .) Intussusception and other adverse events following rotavirus vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS,",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with RV5, cases of Kawasaki Disease (KD) have been reported among vaccine recipients, but a causal association has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/63\">",
"     63",
"    </a>",
"    ]. Cases of KD and other adverse events should be reported to the VAERS (",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H8#H8\">",
"     \"Standard immunizations for children and adolescents\", section on 'Adverse event reporting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Rotavirus shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotavirus shedding in the stool following administration of the first dose of the vaccine peaks at approximately seven days after administration; transmission of vaccine virus was not evaluated in prelicensure studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/63\">",
"     63",
"    </a>",
"    ]. Horizontal transmission of RV1 was detected among twins enrolled in RV1 studies in which one twin received vaccine and the other received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/84\">",
"     84",
"    </a>",
"    ], but such transmission is unique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     PCV1 contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In March 2010, RV1 was found to contain components of porcine circovirus 1 (PCV1) when it was analyzed by an academic team using a novel technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/85\">",
"     85",
"    </a>",
"    ]. The FDA recommended that the use of RV1 be temporarily suspended while it gathered more information.",
"   </p>",
"   <p>",
"    The suspension was lifted in May 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/57\">",
"     57",
"    </a>",
"    ]. PCV1 components have been present since the early stages of RV1 development, including during the prelicensure clinical trials. Millions of children have received RV1 without adverse events related to PCV1. PCV1 is not known to cause illness in humans, and there is no evidence that recipients of RV1 are at increased risk of adverse events. The known benefits of the oral vaccination outweigh the theoretic risk related to PCV1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/59\">",
"     59",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Additional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    updated information is available through the",
"    <a class=\"external\" href=\"file://www.fda.gov/\">",
"     FDA",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HUMAN-RHESUS ROTAVIRUS REASSORTANT (RRV-TV, ROTASHIELD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oral tetravalent human-rhesus rotavirus reassortant vaccine (RRV-TV, RotaShield) was licensed in 1998 and recommended for universal immunization of term infants in the United States in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/12\">",
"     12",
"    </a>",
"    ]. The RRV-TV vaccine contained reassortants representing the human G1, G2, and G4 serotypes, and the unmodified rhesus rotavirus (which has G3 specificity like naturally circulating human rotaviruses). In addition, each reassortant contained the rhesus rotavirus VP4 in each of its four components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Association with intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Just over a year after RRV-TV was licensed, it was withdrawn from the market because of an epidemiologic link to intussusception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The increased risk was estimated to be approximately 22-fold over the background risk within five to seven days of vaccination and overall approximately one excess case for every 10,000 to 12,000 infants vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/15,86\">",
"     15,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of this association and its public health significance are unclear. It has been hypothesized that vaccination triggered intussusception in infants who were likely to develop intussusception with any enteric infection, based upon the observation that rates of intussusception were actually lower among vaccine recipients than non-vaccinees in the period 4 to 12 weeks after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, RRV-TV may have caused intussusception in infants who otherwise would not have experienced intussusception, but it also may have protected against natural rotavirus infection-induced intussusception in others.",
"   </p>",
"   <p>",
"    Rotavirus strain differences make a difference in intussusception risk as the results with RV5 and RV1 make clear. In mice, rotavirus strains differ in their enhancement of intussusception risk in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, rotavirus vaccines differ in their reactogenicity after administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40937/abstract/18,52,69,88-91\">",
"     18,52,69,88-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/13/27858?source=see_link\">",
"       \"Patient information: Rotavirus infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotavirus is the single most important viral cause of severe gastroenteritis in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"       \"Epidemiology and causes of acute diarrhea in developed countries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In accordance with the Centers for Disease Control and Prevention, the American Academy of Pediatrics, the American Academy of Family Physicians, the European Society for Paediatric Infectious Diseases, and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition, we recommend universal immunization of infants against rotavirus disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two oral vaccines are available for the prevention of rotavirus disease: pentavalent human-bovine reassortant",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       rotavirus vaccine",
"      </a>",
"      (RV5, PRV, RotaTeq) and attenuated human rotavirus vaccine (RV1, HRV, Rotarix). These vaccines have different doses and schedules for administration (",
"      <a class=\"graphic graphic_table graphicRef70478 \" href=\"mobipreview.htm?20/22/20844\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pentavalent human-bovine reassortant rotavirus vaccine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Attenuated human rotavirus vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       rotavirus vaccine",
"      </a>",
"      series should be completed with the same vaccine product, but vaccination should not be deferred if the product used for previous doses is not known. A total of three doses should be given to infants who received RV5 for any dose and infants in whom the vaccine product for previous dose(s) is unknown. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       Rotavirus vaccine",
"      </a>",
"      is contraindicated in infants who are allergic to any of the ingredients of the vaccine, those who had an allergic reaction after a previous dose, and those with a history of intussusception. It should not be administered to infants with immunodeficiency. RV1 is contraindicated in infants with a history of severe hypersensitivity reaction to latex, but RV5 may be administered to such infants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'RV5 contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'RV1 contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions that are precautions for administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       rotavirus vaccine",
"      </a>",
"      include acute moderate or severe illness, preexisting chronic gastrointestinal disorder, and receipt of blood products. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'RV5 contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In prelicensure studies, the rates of serious adverse events and of intussusception were the same among vaccine and placebo recipients. Postmarketing surveillance, based upon preliminary data from one of several safety studies, indicates a slightly increased risk of intussusception with RV1, but not with RV5. The risk of intussusception after rotavirus vaccination is much lower than the risk of severe rotavirus gastroenteritis in children who do not receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"       rotavirus vaccine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'RV5 adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'RV1 safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/1\">",
"      Bresee JS, Hummelman E, Nelson EA, Glass RI. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 2005; 192 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/2\">",
"      Nakagomi T, Nakagomi O, Takahashi Y, et al. Incidence and burden of rotavirus gastroenteritis in Japan, as estimated from a prospective sentinel hospital study. J Infect Dis 2005; 192 Suppl 1:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/3\">",
"      Moe K, Hummelman EG, Oo WM, et al. Hospital-based surveillance for rotavirus diarrhea in children in Yangon, Myanmar. J Infect Dis 2005; 192 Suppl 1:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/4\">",
"      Van Man N, Luan le T, Trach DD, et al. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998-2003. J Infect Dis 2005; 192 Suppl 1:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/5\">",
"      Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Rotavirus infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.626.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/7\">",
"      Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008; 46 Suppl 2:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/8\">",
"      Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. J Infect 2002; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/9\">",
"      Conner ME, Matson DO, Estes MK. Rotavirus vaccines and vaccination potential. Curr Top Microbiol Immunol 1994; 185:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/10\">",
"      Vesikari T. Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Ann Med 1999; 31:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/11\">",
"      Glass RI, Parashar UD. The promise of new rotavirus vaccines. N Engl J Med 2006; 354:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/12\">",
"      Recommended childhood immunization schedule-United States, January-December 1999. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1999; 103:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/13\">",
"      Peter G, Myers MG, National Vaccine Advisory Committee, National Vaccine Program Office. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002; 110:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/15\">",
"      Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/16\">",
"      Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003; 187:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/17\">",
"      Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/18\">",
"      Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/19\">",
"      Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/20\">",
"      Soares-Weiser K, Maclehose H, Ben-Aharon I, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2010; :CD008521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/21\">",
"      Grant LR, Watt JP, Weatherholtz RC, et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatr Infect Dis J 2012; 31:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/22\">",
"      Vesikari T, Karvonen A, Ferrante SA, et al. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010; 29:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/24\">",
"      Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction--United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/26\">",
"      Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/27\">",
"      Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:e208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/28\">",
"      Cortese MM, Tate JE, Simonsen L, et al. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/29\">",
"      Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/30\">",
"      Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011; 204:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/31\">",
"      Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/32\">",
"      Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 2011; 365:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/33\">",
"      Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007; 26:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/34\">",
"      Goveia MG, Suprun L, Itzler RF, et al. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatr Infect Dis J 2010; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/35\">",
"      Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009; 28:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/36\">",
"      Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007; 26:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/37\">",
"      Goveia MG, DiNubile MJ, Dallas MJ, et al. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008; 27:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010; 59:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR Morb Mortal Wkly Rep 2011; 60:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/40\">",
"      Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/41\">",
"      Uygungil B, Bleesing JJ, Risma KA, et al. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol 2010; 125:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/42\">",
"      Werther RL, Crawford NW, Boniface K, et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009; 124:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/43\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/44\">",
"      Santosham M. Rotavirus vaccine--a powerful tool to combat deaths from diarrhea. N Engl J Med 2010; 362:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/45\">",
"      Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. Pediatr Infect Dis J 2011; 30:125.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. FDA Public Health Notification. Information on RotaTeq and intussusception file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm100895.htm (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/48\">",
"      Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012; 307:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/49\">",
"      Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011; 29:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/50\">",
"      Zickafoose JS, Benneyworth BD, Riebschleger MP, et al. Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. Arch Pediatr Adolesc Med 2012; 166:350.",
"     </a>",
"    </li>",
"    <li>",
"     RotaTeq&reg; [Rotavirus Vaccine, Live, Oral, Pentavalent] product label file://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     Patient Information. RotaTeq&reg; rotavirus vaccine, live, oral, pentavalent. Merck &amp; Co, Inc file://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_ppi.pdf (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     Information pertaining to labeling revision for RotaTeq file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm142393.htm (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/54\">",
"      Loughlin J, Mast TC, Doherty MC, et al. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012; 31:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/55\">",
"      Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007; 11 Suppl 2:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/56\">",
"      Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010; 125:e438.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Update on recommendations for the use of rotavirus vaccines. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm212140.htm (Accessed on May 17, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/58\">",
"      Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010; 84:6033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/59\">",
"      Kuehn BM. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010; 304:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/60\">",
"      Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis 2011; 204:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/61\">",
"      Dennehy PH, Bertrand HR, Silas PE, et al. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122:e1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/62\">",
"      Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30:e103.",
"     </a>",
"    </li>",
"    <li>",
"     Rotarix (Rotavirus vaccine, live, oral) prescribing information, 2011. file://us.gsk.com/products/assets/us_rotarix.pdf (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/64\">",
"      Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/65\">",
"      Vesikari T, Prymula R, Schuster V, et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J 2012; 31:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/66\">",
"      Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/67\">",
"      Salinas B, P&eacute;rez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/68\">",
"      De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004; 23:S179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/69\">",
"      Ruiz-Palacios GM, P&eacute;rez-Schael I, Vel&aacute;zquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/70\">",
"      Perez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis 2007; 196:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/71\">",
"      Ruiz-Palacios GM, Guerrero ML, Bautista-M&aacute;rquez A, et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics 2007; 120:e253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/72\">",
"      Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/73\">",
"      Linhares AC, Vel&aacute;zquez FR, P&eacute;rez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/74\">",
"      Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/75\">",
"      Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010; 362:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/76\">",
"      Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/77\">",
"      Meeting of the immunization Strategic Advisory Group of Experts, April 2009--conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220.",
"     </a>",
"    </li>",
"    <li>",
"     MedWatch. The FDA safety information and adverse event reporting program. Drug safety labeling changes. Rotarix (rotavirus vaccine, live, oral) oral suspension. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm230397.htm (Accessed on April 18, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Rotarix&reg; rotavirus vaccine: Rare side effect possible. Questions and answers for parents and caregivers. file://www.cdc.gov/vaccines/vpd-vac/rotavirus/Vac-label-parents.htm (Accessed on September 23, 2010).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Information on Rotarix--Labeling revision pertaining to intussusception. file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm226690.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/81\">",
"      Patel MM, L&oacute;pez-Collada VR, Bulh&otilde;es MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/82\">",
"      Escolano S, Farrington CP, Hill C, Tubert-Bitter P. Intussusception after rotavirus vaccination--spontaneous reports. N Engl J Med 2011; 365:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/83\">",
"      Vel&aacute;zquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012; 31:736.",
"     </a>",
"    </li>",
"    <li>",
"     Han HH. Summary of human rotavirus vaccine Rotarix: safety and efficacy trials. Paper presented at: The Vaccines for Enteric Disease Conference, September 10, 2009, Malaga, Spain.",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Components of extraneous virus detected in Rotarix vaccine; no known safety risk www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm205625.htm (Accessed on March 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/86\">",
"      DeStefano F, Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 2001; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/87\">",
"      Warfield KL, Blutt SE, Crawford SE, et al. Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse model. J Virol 2006; 80:12377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/88\">",
"      Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. FDA Public Health Notification. Information on RotaTeq and intussusception. file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm100895.htm (Accessed on August 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/90\">",
"      Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40937/abstract/91\">",
"      Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6023 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40937=[""].join("\n");
var outline_f39_62_40937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy/effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43376967\">",
"      - Herd immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Special situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RV5 contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43377109\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RV5 adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intussusception after RV5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Porcine circovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ATTENUATED HUMAN ROTAVIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Route and schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H539692945\">",
"      - Special situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RV1 contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43377178\">",
"      RV1 precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RV1 efficacy and effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RV1 safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Intussusception after RV1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Rotavirus shedding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PCV1 contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HUMAN-RHESUS ROTAVIRUS REASSORTANT (RRV-TV, ROTASHIELD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Association with intussusception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6023|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/49/10000\" title=\"figure 1\">",
"      Rotavirus effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/22/20844\" title=\"table 1\">",
"      Rotavirus vaccines summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/13/27858?source=related_link\">",
"      Patient information: Rotavirus infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9912?source=related_link\">",
"      Prevention and treatment of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40938="Radiofrequency catheter ablation to prevent recurrent atrial fibrillation";
var content_f39_62_40938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Rod Passman, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     N A Mark Estes, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/62/40938/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/62/40938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two principal goals of therapy in all patients with atrial fibrillation (AF) are the reduction of the risk of stroke and the alleviation of symptoms. To accomplish the former, most patients with AF will require oral anticoagulant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to control of symptoms, a decision needs to be made regarding treatment with either a rhythm control or rate control strategy in most patients. Randomized trials such as AFFIRM and RACE have shown no significant difference in major outcomes (mortality and stroke) with rate control in minimally symptomatic or asymptomatic individuals with other stroke risk factors who are candidates for either approach. This finding may have been due, in part, to inadequate anticoagulation among patients whose rhythm was thought to be controlled with antiarrhythmic agents, but may in fact been having recurrences of asymptomatic AF. In addition, the findings of AFFIRM and RACE may reflect the limited efficacy of our current methods for restoring and maintaining sinus rhythm with antiarrhythmic agents, rather than equivalence between AF and sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two limitations of antiarrhythmic drugs include inconsistent efficacy in maintaining sinus rhythm and frequent side effects. Because of these limitations, nonpharmacologic approaches have been evaluated to prevent recurrent AF. The two most common nonpharmacologic approaches are radiofrequency catheter ablation (RFA) and surgery. Additional nonpharmacologic therapies have been studied, including atrial pacing, and implantable atrial defibrillators, although neither of these is commonly used in current clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=see_link\">",
"     \"The role of pacemakers in the prevention of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link&amp;anchor=H2161774#H2161774\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Atrial defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to surgical procedures, ablation procedures for preventing recurrent AF are directed at the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elimination of the triggers of AF &ndash; Triggers are usually eliminated by disrupting the conduction of electrical activity between the tissues that contain these arrhythmogenic triggers (most commonly the ostial portion of the pulmonary veins), and the atrial myocardium. Less commonly, triggers within the atrial myocardium can be directly ablated.",
"     </li>",
"     <li>",
"      Modifying the atrial substrate(s) responsible for the maintenance of AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of RFA in the management of patients with AF has not yet been fully defined. Reports of outcomes with RFA have generally heterogenous populations of patients using several ablation techniques and variable intensities and duration of follow-up. Such differences make comparison of the outcomes from different studies problematic.",
"   </p>",
"   <p>",
"    The data evaluating the efficacy of RFA will be reviewed here. The discussion of surgery is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of nonpharmacologic strategies for rate control in AF or to minimize thrombotic risk by left atrial appendage ligation and an overview of the management of patients with AF are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=see_link\">",
"     \"Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620592292\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal AF is defined as recurrent AF (&ge; two episodes) that terminates spontaneously in less than seven days, usually less than 24 hours. Persistent AF is defined as AF that fails to self-terminate within seven days. Episodes often require pharmacologic or electrical cardioversion to restore sinus rhythm. While a patient who has had persistent AF can have later episodes of paroxysmal AF, AF is generally considered a progressive disease. In individuals with paroxysmal AF, progression to persistent and permanent AF occur in &gt;50 percent beyond 10 years despite antiarrhythmic therapy. Longstanding persistent AF refers to AF that has lasted for one year or more when it has been decided to adopt a rhythm control strategy; it is sometimes referred to as chronic AF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of atrial fibrillation\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC ORIGIN OF AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is thought that the initiation of AF requires both a trigger either within or near the atria and a susceptible substrate within the atria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=see_link&amp;anchor=H186294596#H186294596\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Basic atrial electrophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anatomic relative significance of triggers and substrate differs depending upon whether the AF is paroxysmal, persistent, or permanent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H356405846#H356405846\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Paroxysmal AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following important observations regarding triggers came from early studies of patients with paroxysmal AF and have guided the development of successful ablation techniques for AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AF is commonly triggered by ectopic beats from muscle fibers (fascicles) extending from the left atrium into the pulmonary veins (PVs).",
"     </li>",
"     <li>",
"      Ectopic foci were localized to the PVs in approximately 90 percent of patients with predominantly structurally normal hearts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most patients have one or two foci [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most (94 percent) of the foci are 2 to 4 cm inside the pulmonary veins, with the left superior vein being the most common site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The remaining foci are usually in the right or left atrium. The superior vena cava is a much less common site of triggering ectopic beats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these observations, early attempts at ablation targeted these focal ectopic beats within the PV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H51\">",
"     'Focal ablation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This approach was limited by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inconsistent ability to elicit the triggering beats during electrophysiology study.",
"     </li>",
"     <li>",
"      Difficulties with precise localization of appropriate ablation sites.",
"     </li>",
"     <li>",
"      The risk of pulmonary vein stenosis which can occur following ablation within the pulmonary veins. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Pulmonary vein stenosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The limitations of techniques aimed at targeting focal ectopic beats within the PV led to the development of approaches to empirically electrically isolate all four PVs from the body of the left atrium. This is accomplished by either segmental ablation at the PV ostium or the ablation of atrial tissue near the PV ostia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Longstanding persistent AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above findings in patients with paroxysmal AF, patients cardioverted from longstanding persistent AF often have multiple ectopic sites distributed throughout the atria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/6\">",
"     6",
"    </a>",
"    ]. This finding can reduce the efficacy of RFA procedures that are limited to PV isolation in patients with longstanding persistent AF in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/7\">",
"     7",
"    </a>",
"    ]. The discussion of the management of these patients is discussed separately. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Special circumstances'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H968282607\">",
"    <span class=\"h2\">",
"     Left atrial appendage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above the pulmonary veins are the most common source for the initiation of AF; however, other sites both within and outside of the left atrium may act as triggers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 987 patients with both paroxysmal and longstanding persistent AF undergoing redo catheter ablation for AF, 27 percent demonstrated firing from the left atrial appendage (LAA). The LAA was the only source of the arrhythmia in about one third.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULMONARY VEIN ISOLATION PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various methods of catheter ablation have been used, but currently most focus on isolating the triggers in the pulmonary veins from the vulnerable substrate in the left atrium. The majority of ablations performed use radiofrequency energy (RFA), but cryoballoon ablation has recently been approved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging and mapping tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablation for AF is one of the most complicated and lengthy nonsurgical procedures used in the treatment of cardiovascular disease, and requires sophisticated adjunctive tools to localize both the appropriate anatomy and the electrical targets for ablation. The two principal techniques discussed below (segmental ostial (PV) ablation and circumferential ablation of left atrial tissue) require advanced imaging and mapping technologies to improve efficacy and reduce complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Three-dimensional mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the tools commonly used during pulmonary vein isolation is a nonfluoroscopic, three-dimensional, catheter-based electroanatomic mapping system. One system, the CARTO mapping system, has a magnetic field emitter and sensor and can create a replica of the anatomy of the cardiac chamber in which the tachycardia focus is located, permitting the creation of anatomy-based linear transmural ablations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Another system, the NavX system, uses electrical localization signals at different frequencies to detect the locations of catheters and to generate similar anatomy-based continuous ablation lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=see_link&amp;anchor=H19#H19\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Electroanatomical mapping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intracardiac echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intracardiac echocardiography permits more accurate and effective targeting of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/12\">",
"     12",
"    </a>",
"    ]. It can also facilitate the deployment of mapping catheters and provide guidance during transseptal puncture. Lastly, it can be used to monitor for complications during the procedure such as pericardial effusion and tamponade. Transesophageal echocardiography has also been used for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CT and MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional radiographic images obtained with MRI and CT scan provide helpful anatomic information about the atria and the pulmonary veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Technologies that incorporate these radiological images into the three-dimensional mapping systems have been developed to guide the ablative procedure during PVI. CT scans are used much more frequently than MRI due to their lower costs and easy scheduling, especially with the availability of faster multi-slice CT scanners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Segmental ostial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental ostial isolation is performed by targeting sites of electrical conduction in the PV ostia. Electrical isolation can often be accomplished without complete encirclement of the PVs within their ostia.",
"   </p>",
"   <p>",
"    In segmental ostial PVI, a circular or \"lasso\" catheter is placed at the orifice of a pulmonary vein. Multiple electrodes around the lasso define the precise location of the sites of electrical connection between the pulmonary vein and the body of the atrium. These connections are ablated near the PV orifice, on the atrial side of the boundary, until no further electrical communication is evident.",
"   </p>",
"   <p>",
"    Placement of ablation lesions is guided by both anatomic landmarks and localization of electrical connections between the PVs and left atrium (mapping). Additional ablation lines connecting anatomic structures are sometimes also made during these procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Selective PVI",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce procedure time and radiation exposure, some investigators have studied the potential efficacy of isolating only those veins in which ectopic foci are evident. However, with this selective approach, as with focal ablation of ectopic foci described above, AF recurrence rates were significantly higher in comparison to empiric isolation of all four pulmonary veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17\">",
"     17",
"    </a>",
"    ]. Because of lower efficacy, selective PVI is now rarely done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Circumferential left atrial ablation or WACA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumferential left atrial (LA) ablation, or circumferential wide-area LA catheter ablation (WACA), involves the creation of confluent ablation lesions that encircle the ostia of all four pulmonary veins, usually in two pairs (ie, a left-circle and a right-sided circle). [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17-26\">",
"     17-26",
"    </a>",
"    ]. These ablation lesions are usually placed based upon anatomic considerations alone (ie, detailed mapping with a lasso catheter is not required), which can simplify the procedure. Additional ablation lines are sometimes made connecting ablation lines to one another or to anatomic landmarks (most often the mitral annulus). These additional lines are intended to prevent the creation of macroreentrant circuits that can lead to left atrial flutter.",
"   </p>",
"   <p>",
"    Circumferential LA ablation results in more extensive ablations across a wider area of the left atrium than does segmental PVI. Because of the more extensive ablation, this technique may provide additional methods for preventing AF, including autonomic denervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/27\">",
"     27",
"    </a>",
"    ], elimination of triggering foci outside the PVs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/28\">",
"     28",
"    </a>",
"    ], and alteration of the left atrial substrate necessary for perpetuating AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/29\">",
"     29",
"    </a>",
"    ]. However, more extensive ablation, particularly in the posterior LA, may increase the rate of complications. The relative efficacy and safety of these methods is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comparison between segmental and circumferential procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comparison between segmental and circumferential procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small randomized comparisons of circumferential and segmental approaches have yielded contradictory results with regard to efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher success rate with circumferential left atrial ablation was noted in a randomized trial in which 80 consecutive patients with symptomatic paroxysmal AF were assigned to either circumferential or segmental ostial PVI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/25\">",
"       25",
"      </a>",
"      ]. At six-month follow-up, the patients treated with circumferential PVI were significantly more likely to be free of symptomatic paroxysmal AF without antiarrhythmic drugs (88 versus 67 percent with segmental ostial ablation). The only complication was left atrial flutter in a patient who underwent left atrial catheter ablation, which was abolished by additional ablation in the mitral isthmus.",
"     </li>",
"     <li>",
"      The results were different in a second trial in which 100 patients were randomly assigned to circumferential left atrial ablation or segmental PVI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30\">",
"       30",
"      </a>",
"      ]. Follow-up was more detailed since, in addition to reports of symptomatic recurrence, all patients underwent seven days of Holter monitoring at six months post-procedure. The rate of symptomatic recurrences (46 versus 18 percent) and atrial arrhythmias on Holter monitoring (58 versus 44 percent) was significantly greater with circumferential ablation compared to segmental ablation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the two studies are not directly comparable due to between study differences in patient severity of illness, technical aspects of the procedures, especially with frequent lack of confirmation of total electrical isolation of pulmonary veins with circumferential isolation, and intensity of surveillance for recurrent AF.",
"   </p>",
"   <p>",
"    The optimal ablative procedure may vary from patient to patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Safety concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to possible efficacy differences, there may be an increased rate of adverse effects with more extensive circumferential ablation. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These include higher rates of left atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/25\">",
"     25",
"    </a>",
"    ] and asymptomatic pericardial effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, two rare but more concerning complications have also been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formation of atrioesophageal fistula, an often lethal complication, has been reported with the more extensive left atrial ablation procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyloric spasm and gastric hypomotility was reported in four of 367 consecutive patients in two centers (1.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/33\">",
"       33",
"      </a>",
"      ]. The mechanism is postulated to be extension of RF injury to the vagus nerve plexus surrounding the esophagus. PVI protocols were different at the two centers, but both involved additional ablation lines connecting isolated pulmonary veins. In our experience, complaint of indigestion after ablation was fairly common (&gt;15 percent) albeit transient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Importance of complete isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving complete conduction block between the pulmonary veins and left atrium (true electrical isolation) is an accepted end point for these procedures. There is a high correlation between AF recurrences and the demonstration of persistent or recurrent conduction between the left atrium and PVs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/26,34-36\">",
"     26,34-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'AF recurrence after three months'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Confirming isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirming isolation is central to PVI. To do this, a circular or a basket mapping catheter is positioned at the PV ostium for the purpose of recording electrograms within the PVs. The elements of electrical isolation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Entrance block &mdash; This refers to the inability of electrical activity in the LA to reach the PVs. Entrance block is present if PV potentials are either completely absent or are dissociated from the LA during sinus rhythm or atrial pacing.",
"     </li>",
"     <li>",
"      Exit block &mdash; This refers to the inability of electrical activity in the PVs to reach the LA. Exit block is present if there is a lack of conduction from the PV to the LA during pacing from the distal PV, or if spontaneous PV potentials are present that are dissociated from the LA.",
"     </li>",
"     <li>",
"      Bidirectional block refers to both entrance and exit block. However, PVI is often said to be present if only entrance block is demonstrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to segmental ostial ablation, demonstration of complete electrical isolation is not always an end point of circumferential LA ablation. In early reports, the end point was demonstration of reduced electrogram voltage inside the encircled regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/22\">",
"     22",
"    </a>",
"    ]. This end point is still used by some operators and investigators. Complete PVI is possible with circumferential ablation, and there is active debate regarding the necessity of demonstrating complete PVI when this approach is used. However, increasing evidence has pointed to an essential role of complete electrical isolation to reduce the recurrence rate. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Importance of complete isolation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066879413\">",
"    <span class=\"h2\">",
"     Ablation of sources within the atria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ablation of sources within the atrial plus conventional ablation was evaluated in the CONFIRM trial and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=see_link&amp;anchor=H186294983#H186294983\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Maintenance of AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three categories of recurrent atrial arrhythmias should be considered separately when evaluating the efficacy of AF ablation procedures: early recurrence of AF, late recurrence of AF, and atrial flutter, which is often atypical and arise in the left atrium. Each has distinct mechanisms and management implications. An occasional patient may develop recurrent, usually paroxysmal atrial tachycardia after circumferential PVI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Early AF recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recurrences of AF are primarily seen within the first two weeks after RFA. This was illustrated in a review of 110 patients in whom symptomatic AF recurred in 35 percent within the first two weeks (mean 3.7 days), an additional 7 percent between two and four weeks, and 3 percent between one and two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/23\">",
"     23",
"    </a>",
"    ]. Approximately one-third of these patients were free of recurrent AF at seven months.",
"   </p>",
"   <p>",
"    Thus early AF may be a transient phenomenon. It is postulated to be related to sterile pericarditis after radiofrequency ablation, recovered pulmonary vein conduction, or proarrhythmic effects of the ablation procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/38\">",
"     38",
"    </a>",
"    ]. As a result, a trial of short-term antiarrhythmic drugs for two to three months is warranted before consideration of repeat ablation in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     AF recurrence after three months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of AF occurring after the three-month blanking period are considered recurrent AF. The frequency of recurrent AF varies somewhat in part due to factors such as the method and intensity of surveillance, whether other atrial arrhythmias are counted, the ablation technique used, the definition of success applied, and patient characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/39\">",
"     39",
"    </a>",
"    ]. In most studies, success has been defined as the absence of recurrent AF or other atrial arrhythmias in patients not taking antiarrhythmic drugs; arrhythmias that occur during the first three months are often not counted in these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available evidence on the rates of AF after RFA come from the DISCERN AF study, which evaluated episodes of symptomatic and asymptomatic AF (as well as atrial flutter and atrial tachycardia) before and after RFA in 50 patients using an implantable cardiac monitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/40\">",
"     40",
"    </a>",
"    ]. The total atrial arrhythmia burden was significantly reduced by 86 percent from a mean of 2.0 hours per day per patient before to 0.3 hours per day after RFA. However, the ratio of asymptomatic to symptomatic episodes increased significantly after ablation from 1.1 to 3.7. After 18 months and a mean of 1.4 ablations, only 58 percent of patients were symptom free.",
"   </p>",
"   <p>",
"    Other observational studies have found rates of AF recurrence of 15 to 27 percent at 10 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17,41\">",
"     17,41",
"    </a>",
"    ] and 22 percent at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/24,42\">",
"     24,42",
"    </a>",
"    ]. In a study of 100 patients at a single center, the arrhythmia-free survival rates after a single catheter ablation procedure were 40, 37, and 29 percent at 1, 2, and 5 years respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence is more likely in patients with underlying cardiovascular disease, such as hypertension, complicated heart disease (including valvular heart disease), older age, persistent as opposed to paroxysmal AF, longer duration of AF, procedure performed at a low-volume center, left atrial dilation, and increasing plasma B-type natriuretic peptide (BNP) level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/22,38,39,44-47\">",
"     22,38,39,44-47",
"    </a>",
"    ].Left atrial dilation should be assessed by volume determination rather than linear measurements if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/48\">",
"     48",
"    </a>",
"    ]. One study has shown that a left atrial volume &ge;130 cc assessed by computed tomography predicts a recurrence rate of &gt;90 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of late recurrent AF following PVI has been debated. In some cases, triggering foci outside of the pulmonary veins may initiate AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/28,50-52\">",
"     28,50-52",
"    </a>",
"    ]. Alternatively, persistence of the substrate for maintaining AF (abnormal electrical properties of the atria themselves) may be more important than the triggering foci, especially in chronic AF.",
"   </p>",
"   <p>",
"    However, there is increasing evidence that, when AF does recur late after PVI, it often represents incomplete electrical isolation of the pulmonary veins, either due to resumption of conduction across the ablation scar or to residual conduction in pulmonary veins that were not successfully ablated. Most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/26,34-36\">",
"     26,34-36",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/53\">",
"     53",
"    </a>",
"    ] studies of the former mechanism support the hypothesis that resumption of PV-LA conduction is associated with an increased risk of recurrent AF. However, recurrent conduction across ablated lesions is more common than clinically evident recurrent AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/35,54\">",
"     35,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preexisting left atrial scarring may predispose patients to late recurrence. In a series of 700 consecutive patients undergoing first-time PVI, scarring was detected in 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/42\">",
"     42",
"    </a>",
"    ]. These patients had a much higher rate of recurrence than those without scarring (57 versus 19 percent).",
"   </p>",
"   <p>",
"    Possible causes of scarring include atrial remodeling and inflammation. The patients with scarring had significant elevations in serum C-reactive protein compared to those without scarring (5.9 versus 0.31",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"    This is consistent with other studies showing a relationship between serum CRP and AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H26#H26\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Inflammation and infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Detection of recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal method for screening for episodes of AF after ablation is not known. In the above studies, late recurrent AF was detected by patient symptoms, serial ECGs, 24 to 48 hour Holter monitoring, and implantable cardiac monitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/22,24,40,42\">",
"     22,24,40,42",
"    </a>",
"    ]. Rhythm transmitters were also used in the first few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/42\">",
"     42",
"    </a>",
"    ]. With the exception of implantable cardiac monitor, these methods may underestimate the incidence of recurrence due to sampling error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, as has been well demonstrated, patients with AF have a high rate of asymptomatic episodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H7#H7\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Natural history'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'AF recurrence after three months'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surveillance for recurrence of atrial arrhythmias is important in patients who have undergone RFA. We agree with the joint",
"    <span class=\"nowrap\">",
"     HRS/EHRA/ECAS",
"    </span>",
"    expert consensus statement of catheter and surgical ablation of atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ], which recommends the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first visit with the electrophysiologist at a minimum of three months, and then every six months for at least two years.",
"     </li>",
"     <li>",
"      ECGs at all visits; symptomatic (palpitations) patients should be evaluated with some form of event monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Left atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;New reentrant circuits created by the RFA lesions can lead to atypical left atrial flutter. These circuits tend to develop around regions of left atrial scar, and often involve the isthmus between the mitral annulus and the left inferior pulmonary vein. Due to anatomic variability and the thickness of the myocardium in this area, successful ablation is more difficult than that for typical right atrial flutter involving the isthmus of the IVC and tricuspid annulus. A significant percentage of left atrial flutter following PVI may also involve the musculature of the coronary sinus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical atrial flutter may also occur after LA ablation due to alterations in activation patterns of the LA and may have an unusual ECG morphology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link&amp;anchor=H3#H3\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\", section on 'Pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left atrial flutter appears to be more common following circumferential, as opposed to segmental, PVI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30,57-60\">",
"     30,57-60",
"    </a>",
"    ]. In a randomized comparison of circumferential and segmental PVI, left atrial flutter developed in nine of the 50 patients undergoing circumferential PVI, and in one of the 50 patients in the segmental PVI group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, many of the recurrent left atrial arrhythmias following segmental PVI are focal atrial tachycardias as opposed to macroreentrant flutter circuits, and are often successfully treated with repeat isolation of the pulmonary veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Comparison to antiarrhythmic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early comparisons of RFA procedures to antiarrhythmic therapy were difficult due to between-study variation in patient populations, RFA procedures, and outcome measures as well as the small size of most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/24,61-64\">",
"     24,61-64",
"    </a>",
"    ]. Three meta-analyses found that recurrence of AF occurred less often in patients who received RFA as opposed to medical therapy (mostly antiarrhythmic drug therapy) in the 12 months after initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first large, multicenter trial (ThermoCool AF) randomly assigned 167 symptomatic patients with PAF, who did not respond to at least one antiarrhythmic drug and who experienced at least three episodes of PAF within six months before randomization, to either catheter ablation or antiarrhythmic drug therapy (AAT) in a 2:1 fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with significant left ventricular dysfunction, persistent AF, and advanced heart failure were excluded. Catheter ablation included pulmonary vein isolation with confirmation of entrance block and AAT included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (36 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    (41 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    at the investigator's discretion. After nine months, there were significantly fewer patients with documented symptomatic PAF in the catheter ablation group (16 versus 66 percent; hazard ratio 0.30, 95% CI 0.19-0.47). In addition, major treatment related adverse events occurred more often in with AAT (9 versus 5 percent) 30 days. Mean quality of life scores improved significantly with catheter ablation compared to AAT.",
"   </p>",
"   <p>",
"    The potential role of RFA as first-line therapy in patients with AF was first evaluated in small trial reported in 2005 in which 70 patients were randomly assigned to either RFA or AAT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/61\">",
"     61",
"    </a>",
"    ]. The MANTRA-PAF trial randomly assigned 294 patients with symptomatic PAF and no history of AAT to an initial treatment strategy of either RFA or therapy with class IC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) or class III (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) antiarrhythmic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/69\">",
"     69",
"    </a>",
"    ]. Exclusion criteria included age greater than 70 years, prior ablation, a left atrial diameter of more than 50 mm, and a left ventricular ejection fraction of less than 40 percent. The primary study end points were burden of AF (defined as the percentage of time in AF on seven-day Holter recordings performed at 3, 6, 12, 18, and 24 months) and the cumulative burden of AF (defined as the percentage of time in AF on all recordings). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ablation group, patients underwent a mean of 1.6 procedures and 9 percent of patients were receiving AAT during long-term follow-up. In the drug-therapy group, the mean number of agents was 1.26 and supplementary RFA was performed in 36 percent of patients.",
"     </li>",
"     <li>",
"      The burden of AF was significantly lower at each follow-up visit in RFA and AAT groups.",
"     </li>",
"     <li>",
"      There were no significant differences between the two groups in the cumulative burden of AF or in the burden of AF at 3, 6, 12, or 18 months. However, at 24 months more patients in the RFA group were free from any AF (85 versus 71 percent, p = 0.004), suggesting that the efficacy of catheter ablation may be more durable than that of AAT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RFA appears to be more effective and safer than antiarrhythmic drug therapy for the long-term maintenance of sinus rhythm. However, there is insufficient evidence to recommend RFA in preference to antiarrhythmic drugs as the first antiarrhythmic therapy in patients in whom a rhythm control strategy is chosen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     After surgical Maze procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial arrhythmias may recur after the surgical Maze procedure, and these arrhythmias may be amenable to RFA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Recurrent arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of RFA in this setting was illustrated in a series of 23 patients who had undergone the conventional surgical \"cut and sew\" Maze operation, but had symptomatic recurrences of atrial arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ]. A variety of arrhythmias were found, including AF, atrial flutter and focal atrial tachycardias. Nearly all (22 of 23) of these arrhythmias were successfully mapped and amenable to ablation, and 19 patients remained free of symptomatic arrhythmias one year later. These results suggest that EP study and RFA are a reasonable strategy for patients who have recurrent atrial arrhythmias after surgical Maze procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Repeat ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the recurrence rates of AF after ablation, many patients are candidates for repeat ablation. We tell our patients that the success rate is in the range of 50 to 80 percent for a single procedure based primarily on AF type and anatomy and that about 20 percent of patients have at least a second procedure. Success rates after a second procedure can be as high as 90 percent. Some experts and some patients have agreed to repeat the procedure a third time. Patients with a history of persistent AF have a lower success rate and are less often felt to be good candidates for repeat procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of successful RFA include the lessening of symptoms in patients who remain symptomatic with either a rate or a rhythm control strategy, the elimination of the potential complications of long-term antiarrhythmic drug therapy in patients whose symptoms are controlled, and the possible elimination of the need for anticoagulation.",
"   </p>",
"   <p>",
"    For those patients in whom RFA is successful, the first two goals are met. Improvement in hospitalization rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/61,65\">",
"     61,65",
"    </a>",
"    ] and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/61,64\">",
"     61,64",
"    </a>",
"    ] have been suggested in patients receiving RFA compared to antiarrhythmic drug therapy.",
"   </p>",
"   <p>",
"    The possible elimination of the long-term need for anticoagulation is controversial. (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Periprocedural embolic events and anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the efficacy and safety of RFA for atrial fibrillation can be affected by the chronicity of AF, coexistent arrhythmias (eg, atrial flutter) and cardiac abnormalities (eg, heart failure and valve disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Longstanding persistent AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the patients in initial studies had paroxysmal AF, including the majority of patients in the two randomized comparisons of segmental PVI and circumferential LA ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. The efficacy of RFA in patients with longstanding persistent AF is likely to be lower than in patients with PAF.",
"   </p>",
"   <p>",
"    The utility of circumferential LA ablation, with or without more extensive ablation, for the treatment of persistent AF has been evaluated in two reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/64,70\">",
"     64,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first study of 146 patients, less than 10 percent of whom had structural heart disease, were randomly assigned to RFA or antiarrhythmic drugs for three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/64\">",
"     64",
"    </a>",
"    ]. Arrhythmia recurrence was evaluated with daily transtelephonic monitoring. At one year, 74 percent of the patients assigned to RFA (and 58 percent of patients on drug therapy) were in sinus rhythm off antiarrhythmic drugs, although 32 percent required a repeat ablation procedure. There were several important limitations to this trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was high rate of crossover to ablation therapy (77 percent of the control patients).",
"     </li>",
"     <li>",
"      Therapy in the control arm included only three months of low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      without a loading regimen, and up to two cardioversions during that time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 27 patients with drug-refractory longstanding persistent AF, complete PV isolation was followed by isolation of the entire posterior left atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/70\">",
"     70",
"    </a>",
"    ]. Posterior LA isolation was accomplished with two additional ablation lines, one each connecting the circumferential lesions of the superior and inferior PV's. Successful posterior LA isolation was demonstrated in all patients, and all patients either converted to sinus rhythm during the procedure or underwent successful cardioversion at the end of the case. At a mean follow-up of 21 months, 17 patients (63 percent) remained in sinus rhythm. However, the likelihood of remaining in sinus rhythm was significantly lower in patients with structural heart disease (25 versus 74 percent with structurally normal hearts).",
"   </p>",
"   <p>",
"    In summary, these results demonstrate that circumferential LA ablation can produce long-term restoration of sinus rhythm in patients with longstanding persistent AF and minimal structural heart disease. However, the relative efficacy of this approach in these patients compared to segmental PVI or appropriately dosed and prolonged antiarrhythmic drug therapy is not known. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Comparison to antiarrhythmic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Simultaneous AF/atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based therapy for typical atrial flutter, as opposed to AF, involves RF ablation of the isthmus between the tricuspid annulus and the inferior vena cava (TA-IVC isthmus) in the right atrium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with paroxysmal AF have periods of atrial flutter. In such patients, PVI, although it does not interrupt the reentrant flutter circuit, may be sufficient to control both arrhythmias. This was demonstrated in a study of 108 patients with both AF and typical atrial flutter who were randomly assigned to either a dual ablative procedure (PVI and TA-IVC isthmus ablation, 49 patients) or PVI alone (59 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/71\">",
"     71",
"    </a>",
"    ]. After ablation, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first eight weeks postprocedure, none of the dual procedure patients, but 32 treated with PVI alone, developed atrial flutter and required cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antiarrhythmic drugs.",
"     </li>",
"     <li>",
"      After eight weeks, all antiarrhythmic drugs were discontinued. Only three patients treated with PVI alone had further recurrences of atrial flutter, which was successfully treated with TA-IVC ablation. Seven of the dual procedure patients and six of those treated with PVI alone developed recurrent AF. Of these 13 patients (12 percent of the total group), 10 underwent successful repeat PVI and three remained in sinus rhythm on antiarrhythmic drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that AF initiated by pulmonary vein triggers may be the precursor rather than the consequence of atrial flutter. This conclusion is consistent with the observation that atrial flutter often starts after a transitional rhythm of variable duration, usually AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexistent heart failure and valve disease may influence both the safety and efficacy of RFA procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary vein isolation by catheter ablation appears to be safe and effective for the prevention of AF recurrence in patients with heart failure or impaired LV function. The experience with ablation in this setting is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary vein isolation as an alternative to CRT with AV node ablation in patients with HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link&amp;anchor=H7#H7\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm versus rate control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Mitral valve prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential concern with RFA in patients with a mitral valve prosthesis is injury to the valve. Furthermore, entrapment of the ablation catheter in a mechanical mitral valve necessitating open heart surgery has been reported in patients undergoing left sided ablation procedures. This issue was addressed in a report of 26 patients with mitral valve prostheses who were compared to a matched group of 52 patients without a mitral valve prosthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/74\">",
"     74",
"    </a>",
"    ]. The rate of maintenance of sinus rhythm was the same in the two groups but the patients with a mitral valve prosthesis had longer fluoroscopy times with greater radiation exposure and a higher rate of postablation atrial tachycardia (23 versus 2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Rheumatic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of RFA for chronic AF in patients with rheumatic heart disease is not well defined. One study performed electrophysiologic mapping in 17 patients with mitral stenosis who had chronic AF and were converted to sinus rhythm after balloon valvulotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/75\">",
"     75",
"    </a>",
"    ]. An organized atrial arrhythmia, which degenerated into AF, was induced in all patients; the focus was most often near the coronary sinus ostium. Radiofrequency ablation was successful in 13 and, after a mean follow-up of 32 weeks, 10 were still in sinus rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347313400\">",
"    <span class=\"h2\">",
"     Use during cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either the Maze procedure or off-pump PVI using an epicardial approach should be considered in patients with AF and an indication for open-heart surgery. These approaches are not generally recommended for patients without an indication for cardiac surgery unless in special circumstances because of the mortality and morbidity associated with surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Pulmonary vein isolation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types and rates of complications that occur in patients undergoing RFA to prevent recurrent AF vary from series to series and depend upon factors such as the technique being used (eg, segmental versus circumferential procedure), the experience of the operator, and the clinical characteristics of the patients undergoing the procedure. There has been a reduction in complication rates with time presumably reflecting not only operator, institutional, and worldwide experience, but also improvements in equipment and anticoagulation strategies.",
"   </p>",
"   <p>",
"    While advanced age and female gender are risk factors for complications in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/76\">",
"     76",
"    </a>",
"    ], more recent reports suggest that patients with age &gt;75 years had similar success rates and complications rates compared to those age 65 to 74 and under 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications reported in series of patients undergoing RFA to prevent recurrent AF will be reviewed here. Other complications that might occur with any electrophysiology study, such as radiation exposure and valve, vascular or myocardial injury, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and causes of mortality from catheter ablation of AF have been compiled using retrospective case series data obtained from 162 centers worldwide between 1995 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/78\">",
"     78",
"    </a>",
"    ]. Death occurred in 1 of 1000 patients (32 deaths during 45,115 procedures in 32,569 patients). The leading causes of death were cardiac tamponade (n = 8, 25 percent), stroke (n = 5, 16 percent), and atrioesophageal fistula (n = 5, 16 percent). Other causes included pneumonia, pulmonary vein perforation, and sepsis. In an updated report from the same authors, which included over 20,000 procedures performed between 2003 and 2006 in over 16,000 patients, there was a similar rate of death (0.15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cardiac tamponade was the leading cause of death, it was lethal in only 2.3 percent of those with this complication (seven of 331 patients). In contrast, atrioesophageal fistula occurred in only seven patients but was fatal in five (71.4 percent). There was no relationship between mortality and center volume or the method of ablation used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade resulting from perforation is the most frequent serious complication of RFA for AF, occurring in slightly more than 1 percent of procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/76,78,80\">",
"     76,78,80",
"    </a>",
"    ], and is the leading cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/78\">",
"     78",
"    </a>",
"    ]. Tamponade results from either catheter perforation of an atrial or ventricular free wall, especially with overheating during energy delivery, or less frequently with transseptal puncture. Some cases of tamponade may be delayed in onset. In one study of delayed tamponade, the median duration was 10 days with a range of several hours up to 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/78\">",
"     78",
"    </a>",
"    ]. The treatment of tamponade caused by RFA is similar to that in other settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link&amp;anchor=H26#H26\">",
"     \"Cardiac tamponade\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85423607\">",
"    <span class=\"h2\">",
"     Catheter entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entrapment of the circular mapping (Lasso) catheter in the mitral valve apparatus as a rare complication that can require cardiac surgery to resolve. The estimated incidence of this complications ranges between 0.01 to 0.9 percent and specific sites of transeptal puncture or catheter manipulation may predispose to this adverse event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/18,81,82\">",
"     18,81,82",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pulmonary vein stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary vein stenosis is a potential complication of ablation near or within the pulmonary veins. The lesion is characterized by intimal thickening, thrombus formation, endocardial contraction, and proliferation of elastic laminae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/83\">",
"     83",
"    </a>",
"    ]. Pulmonary vein stenosis can cause symptoms of dyspnea with exertion or less often at rest, cough, chest pain, and hemoptysis, and recurrent lung infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17,84\">",
"     17,84",
"    </a>",
"    ]. The mean onset of symptoms is two to five months after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17,84,85\">",
"     17,84,85",
"    </a>",
"    ]. The intensity of symptoms may be directly related to the degree of obstruction and inversely related to the duration of time to develop the stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported rate of pulmonary vein stenosis depends not only on the factors described above, but also on the definition of stenosis severity and the intensity of screening. Early reports cited rates as high as 38 percent, but more recent studies cite rates for severe stenosis as low as 1.0 to 3.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/18,76,84,86\">",
"     18,76,84,86",
"    </a>",
"    ]. A minority of diagnosed patients appears to develop symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/87,88\">",
"     87,88",
"    </a>",
"    ] and the rate of pulmonary vein stenosis requiring intervention may be as low as 0.1 to 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation for pulmonary vein stenosis should be performed in patients who develop respiratory symptoms after RFA. The joint",
"    <span class=\"nowrap\">",
"     HRS/EHRA/ECAS",
"    </span>",
"    expert consensus statement of catheter and surgical ablation of atrial fibrillation suggests computed tomography or magnetic resonance imaging as the preferred tests in suspected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous balloon angioplasty, with stent placement for suboptimal anatomic results, is an effective therapy for PV stenosis. It is associated with a significant and almost immediate improvement in symptoms and pulmonary blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17,84,85\">",
"     17,84,85",
"    </a>",
"    ]. In two series of patients who underwent balloon angioplasty, with or without stenting, in-segment stenosis or in-stent stenosis requiring repeat intervention developed in approximately fifty percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. The role of either elective stenting or surgery is not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the incidence of PV stenosis has significantly decreased due to improvement in ablative techniques, especially with moving the ablation lesions towards the atrial side of the PV-atrial junction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Periprocedural embolic events and anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing RFA to prevent recurrent AF are at risk of embolic events before, during, and after the procedure for multiple reasons: withdrawal of anticoagulation pre-procedurally; catheter manipulation within the left atrium which may dislodge pre-existing thrombus; catheter trauma to the left atrial endothelium which increases the risk of thrombus formation; thrombus formation on the ablation catheters or left atrial guide sheaths; and conversion to sinus rhythm during the procedure in some patients.",
"   </p>",
"   <p>",
"    The risk of stroke or transient ischemic attack around the time of RFA has been reported from 0.4 to 2 percent in reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30,76,78,89,90\">",
"     30,76,78,89,90",
"    </a>",
"    ]. One study of 234 patients who underwent cerebral magnetic resonance imaging at baseline and one day after RFA suggested that the rate of asymptomatic embolic episodes is significantly higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This increase in risk for embolic events has led to the use of continuous or nearly continuous anticoagulation in the periprocedural period. The standard of care for anticoagulation in the early years of RFA was characterized by the use of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bridge, usually with a low molecular weight heparin, between periods of oral anticoagulation; this was based more on expert opinion than high quality evidence.",
"   </p>",
"   <p>",
"    More studies have demonstrated better outcomes when the ablation is performed on continuous oral anticoagulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2012 meta-analysis of nine studies including over 27,402 patients compared outcomes between patients receiving continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (n = 6400) and those receiving warfarin discontinuation with periprocedural bridging with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/91\">",
"       91",
"      </a>",
"      ]. Continuous warfarin was associated with a decreased risk of thromboembolic (ischemic stroke or transient ischemic attack [TIA]) complications (0.06 versus 0.94 percent; odds ratio [OR] 0.10, 95% CI 0.05-0.23) and minor bleeding (OR 0.38, 95% CI0.21-0.71). In addition, continuous warfarin did not increase the risk of major bleeding (0R 0.67, 95% CI 0.31-1.43) or cardiac tamponade (OR 0.69, 95% CI 0.19-2.47).",
"     </li>",
"     <li>",
"      A retrospective study of 3280 patients who received either continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or warfarin discontinuation with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      bridging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/92\">",
"       92",
"      </a>",
"      ]. Symptomatic stroke or TIA occurred less often in the continuous warfarin group (0.15 versus 0.67 percent, respectively; p = 0.021). No thromboembolic events occurred in patients with therapeutic international normalized ratios. Hemorrhagic complications were similar between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as no randomized trials have compared continuous oral anticoagulation to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    discontinuation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bridging, we believe both approaches are reasonable.",
"   </p>",
"   <p>",
"    For those physicians who choose to not perform AF ablation on therapeutic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the newer oral anticoagulants offer an attractive alternative, as they may also obviate the need for bridging therapy with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pre-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    post-procedure. While a few studies have evaluated the use of periprocedural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in this setting, the ideal timing of drug discontinuation and reinitiation has yet to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Additional experience with these new drugs is necessary before their routine use can be recommended. If used, we recommend holding the drug 24 to 36 hours before the procedure and resume them the morning after the procedure with a bridge of intravenous unfractionated heparin starting six hours after hemostasis has been achieved.",
"   </p>",
"   <p>",
"    We recommend the following strategy, which is consistent with those made by the joint 2012",
"    <span class=\"nowrap\">",
"     HRS/EHRA/ECAS",
"    </span>",
"    expert consensus statement regarding catheter and surgical ablation of atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/97\">",
"     97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who have been in atrial fibrillation 48 hours or more prior to RFA should receive three weeks of effective oral anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or undergo transesophageal echocardiography immediately prior to the procedure. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Role of TEE'",
"      </a>",
"      below.) Some of our experts continue therapeutic warfarin anticoagulation during the procedure, while others discontinue warfarin before the procedure and use a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      bridge during the period of inadequate oral anticoagulation. For patients in whom oral anticoagulation is discontinued prior to the procedure it is restarted soon after the procedure.",
"      <br/>",
"      <br/>",
"      For those patients who are already taking one of the newer oral anticoagulants, we hold them for 24 to 36 hours before the procedure and resume them as soon as possible after the procedure.",
"     </li>",
"     <li>",
"      Many patients should have a TEE performed to screen for thrombus. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Role of TEE'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is given as a 100",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      loading dose prior to or at the time of septal puncture and as a continuous infusion or by intermittent boluses to achieve ACT at target levels (300 to 400 seconds) throughout the procedure. Therapeutic oral anticoagulation does not alter the need for intravenous heparin during the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general management of anticoagulation in patients with atrial fibrillation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Role of TEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who are in atrial fibrillation for 48 hours or more prior to AF ablation in whom adequate systemic anticoagulation at a therapeutic level has not been present for at least three weeks should have a transesophageal electrocardiogram (TEE) performed prior to RFA. The presence of left atrial thrombus is a contraindication to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. However, some experts do not perform TEE in patients in sinus rhythm at the time of the ablation who have no significant structural heart disease and a CHADS2 score of 0 (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ), since it is assumed that the likelihood of finding left atrial thrombus is low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Risk models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An attempt to determine the need for preprocedural TEE in patients at low risk for embolization was made in an analysis of 1058 patients who had TEE performed within 24 hours of pulmonary vein isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/99\">",
"     99",
"    </a>",
"    ]. The frequency of left atrial thrombus or sludge was evaluated according to the CHADS2 score. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link&amp;anchor=H2#H2\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\", section on 'Major sources of emboli'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A CHADS2 score of 0 was present in 47 percent of patients. Left atrial or left atrial appendage thrombus or sludge was found in 0.6 and 1.5 percent of all patients and the frequency increased with ascending CHADS2 scores (percents in parentheses): 0 (0), 1 (2), 2 (5), 3 (9), 4 to 6 (11).",
"   </p>",
"   <p>",
"    Potential reasons to not perform TEE include cost, additional time added to the procedure, and potential complications. With regard to the latter, the risk of a major complication is extremely low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/24/38280?source=see_link\">",
"     \"Transesophageal echocardiography: Indications, complications, and normal views\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the available evidence, our experts believe that it is reasonable to not perform a routine TEE in those patients who are in sinus rhythm, have a low burden of AF, and have a CHADS2 score of 0, even if they have not adequately anticoagulated with an oral agent. Some experts, however, still recommend TEE in this setting. Intracardiac echocardiography can be used at the time of ablation to evaluate for the presence of thrombus in patients when a preoperative TEE was not performed, though it may be less sensitive for this purpose compared to transesophageal echo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/100\">",
"     100",
"    </a>",
"    ]. In some centers, cardiac MRI can be used to assess for LAA thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Chronic post procedural anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chronic anticoagulation after successful RFA-based PVI is uncertain since the embolic risk has not been well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/101\">",
"     101",
"    </a>",
"    ]. As mentioned above, late recurrent AF is reported in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17,22,24,42\">",
"     17,22,24,42",
"    </a>",
"    ]. However, the methods used in some studies underestimate the incidence of recurrent AF. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'AF recurrence after three months'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Asymptomatic episodes of AF probably explain at least part of the persistent embolic risk in patients treated medically with a rhythm control strategy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H7#H7\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Natural history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not known if asymptomatic recurrences will result in a persistent thromboembolic risk in patients who have undergone RFA procedures for AF. A low risk of stroke was reported in a series of 755 patients with longstanding persistent AF who underwent circumferential left atrial ablation or a tailored approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/102\">",
"     102",
"    </a>",
"    ]. In this cohort, anticoagulation was discontinued three months after the procedure in the majority of the 522 patients who did not have evidence of recurrent AF. During a median follow-up of 25 months, none of the patients who stopped anticoagulation had a stroke. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Circumferential left atrial ablation or WACA'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H53\">",
"     'Tailored approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although these results are encouraging, the study cohort had a low baseline thromboembolic risk, with most having a CHADS2 score of 0 to 2 (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). Some of these patients, such as those with lone atrial fibrillation, would not require chronic oral anticoagulation whether or not they had a successful RFA procedure.",
"   </p>",
"   <p>",
"    Observational evidence raises the possibility that not all patients with successful AF ablation require oral anticoagulation at discharge. In a study of 123 patients with CHADS2 scores of 0 or 1 who underwent successful RFA (with periprocedural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ), there were no strokes or transient ischemic attacks at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence does not currently exist that supports the cessation of long-term anticoagulant therapy after successful RFA ablation in patients who are otherwise candidates for long-term anticoagulation. We agree with the following recommendations made in the 2012 joint Heart Rhythm",
"    <span class=\"nowrap\">",
"     Society/European",
"    </span>",
"    Heart Rhythm",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Cardiac Arrhythmia Society expert Consensus Statement on catheter and surgical ablation of atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/97\">",
"     97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic anticoagulation was recommended for at least two months in all patients following RFA.",
"     </li>",
"     <li>",
"      After two months, the decision to continue anticoagulation should be based on the patient&rsquo;s risk factors for stroke and not on the type of AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend the CHADS2 score for risk stratification to determine which patients require long-term anticoagulation and which patients can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H23#H23\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Specific patient groups'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Risk models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts are comfortable stopping anticoagulation in patients with low CHADS2 risk scores (0-2) after sufficient documentation of the absence of recurrent episodes of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/104\">",
"     104",
"    </a>",
"    ]. We believe this approach, while attractive, has not been adequately tested. Therefore, we tell patients and referring physicians that the desire to stop long-term anticoagulation is not an indication for RFA by itself.",
"   </p>",
"   <p>",
"    However, all patients, including those who have been on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , should receive anticoagulation for two to three months after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16900209\">",
"    <span class=\"h2\">",
"     Vascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular complications are among the most common adverse events related to AF ablation, likely due to the number and size of intravascular sheaths and the need for anticoagulation both during and immediately following the procedure. These complications include hematoma at the sites of catheter insertion, pseudoaneurysm, arteriovenous fistula, or retroperitoneal bleeding. Pseudoaneurysm and arteriovenous fistulae rates of 0.53 and 0.43 percent, respectively, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/18,80\">",
"     18,80",
"    </a>",
"    ]. Conservative management alone is usually sufficient for large hematomas and retroperitoneal bleeding, though anticoagulation may need to be held and transfusion may be necessary in those patients where the risks of such interventions are warranted. Echo-guided manual compression and percutaneous intervention are usually effective treatments of femoral pseudoaneurysms or arteriovenous fistula but direct surgical intervention is sometimes required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960431348\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential complications and their incidence include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phrenic nerve injury (&lt;1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/18,80\">",
"       18,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rare (0.3 to 0.54 percent) but often fatal atrioesophageal fistulas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/31,32,80\">",
"       31,32,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Periesophageal vagal injury (gastric hypomotility) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/33,106\">",
"       33,106",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute coronary artery",
"      <span class=\"nowrap\">",
"       occlusion/injury",
"      </span>",
"      (&lt;1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1,107\">",
"       1,107",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     ALTERNATIVE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumferential left atrial ablation and segmental isolation are currently the most widely used RFA procedures for the treatment of AF.",
"   </p>",
"   <p>",
"    However, several alternative strategies have been considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Focal ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal ablation of ectopic foci eliminates AF only in highly selected patients. Early attempts to treat AF with focal ablation usually involved limited ablation of triggering sites, often in the PVs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2,3,108\">",
"     2,3,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that limit the efficacy of this approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty identifying the location of the responsible focus.",
"     </li>",
"     <li>",
"      Absence of spontaneous AF during the procedure.",
"     </li>",
"     <li>",
"      The presence of multiple triggering foci at the time of ablation.",
"     </li>",
"     <li>",
"      The later development of new foci that trigger recurrent AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interest in focal ablation has re-emerged, with attention turned to foci outside of the PVs, most commonly in the posterior left atrium near the PV ostia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/29,52,109,110\">",
"     29,52,109,110",
"    </a>",
"    ]. In this setting, focal ablation is usually intended to augment the efficacy of PVI, either by eliminating additional triggers or by altering the arrhythmic substrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for this approach is based in part upon the hypothesis that very small reentrant circuits, called rotors, may cause AF. These rotors are so rapid that when the impulse from the rotor conducts to the rest of the atrium, it fragments into multiple wavelets, causing the rapid, irregular pattern characteristic of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=see_link&amp;anchor=H8804404#H8804404\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Reentrant mechanism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several methods for identifying such foci have been under investigation, including the presence of fractionated electrograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/29\">",
"     29",
"    </a>",
"    ], the use of multi-pronged mapping catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/52,114\">",
"     52,114",
"    </a>",
"    ], and atrial electrogram frequency analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     Complex fractionated atrial electrograms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex fractionated atrial electrograms (CFAEs) are found mostly in areas of slow conduction or at pivot points where wavelets of atrial activation \"turn around\" at the end of an arc of functional block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/109\">",
"     109",
"    </a>",
"    ]. These sites may be important components of the substrate for maintaining AF and, therefore, could be useful ablation targets.",
"   </p>",
"   <p>",
"    The first two reports using this technique differed in their efficacy outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of ablating CFAE sites without PVI was evaluated in 121 patients with either paroxysmal or chronic AF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/29\">",
"       29",
"      </a>",
"      ]. CFAE sites were identified in the interatrial septum, the PVs, the roof of the LA, the mitral annulus and the coronary sinus ostium. Ablation of these sites terminated AF in 115 patients (95 percent). At one year, 91 percent were free of arrhythmia and symptoms; 15 percent required a second ablation procedure.",
"     </li>",
"     <li>",
"      The success rate for this approach in patients with chronic AF was 57 percent at 13 months in a second series of 100 patients with chronic AF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more recent observational study evaluated long term outcomes in 635 high-risk AF patients with paroxysmal, persistent, or chronic AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/104\">",
"     104",
"    </a>",
"    ]. After a mean follow-up period of 28 months, the following were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus rhythm was present in 81 percent.",
"     </li>",
"     <li>",
"      Five-year survival was higher in those patients who remained in sinus rhythm (92 versus 64 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      was discontinued in 84 percent of patients who remained in sinus rhythm; in these patients the annual stroke rate was low (0.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Tailored approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tailored approach to ablation has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/111\">",
"     111",
"    </a>",
"    ]. In this procedure, only PVs with triggering foci are treated, and if AF remains inducible, sites of fractionated electrograms and high electrogram frequencies in the left atrium and SVC are ablated until AF is no longer inducible. This approach was proposed to reduce procedure times, radiation exposure, and the risk of esophageal injury.",
"   </p>",
"   <p>",
"    The efficacy of this approach was evaluated in a series of 153 patients with paroxysmal AF. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      47 patients (31 percent) were not inducible after ablation of one or more pulmonary veins. The procedure was considered complete in these patients.",
"     </li>",
"     <li>",
"      The remaining 106 patients had further ablations in the left atrium, the coronary sinus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the SVC. Among these patients, an additional 41 patients were not inducible after these ablations.",
"     </li>",
"     <li>",
"      A second ablation procedure was required in 28 patients (18 percent) for recurrent AF or less often atypical atrial flutter. In 12 of these patients, arrhythmogenic foci were found in PVs that were not previously targeted because triggering foci were not present at the time of the original procedure.",
"     </li>",
"     <li>",
"      At a mean follow-up of 11 months after the last ablation procedure, 77 percent of patients were free of recurrent AF or atrial flutter on no antiarrhythmic drugs. Although ambulatory monitoring was offered to all patients, 30 percent did not comply, and therefore recurrence rates were in part defined by symptoms (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Detection of recurrences'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to incomplete follow-up monitoring and the absence of a comparative strategy, the efficacy of a tailored approach cannot be directly compared to left atrial ablation or pulmonary vein isolation.",
"   </p>",
"   <p>",
"    The importance of this study is the emphasis on an approach that is individualized to the type of AF that is detected during atrial mapping. Most studies have applied a uniform, anatomically based ablation approach to every patient. Furthermore, efforts are underway to develop tools, such as balloon-based catheters, that facilitate a standardized approach, but ignore the underlying electrophysiology. Although optimization of standard approaches will be helpful, some patients can clearly be identified as having focal AF. It is important to identify these patients who can be cured without extensive left atrial ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Rotors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, vortex-like reentrant circuits, called rotors, have been identified in experimental models of AF. Two methods that have been evaluated for localizing and ablating rotors are mapping with multipronged catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/52,114\">",
"     52,114",
"    </a>",
"    ] and frequency analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/110\">",
"     110",
"    </a>",
"    ]. The role of rotors in patients with recurrent AF and the use of ablation to eliminate these sites are under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Ablation of cardiac autonomic nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal stimulation can induce and maintain AF, and there is clinical evidence that the parasympathetic nervous system plays a role in the occurrence of AF in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H5#H5\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Autonomic dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data in animals and humans suggests that transvascular atrial parasympathetic nerve system modification with RFA can abolish vagally mediated AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. The role of ganglionated plexi that provide cardiac autonomic innervation in AF and ablative therapy targeting these ganglionated plexi are an area of intense research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32876014\">",
"    <span class=\"h2\">",
"     Cryoballoon ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation has been used for targeted ablation of slow pathways and accessory pathways under specific circumstances. The release of a cryoablation balloon that delivers a circumferential lesion at the antrum of the pulmonary vein has made the technology available for the treatment of AF. This technology may reduce procedure times and reduce the risk of complications related to RF energy, specifically thrombus formation at the lesion site and cardiac perforation due to direct catheter related trauma or excessive heating at the catheter-tissue interface. &nbsp;",
"   </p>",
"   <p>",
"    The efficacy and adverse events associated with cryoballoon ablation for the treatment of AF have been evaluated in clinical studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two small non-randomized trials comparing cryoballoon to standard radiofrequency ablation, cryoballoon has similar efficacy rates in maintaining sinus rhythm at 6 and 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/120,121\">",
"       120,121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complications of cryoballoon ablation may differ somewhat from standard radiofrequency ablation. Tamponade and atrioesophageal fistula have been reported less frequently in cryoballoon ablation. However, phrenic nerve paralysis has been reported in 6.3 percent of 1349 procedures, significantly higher than seen with standard radiofrequency ablation. Resolution occurs acutely in some patients and in &gt;90 percent within one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H700377964\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AF treated with RFA, the recurrence rate at one year is in excess of 50 percent, with a majority of cases occurring within the first two weeks. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615512118\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two observations raise the possibility that corticosteroid therapy might be useful for the prevention of early recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation is associated with the development of AF and a systemic as well as a local inflammatory response may result from RFA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/123\">",
"       123",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H26#H26\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Inflammation and infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoid prophylaxis reduces the risk of the development of perioperative AF in patients undergoing coronary artery bypass graft surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H97330379#H97330379\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Ineffective or possibly effective therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of benefit from prophylactic glucocorticoid therapy was evaluated in a study of 125 patients with paroxysmal AF who were randomly assigned to either three days of glucocorticoid therapy or placebo starting immediately after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/124\">",
"     124",
"    </a>",
"    ]. The rate of AF recurrence (primary endpoint) was significantly lower in the glucocorticoid group at one month (27 versus 49 percent), with most of the benefit occurring during the first three days (7 versus 31 percent).",
"   </p>",
"   <p>",
"    We do not believe there is sufficient evidence to recommend the use of prophylactic glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118892756\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    , another drug with antiinflammatory properties, has been shown to decrease the risk of postoperative AF after cardiac surgery, particularly in patients with the post-pericardiotomy syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=see_link&amp;anchor=H5921218#H5921218\">",
"     \"Post-cardiac injury syndromes\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential ability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    to reduce the incidence of early recurrent AF after pulmonary vein isolation was evaluated in a study of 170 individuals with paroxysmal AF who were randomly assigned to colchicine 0.5 mg twice daily or placebo beginning on the day of RFA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/125\">",
"     125",
"    </a>",
"    ]. After three months of therapy, there was a lower recurrence rate of AF in patients taking colchicine (16.0 versus 33.5 percent; odds ratio 0.38, 95% CI 0.18-0.80). This study does not inform us as to whether such therapy will reduce the long-term need for repeat RFA or additional antiarrhythmic therapy. Thus, we do not recommend the use of colchicine to prevent the early recurrence of AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615512132\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data are mixed as to whether ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs",
"    </span>",
"    reduce AF after catheter ablation procedures. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20503?source=see_link&amp;anchor=H615512079#H615512079\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\", section on 'Catheter ablation of AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246147310\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of RFA are available in societal guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2011, the American College of Cardiology",
"      <span class=\"nowrap\">",
"       Foundation/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society updated the 2006 guidelines on the management of patients with AF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/126\">",
"       126",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We believe that recommendations made in the 2012 Heart Rhythm",
"      <span class=\"nowrap\">",
"       Society/European",
"      </span>",
"      Heart Rhythm",
"      <span class=\"nowrap\">",
"       Association/European",
"      </span>",
"      Cardiac Arrhythmia Society expert consensus statement on catheter and surgical ablation of atrial fibrillation supercede those made in the 2011 guideline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/97\">",
"       97",
"      </a>",
"      ]. The 2012 expert consensus document makes the following recommendations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A strong recommendation for RFA for patients with symptomatic, paroxysmal AF who have failed treatment with an antiarrhythmic drug.",
"     </li>",
"     <li>",
"      A weak recommendation for RFA for patients with symptomatic, persistent AF or those with symptomatic paroxysmal AF prior to the initiation of antiarrhythmic drug therapy.",
"     </li>",
"     <li>",
"      Very weak recommendations were made for RFA for patients with longstanding persistent AF (with failed drug therapy) or those with persistent or longstanding persistent AF without a prior trial of drug therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2011 European Society of Cardiology guidelines for the management of AF makes the following recommendations (with different levels of evidence) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/127\">",
"       127",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A weak recommendation was made for RFA for symptomatic patients with paroxysmal AF who have failed a trial of antiarrhythmic drug therapy.",
"     </li>",
"     <li>",
"      A weak recommendation was made for RFA for patients with persistent symptomatic AF who have failed a trial of antiarrhythmic drug therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of RFA as a primary treatment of symptomatic AF is under investigation. Patients who might be reasonable candidates for this strategy include younger, healthy individuals who wish to avoid the long-term use of antiarrhythmic drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two goals of therapy in patients with atrial fibrillation (AF) are the alleviation of symptoms and the reduction of the risk of stroke. Medical approaches to either rate or rhythm control are not always effective and both require chronic anticoagulation (except for patients deemed to be at low risk for embolic events who are usually treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link\">",
"       \"Rhythm control versus rate control in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link\">",
"       \"Paroxysmal atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonpharmacologic therapy, particularly with pulmonary vein isolation using catheter-based radiofrequency catheter ablation (RFA), may offer a long-term cure in a significant percentage of such patients, and there is evidence that it can produce better outcomes than medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/62/40938/abstract/24\">",
"       24",
"      </a>",
"      ]. However, the technique of RFA is evolving and there is a risk for significant complications. This procedure should only be performed in centers with adequate experience in AF ablation. The individual operator's experience is a major determinant of outcome, especially the rate of complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=see_link\">",
"       \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with symptomatic paroxysmal AF and who have failed or become intolerant to one or more antiarrhythmic drugs, we recommend RFA (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Comparison to antiarrhythmic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic paroxysmal AF who choose to not receive antiarrhythmic drug therapy and who are similar to individuals enrolled in the MANTRA-PAF trial (eg, age 70 years or less, left ventricular ejection fraction of 40 percent or greater), we suggest RFA (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Comparison to antiarrhythmic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For these patients with symptomatic paroxysmal AF who prefer neither antiarrhythmic drug therapy nor an attempt at RFA, it is reasonable to manage AF with a rate control approach.",
"     </li>",
"     <li>",
"      For patients with symptomatic persistent or longstanding persistent AF who have failed or become intolerant of one",
"      <strong>",
"      </strong>",
"      or more antiarrhythmic drugs or who choose not to start antiarrhythmic therapy, we suggest RFA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Comparison to antiarrhythmic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Longstanding persistent AF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/1\">",
"      European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Scoiety (ECAS), American College of Cardiology (ACC), et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/2\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/3\">",
"      Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/4\">",
"      Tsai CF, Tai CT, Hsieh MH, et al. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation 2000; 102:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/5\">",
"      Ha&iuml;ssaguerre M, Shah DC, Ja&iuml;s P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/6\">",
"      Lin JL, Lai LP, Tseng YZ, et al. Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study. J Am Coll Cardiol 2001; 37:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/7\">",
"      Cheema A, Dong J, Dalal D, et al. Circumferential ablation with pulmonary vein isolation in permanent atrial fibrillation. Am J Cardiol 2007; 99:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/8\">",
"      Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation 2010; 122:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/9\">",
"      Schwartzman D, Kuck KH. Anatomy-guided linear atrial lesions for radiofrequency catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 1998; 21:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/10\">",
"      Pappone C, Oreto G, Lamberti F, et al. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation 1999; 100:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/11\">",
"      Tse HF, Lee KL, Fan K, Lau CP. Nonfluoroscopic magnetic electroanatomic mapping to facilitate focal pulmonary veins ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2002; 25:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/12\">",
"      Marrouche NF, Martin DO, Wazni O, et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation 2003; 107:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/13\">",
"      Kinnaird TD, Uzun O, Munt BI, et al. Transesophageal echocardiography to guide pulmonary vein mapping and ablation for atrial fibrillation. J Am Soc Echocardiogr 2004; 17:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/14\">",
"      Dong J, Calkins H, Solomon SB, et al. Integrated electroanatomic mapping with three-dimensional computed tomographic images for real-time guided ablations. Circulation 2006; 113:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/15\">",
"      Ahmed J, Sohal S, Malchano ZJ, et al. Three-dimensional analysis of pulmonary venous ostial and antral anatomy: implications for balloon catheter-based pulmonary vein isolation. J Cardiovasc Electrophysiol 2006; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/16\">",
"      Hocini M, Ja&iuml;s P, Sanders P, et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 2005; 112:3688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/17\">",
"      Saad EB, Marrouche NF, Saad CP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med 2003; 138:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/18\">",
"      Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/19\">",
"      Pappone C, Santinelli V. The who, what, why, and how-to guide for circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol 2004; 15:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/20\">",
"      Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/21\">",
"      Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002; 105:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/22\">",
"      Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/23\">",
"      Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/24\">",
"      Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/25\">",
"      Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/26\">",
"      Ouyang F, Ernst S, Chun J, et al. Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique. Circulation 2005; 112:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/27\">",
"      Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/28\">",
"      Lin WS, Tai CT, Hsieh MH, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation 2003; 107:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/29\">",
"      Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/30\">",
"      Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 2005; 111:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/31\">",
"      Pappone C, Oral H, Santinelli V, et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004; 109:2724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/32\">",
"      Scanavacca MI, D'&aacute;vila A, Parga J, Sosa E. Left atrial-esophageal fistula following radiofrequency catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2004; 15:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/33\">",
"      Shah D, Dumonceau JM, Burri H, et al. Acute pyloric spasm and gastric hypomotility: an extracardiac adverse effect of percutaneous radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2005; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/34\">",
"      Gerstenfeld EP, Callans DJ, Dixit S, et al. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. J Cardiovasc Electrophysiol 2003; 14:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/35\">",
"      Nanthakumar K, Plumb VJ, Epstein AE, et al. Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation 2004; 109:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/36\">",
"      Verma A, Kilicaslan F, Pisano E, et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation 2005; 112:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/37\">",
"      Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation 2005; 111:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/38\">",
"      Lubitz SA, Fischer A, Fuster V. Catheter ablation for atrial fibrillation. BMJ 2008; 336:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/39\">",
"      Marine JE. Catheter ablation therapy for supraventricular arrhythmias. JAMA 2007; 298:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/40\">",
"      Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013; 173:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/41\">",
"      Pokushalov E, Romanov A, Corbucci G, et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. J Cardiovasc Electrophysiol 2011; 22:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/42\">",
"      Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005; 45:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/43\">",
"      Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/44\">",
"      Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007; 28:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/45\">",
"      Miyazaki S, Kuwahara T, Kobori A, et al. Catheter ablation of atrial fibrillation in patients with valvular heart disease: long-term follow-up results. J Cardiovasc Electrophysiol 2010; 21:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/46\">",
"      Balk EM, Garlitski AC, Alsheikh-Ali AA, et al. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol 2010; 21:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/47\">",
"      Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation 2011; 123:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/48\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/49\">",
"      Parikh SS, Jons C, McNitt S, et al. Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. Pacing Clin Electrophysiol 2010; 33:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/50\">",
"      Chen SA, Tai CT. Catheter ablation of atrial fibrillation originating from the non-pulmonary vein foci. J Cardiovasc Electrophysiol 2005; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/51\">",
"      Lee SH, Tai CT, Hsieh MH, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. J Am Coll Cardiol 2005; 46:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/52\">",
"      Ha&iuml;ssaguerre M, Hocini M, Sanders P, et al. Localized sources maintaining atrial fibrillation organized by prior ablation. Circulation 2006; 113:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/53\">",
"      Pratola C, Baldo E, Notarstefano P, et al. Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm? Circulation 2008; 117:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/54\">",
"      Cappato R, Negroni S, Pecora D, et al. Prospective assessment of late conduction recurrence across radiofrequency lesions producing electrical disconnection at the pulmonary vein ostium in patients with atrial fibrillation. Circulation 2003; 108:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/55\">",
"      Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/56\">",
"      Senatore G, Stabile G, Bertaglia E, et al. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol 2005; 45:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/57\">",
"      Chugh A, Oral H, Good E, et al. Catheter ablation of atypical atrial flutter and atrial tachycardia within the coronary sinus after left atrial ablation for atrial fibrillation. J Am Coll Cardiol 2005; 46:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/58\">",
"      Kanagaratnam L, Tomassoni G, Schweikert R, et al. Empirical pulmonary vein isolation in patients with chronic atrial fibrillation using a three-dimensional nonfluoroscopic mapping system: long-term follow-up. Pacing Clin Electrophysiol 2001; 24:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/59\">",
"      Cummings JE, Schweikert R, Saliba W, et al. Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy: linear lesions or repeat isolation. J Cardiovasc Electrophysiol 2005; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/60\">",
"      Gerstenfeld EP, Callans DJ, Dixit S, et al. Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation. Circulation 2004; 110:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/61\">",
"      Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/62\">",
"      Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/63\">",
"      Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006; 48:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/64\">",
"      Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/65\">",
"      Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/66\">",
"      Terasawa T, Balk EM, Chung M, et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med 2009; 151:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/67\">",
"      Chen HS, Wen JM, Wu SN, Liu JP. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev 2012; 4:CD007101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/68\">",
"      Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/69\">",
"      Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/70\">",
"      Sanders P, Hocini M, Ja&iuml;s P, et al. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome. Eur Heart J 2007; 28:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/71\">",
"      Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation. Circulation 2003; 108:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/72\">",
"      Waldo AI, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/73\">",
"      Waldo AL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res 2002; 54:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/74\">",
"      Lang CC, Santinelli V, Augello G, et al. Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy. J Am Coll Cardiol 2005; 45:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/75\">",
"      Nair M, Shah P, Batra R, et al. Chronic atrial fibrillation in patients with rheumatic heart disease: mapping and radiofrequency ablation of flutter circuits seen at initiation after cardioversion. Circulation 2001; 104:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/76\">",
"      Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008; 19:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/77\">",
"      Zado E, Callans DJ, Riley M, et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2008; 19:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/78\">",
"      Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/79\">",
"      Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/80\">",
"      Maan A, Shaikh AY, Mansour M, et al. Complications from catheter ablation of atrial fibrillation: a systematic review. Crit Pathw Cardiol 2011; 10:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/81\">",
"      Zeljko HM, Mont L, Sitges M, et al. Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation. Europace 2011; 13:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/82\">",
"      Kesek M, Englund A, Jensen SM, Jensen-Urstad M. Entrapment of circular mapping catheter in the mitral valve. Heart Rhythm 2007; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/83\">",
"      Taylor GW, Kay GN, Zheng X, et al. Pathological effects of extensive radiofrequency energy applications in the pulmonary veins in dogs. Circulation 2000; 101:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/84\">",
"      Packer DL, Keelan P, Munger TM, et al. Clinical presentation, investigation, and management of pulmonary vein stenosis complicating ablation for atrial fibrillation. Circulation 2005; 111:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/85\">",
"      Qureshi AM, Prieto LR, Latson LA, et al. Transcatheter angioplasty for acquired pulmonary vein stenosis after radiofrequency ablation. Circulation 2003; 108:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/86\">",
"      Saad EB, Rossillo A, Saad CP, et al. Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy. Circulation 2003; 108:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/87\">",
"      Arentz T, Weber R, Jander N, et al. Pulmonary haemodynamics at rest and during exercise in patients with significant pulmonary vein stenosis after radiofrequency catheter ablation for drug resistant atrial fibrillation. Eur Heart J 2005; 26:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/88\">",
"      Di Biase L, Fahmy TS, Wazni OM, et al. Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: clinical implications after long-term follow-up. J Am Coll Cardiol 2006; 48:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/89\">",
"      Michaud GF. Silent cerebral embolism during catheter ablation of atrial fibrillation: how concerned should we be? Circulation 2010; 122:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/90\">",
"      Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/91\">",
"      Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/92\">",
"      Kuwahara T, Takahashi A, Takahashi Y, et al. Prevention of Periprocedural Ischemic Stroke and Management of Hemorrhagic Complications in Atrial Fibrillation Ablation Under Continuous Warfarin Administration. J Cardiovasc Electrophysiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/93\">",
"      Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/94\">",
"      Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013; 10:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/95\">",
"      Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013; 36:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/96\">",
"      Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/97\">",
"      Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thor",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/98\">",
"      Knight BP. Transesophageal echocardiography before atrial fibrillation ablation: looking before cooking. J Am Coll Cardiol 2009; 54:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/99\">",
"      Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009; 54:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/100\">",
"      Saksena S, Sra J, Jordaens L, et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study. Circ Arrhythm Electrophysiol 2010; 3:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/101\">",
"      Kaufman ES, Waldo AL. The impact of asymptomatic atrial fibrillation. J Am Coll Cardiol 2004; 43:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/102\">",
"      Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/103\">",
"      Bunch TJ, Crandall BG, Weiss JP, et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2009; 20:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/104\">",
"      Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 2008; 51:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/105\">",
"      Waigand J, Uhlich F, Gross CM, et al. Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. Catheter Cardiovasc Interv 1999; 47:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/106\">",
"      Dumonceau JM, Giostra E, Bech C, et al. Acute delayed gastric emptying after ablation of atrial fibrillation: treatment with botulinum toxin injection. Endoscopy 2006; 38:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/107\">",
"      Roberts-Thomson KC, Steven D, Seiler J, et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation 2009; 120:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/108\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/109\">",
"      Konings KT, Smeets JL, Penn OC, et al. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 1997; 95:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/110\">",
"      Lin YJ, Tai CT, Kao T, et al. Frequency analysis in different types of paroxysmal atrial fibrillation. J Am Coll Cardiol 2006; 47:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/111\">",
"      Oral H, Chugh A, Good E, et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation 2006; 113:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/112\">",
"      Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. Cardiovasc Res 2002; 54:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/113\">",
"      Mansour M. Highest dominant frequencies in atrial fibrillation: a new target for ablation? J Am Coll Cardiol 2006; 47:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/114\">",
"      Takahashi Y, Hocini M, O'Neill MD, et al. Sites of focal atrial activity characterized by endocardial mapping during atrial fibrillation. J Am Coll Cardiol 2006; 47:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/115\">",
"      Oral H, Chugh A, Good E, et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation 2007; 115:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/116\">",
"      Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000; 102:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/117\">",
"      Zhang, S, Olivier, B, Sanders, RA, et al. Effects of pulmonary vein isolation on atrial response to vagal stimulation (abstract). Circulation 2002; 106 (Suppl II):370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/118\">",
"      Scanavacca M, Pisani CF, Hachul D, et al. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation 2006; 114:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/119\">",
"      Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. J Am Coll Cardiol 2007; 50:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/120\">",
"      Linhart M, Bellmann B, Mittmann-Braun E, et al. Comparison of cryoballoon and radiofrequency ablation of pulmonary veins in 40 patients with paroxysmal atrial fibrillation: a case-control study. J Cardiovasc Electrophysiol 2009; 20:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/121\">",
"      Kojodjojo P, O'Neill MD, Lim PB, et al. Pulmonary venous isolation by antral ablation with a large cryoballoon for treatment of paroxysmal and persistent atrial fibrillation: medium-term outcomes and non-randomised comparison with pulmonary venous isolation by radiofrequency ablation. Heart 2010; 96:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/122\">",
"      Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm 2011; 8:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/123\">",
"      Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol 2009; 103:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/124\">",
"      Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol 2010; 56:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/125\">",
"      Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 2012; 60:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/126\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/62/40938/abstract/127\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 949 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40938=[""].join("\n");
var outline_f39_62_40938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H58\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H620592292\">",
"      CLASSIFICATION OF AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC ORIGIN OF AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Paroxysmal AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Longstanding persistent AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H968282607\">",
"      Left atrial appendage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULMONARY VEIN ISOLATION PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging and mapping tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Three-dimensional mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intracardiac echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CT and MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Segmental ostial ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Selective PVI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Circumferential left atrial ablation or WACA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comparison between segmental and circumferential procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Safety concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Importance of complete isolation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Confirming isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066879413\">",
"      Ablation of sources within the atria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Early AF recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      AF recurrence after three months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Detection of recurrences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Left atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Comparison to antiarrhythmic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      After surgical Maze procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Repeat ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Longstanding persistent AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Simultaneous AF/atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Mitral valve prosthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Rheumatic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347313400\">",
"      Use during cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85423607\">",
"      Catheter entrapment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pulmonary vein stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Periprocedural embolic events and anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Role of TEE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Chronic post procedural anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16900209\">",
"      Vascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H960431348\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      ALTERNATIVE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Focal ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - Complex fractionated atrial electrograms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Tailored approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Rotors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Ablation of cardiac autonomic nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32876014\">",
"      Cryoballoon ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H700377964\">",
"      PREVENTION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615512118\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118892756\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615512132\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H246147310\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=related_link\">",
"      Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/24/38280?source=related_link\">",
"      Transesophageal echocardiography: Indications, complications, and normal views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_62_40939="Clin manif hypocalcemia";
var content_f39_62_40939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of hypocalcemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Neuromuscular irritability (Tetany)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Paresthesias (peri-oral, extremities)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Muscle twitching",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Carpopedal spasm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Trousseau's sign",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chvostek's sign",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Laryngospasm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bronchospasm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Cardiac",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Prolonged QT interval",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hypotension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Arrhythmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papilledema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chronic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ectopic calcification (basal ganglia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extrapyramidal signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinsonism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dementia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subcapsular cataracts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal dentition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dry skin",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40939=[""].join("\n");
var outline_f39_62_40939=null;
var title_f39_62_40940="Enzymatic debriding agents";
var content_f39_62_40940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enzymatic debriding agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"15%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"23%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzyme source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Collagenase",
"       </td>",
"       <td>",
"        Strain of",
"        <em>",
"         Clostridium histolyticum",
"        </em>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Approved by the United States FDA for the debridement of chronic wounds and burns",
"         </li>",
"         <li>",
"          Selective for collagen",
"         </li>",
"         <li>",
"          Generally pain-free delivery",
"         </li>",
"         <li>",
"          May be combined with a variety of other topical dressings",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Effectiveness compared with other forms of debridement may be questionable",
"         </li>",
"         <li>",
"          Prescription based upon wound area",
"         </li>",
"         <li>",
"          High cost",
"         </li>",
"         <li>",
"          Relatively slow-acting",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Moist wound environment required for activation",
"         </li>",
"         <li>",
"          Topical silver dressings significantly inhibit collagenase activity",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Papain",
"       </td>",
"       <td>",
"        Papaya",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Provides relatively \"aggressive\" enzymatic debridement",
"         </li>",
"         <li>",
"          Generally pain-free delivery",
"         </li>",
"         <li>",
"          May be combined with a variety of other topical dressings",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Not readily available in the United States",
"         </li>",
"         <li>",
"          Nonselective (ie, will cleave any protein containing cysteine)",
"         </li>",
"         <li>",
"          Relatively slow-acting",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Agent is often combined with a chlorophyll-complex that causes green wound discoloration following application",
"         </li>",
"         <li>",
"          Need to avoid adjacent healthy tissues",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bromolain",
"       </td>",
"       <td>",
"        Pineapple",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Relatively rapid-acting",
"         </li>",
"         <li>",
"          Selective for non-viable tissue",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Removal from base of wound required after several hours",
"         </li>",
"         <li>",
"          Inhibits platelet function but is reversible",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Evidence of efficacy is based on acute wounds or burns, not chronic wounds",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FDA: Food and Drug Administration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Ramundo J, Gray M. Collagenase for enzymatic debridement: a systematic review. J Wound Ostomy Continence Nurs 2009; 36:S4.",
"      </li>",
"      <li>",
"       Kravitz SR, McGuire J, Zinszer K. Management of skin ulcers: understanding the mechanism and selection of enzymatic debriding agents. Adv Skin Wound Care 2008; 21:72.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40940=[""].join("\n");
var outline_f39_62_40940=null;
var title_f39_62_40941="Genetic model CRC tumorigenesis";
var content_f39_62_40941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    A genetic model for colorectal tumorigenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 184px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LOH: loss of heterozygosity; DCC: deleted in colon cancer gene; APC: adenomatous polyposis coli gene; ACF: aberrant crypt foci; MMR: DMA mismatch repair enzyme.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Lynch, JP, Hoops, TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am 2002; 16:775.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40941=[""].join("\n");
var outline_f39_62_40941=null;
var title_f39_62_40942="Dilatory eustachian tube dysfunction";
var content_f39_62_40942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilatory eustachian tube dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left eustachian tube with a large adenoid mass compressing posterior cushion causing a dilatory dysfunction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40942=[""].join("\n");
var outline_f39_62_40942=null;
var title_f39_62_40943="Actinic purpura";
var content_f39_62_40943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic (solar) purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ecchymoses are present on the dorsal forearms in an elderly person.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_62_40943=[""].join("\n");
var outline_f39_62_40943=null;
